Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
02/2011 | Recent  |  14:  |  |  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions February patent applications/inventions, industry category 02/11

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
02/24/2011 > patent applications in patent subcategories. patent applications/inventions, industry category

20110046038 - Polypeptide-polymer conjugates and methods of use thereof: The present invention provides polypeptide-polymer conjugates. A subject polypeptide-polymer conjugate is useful in a variety of applications, cations, which are also provided.... Agent: Bozicevic, Field & Francis LLP

20110046039 - Post-exposure prophylaxis and treatment of infections: The invention provides methods and materials for identifying agents for preventing and/or treating anthrax and similar diseases. Embodiments provide strains and model systems for studying non-lethal and lethal exposure to anthrax and similar disease vectors. Embodiments provide materials and methods for using the strains and model systems for differential profiling,... Agent: Millen, White, Zelano & Branigan, P.C.

20110046040 - Microorganism-inactivating agent: With a microorganism-inactivating agent comprising a composition containing γ-polyglutamic acid and/or cross-linked product of γ-polyglutamic acid; a calcium ion donor; a sodium ion donor; and an aluminum ion donor, microorganisms in water are inactivated. By further including one or more selected from microbiostatic agents and microbicides into the microorganism-inactivating agent,... Agent: Hogan Lovells US LLPIPGroup, Columbia Square

20110046041 - Methods of inhibiting and treating biofilms using glycopeptide antibiotics: The present invention is directed to methods of inhibition, delay of formation, treatment, prophylaxis and/or prevention of infections caused by bacteria that exhibit tolerance to antimicrobial agents, including slow growing, stationary-phase and biofilm forming bacteria, through the use of glycopeptide antibiotics, such as oritavancin.... Agent: Roylance Abrams Berdo & Goodman, LLP

20110046042 - Long interspersed nuclear element polypeptide compositions and methods of use thereof: The present invention provides LINE polypeptides; and compositions, including immunogenic compositions, comprising a subject LINE polypeptide. The present invention provides a recombinant nucleic acid comprising a nucleotide sequence encoding a subject LINE polypeptide. A subject composition is useful for stimulating a T-cell immune response to a LINE peptide. The present... Agent: Bozicevic, Field & Francis LLP

20110046043 - Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices: The present invention relates to a peptide having one or more stable, internally-constrained HBS α-helices, where the peptide mimics at least a portion of a class I C-peptide helix or at least a portion of a class I N-peptide helix of a viral (e.g., HIV-I) coiled-coil assembly. Methods of inhibiting... Agent: Wilson, Sonsini, Goodrich & Rosati

20110046044 - Use of a cysteine protease of plasmodium vivax: A use of vivapain-4 (VX-4), which is a cysteine protease of Plasmodium vivax, showing pH-dependent switching of substrate specificity, is provided. More specifically, a method of treating a parasitic disease caused by Plasmodium vivax by inhibiting VX-4; a method of screening a protease inhibitor acting on VX-4, wherein the protease... Agent: LexyoumeIPGroup, PLLC

20110046045 - Method of treating obesity and metabolic disorders related to excess adipose tissue by administration of sfrp-5 peptide: Disclosed is a method of reducing the amount of adipose tissue in a subject comprising administering to the subject an amount of an sFRP-5 peptide effective to reduce the amount of adipose tissue, or an amount of a molecule effective to stimulate expression of the sFRP-5 peptide in the subject.... Agent: Cooper & Dunham, LLP

20110046046 - Prophylactic or therapeutic composition for diabetes or obesity: Disclosed is a safe and non-toxic prophylactic or therapeutic composition for diabetes or obesity. The prophylactic or therapeutic composition for diabetes or obesity comprises as an active ingredient, a calcium receptor activator such as γ-Glu-X-Gly, wherein X represents an amino acid or an amino acid derivative; γ-Glu-Val-Y, wherein Y represents... Agent: Cermak Nakajima LLP Acs LLC

20110046047 - Bone morphogenetic proteins for appetite control: Methods of decreasing appetite for food intake by administering bone morphogenetic proteins (BMPs), e.g., BMP7, or agonists/peptidomimetics thereof.... Agent: Fish & Richardson P.C. (bo)

20110046048 - High protein liquid enteral nutritional composition: The present invention relates in general to a shelf-stable liquid enteral composition for providing nutrition, either as a supplement, or as a complete nutrition, with a high protein content of a non-hydrolysed globular protein, in particular a whey protein.... Agent: Foley And Lardner LLP Suite 500

20110046051 - Method and device for utilizing analyte levels to assist in the treatment of diabetes: A health-monitoring device assesses the health of a user based on levels of two analytes in a biological fluid. A first analyte that is utilized to assess a user's health is a fat metabolism analyte, such as ketones, free fatty acids and glycerol, which is indicative of fat metabolism. A... Agent: Abbott Diabetes Care Inc. Bozicevic, Field & Francis LLP

20110046050 - Phenylalkylcarboxylic acid delivery agents: The present invention provides phenylalkylcarboxylic acid compounds and compositions containing such compounds which facilitate the delivery of biologically active agents.... Agent: Emisphere Technologies, Inc. C/o Blank Rome LLP

20110046049 - Soluble, stable insulin-containing formulations with a protamine salt: The present invention relates to pharmaceutical formulations comprising insulin, an insulin analog, an insulin derivative, or a combination of any of the foregoing, and a salt of protamine, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use... Agent: Novo Nordisk, Inc. Intellectual Property Department

20110046052 - Excipients for protein stabilization: This invention is a method of using a class of excipients for protein formulation to reduce and/or eliminate protein aggregation in solutions or solids. This class of compounds contains carbonyl group(s) to form Schiff base(s) with amino groups of proteins and also contains moieties to keep protein molecules spatially separated.... Agent: Morrison & Foerster LLP

20110046053 - Methods and compositions for oral administration of exenatide: This invention provides compositions comprising a byetta, fish oil, and a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral or rectal administration of a byetta.... Agent: Wolf Greenfield & Sacks, P.C.

20110046054 - Anti diabetic protein: The present invention relates to a novel hypoglycemic/anti-hyperglycemic protein named ADMc1 purified from the seeds of Momordica charantia for control of hyperglycemia. The process for the purification of novel hypoglycemic/anti-hyperglycemic protein named ADMc1 is also disclosed. The invention also relates to process for preparation and purification of the recombinant novel... Agent: Ladas & Parry LLP

20110046055 - Therapeutic agent for diabetes: Disclosed are method for treating diabetes, a protein for treatment of diabetes, and pharmaceutical composition comprising the same. The protein is human mature chemerin, which can be used to treat diabetes, in particular type 2 diabetes, inter alia to treat diabetes in a patient who is concurrently administered with insulin.... Agent: Millen, White, Zelano & Branigan, P.C.

20110046056 - Apoa-1 peptide mimetics: The invention relates to peptide mimetics for treating disorders associated with hypercholesterolemia and cardio-vascular disease. In particular, the invention relates to peptides that mimic the activity of apolipoprotein A-I (Apo AI).... Agent: Merck

20110046057 - Uses of cerberus and derivatives thereof: The disclosure relates to Cerberus/Coco polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11.... Agent: Ropes & Gray LLP Iprm - Floor 43

20110046058 - Compositions for enteral absorption and sustained action of leptin-related peptides useful in the treatment of obesity and leptin-modulated disease: The invention relates generally to enterally absorbed peptide compositions and more specifically to leptin-related peptide compositions, methods of administration, and methods of modulating the speed and sustained action of systemic absorption of such peptides useful in the treatment of obesity and other leptin modulated diseases.... Agent: Dla Piper LLP (us)

20110046059 - Pharmaceutically acceptable formulations/compositions for peptidyl drugs: The present invention provides for pharmaceutically acceptable compositions for peptidyl drugs, method of making thereof, and methods of use thereof. Compositions are disclosed comprising a pharmaceutically effective amount of a peptidyl drug and a bioavailability enhancer in an amount sufficient to increase the bioavailability of the peptidyl drug.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20110046060 - Coagulation factor ix compositions and methods of making and using same: The present invention relates to compositions comprising factor IX coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.... Agent: Amunix, Inc. / Wsgr

20110046061 - Coagulation factor vii compositions and methods of making and using same: The present invention relates to compositions comprising factor VII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.... Agent: Amunix, Inc. / Wsgr

20110046062 - Factor h for the treatment of chronic nephropathies and production thereof: The invention relates to the use of Factor H for the manufacture of a medicament to treat both chronic nephropathies which are not causally associated with proteinuria and chronic nephropathies which are causally associated with proteinuria. The invention also relates to large scale purification methods for Factor H.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20110046063 - Ready-to-use bivalirudin compositions: Ready-to-use bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use bivalirudin compositions. The ready-to-use bivalirudin compositions comprise bivalirudin and one or more stabilizing agents. The one or more stabilizing agents may be buffering agents having a pKa of about 2.5 to about 6.5, pH-adjusting... Agent: Frommer Lawrence & Haug

20110046064 - Methods and compositions using selective delta opioid receptor-1 agonists, delta opioid receptor-2 antagonists, and/or mu opioid receptor antagonists for treatment of substance-related disorders: The present invention provides methods of treating or preventing a substance-related disorder using selective delta opioid receptor-1 (DOP-R1) agonists, delta opioid receptor-2 (DOP-R2) antagonists, and/or mu opioid receptor (MOP-R) antagonists, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The methods provided herein further comprise administering a therapeutically effective... Agent: Fenwick & West LLP

20110046065 - Low frequency glatiramer acetate therapy: A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three... Agent: Cooper & Dunham, LLP

20110046066 - Inhibitors of iap: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula (I), and G, X1, X2, R1, R2, R3, R4, R4′, R5, Ra, Rb, and Rc are as described herein.... Agent: Genentech, Inc.

20110046067 - Compositions comprising human egfr-sirna and methods of use: The present invention provides nucleic acid molecules that inhibit EGFR expression. Methods of using the nucleic acid molecules are also provided.... Agent: Ropes & Gray LLP

20110046068 - Compound, use and method: The present invention relates to the use of an antagonist of kisspeptin in the manufacture of a medicament for the treatment of a condition induced and/or worsened by kisspeptin activity in an individual. The invention also provides certain defined peptide molecules, which may act as an antagonist of kisspeptin, which... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20110046070 - Gene expression inhibitor selective for matrix metalloproteinase-9 gene: Disclosed are: an inhibitor of the expression of matrix metalloproteinase-9 gene; a therapeutic agent for a disease associated with matrix metalloproteinase-9; and a carcinostatic agent. Each of the agents comprises a pyrrole-imidazole polyamide having an N-methylpyrrole unit, an N-methylimidazole unit and a γ-aminobutyric acid unit. The pyrrole-imidazole polyamide can be... Agent: Birch Stewart Kolasch & Birch

20110046069 - Uses of modified elr-cxc chemokine g31p: Described herein is the use of a modified human chemokine, GS-CXCL8(3-73)K11R/G31P or G31P in the treatment of a number of diseases or disorders, including but by no means limited to pulmonary disorders, inflammatory diseases and disorders, cancers and surgical/ischemia reperfusion applications.... Agent: Ade & Company Inc.

20110046071 - Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer: Disclosed are methods and compositions for increasing concentrations of GLP-1 receptor agonists in the body for the treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents.... Agent: The Law Office Of Michael E. Kondoudis

20110046072 - Solid pharmaceutical formulation with delayed release: The invention relates to a solid pharmaceutical preparation with delayed release of the active ingredients which is suitable in particular for use in animals.... Agent: Bayer Healthcare LLC

20110046074 - Highly permeable polymeric membranes: Provided are substantially flat membranes that include a block or graft co-polymer and a water transport protein, such as Aquaporin-Z, or a synthetic mimic of such proteins. Also provided are methods of removing contaminants from a liquid, by contacting the liquid with a substantially flat membrane that includes a block... Agent: Uiuc Docket

20110046073 - Soluble lymphotoxin-beta receptor fusion protein and methods for inhibiting lymphotoxin beta-receptor signaling: This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β.receptor extracellular domain that act as... Agent: Nelson Mullins Riley & Scarborough LLP Floor 30, Suite 3000

20110046075 - Secreted staphylococcus aureus proteins and peptides for use in inhibiting activation of the complement system: Compounds comprising peptides and peptide analogs capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds mimic the structure and activity of secreted Staphylococcus aureus proteins, Efb and the previously uncharacterized SAV1 155.... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20110046076 - Pharmaceutical composition, methods for treating and uses thereof: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20110046077 - Process for the extraction of mangiferin and isomangiferin: The present invention relates to methods for extracting and isolating glycosyl xanthone derivatives, in particular mangiferin and isomangiferin, from plants of the Rubiaceae family, especially of the Coffea genus. The invention also relates to extracts obtained using such methods, as well as compositions comprising such extracts that are useful in... Agent: Marshall, Gerstein & Borun LLP

20110046078 - Methods and compositions for treating diseases and disorders associated with siglec-8: The invention provides therapeutic methods and compositions for the prevention and treatment of Siglec-8 associated diseases and disorders such as asthma and allergic reactions. In particular, the invention provides methods and compositions for the prevention and treatment of diseases and disorders associated with Siglec-8 expressing cells in humans, as well... Agent: Edwards Angell Palmer & Dodge LLP

20110046080 - Composition for treating a skin disorder: The present invention relates to the use of a plant of the genus, Capsicum, or part thereof or extract thereof for treating or alleviating the symptoms of a skin condition or disorder, including dermatitis. The present invention also relates to compositions comprising the same for such use, together with methods... Agent: Macmillan Sobanski & Todd, LLC

20110046079 - Use of proton pump inhibitors as drug delivery adjuvants: Compositions and methods for drug delivery are disclosed.... Agent: Dann, Dorfman, Herrell & Skillman

20110046081 - Classical cannabinoid metabolites and methods of use thereof: The present invention encompasses classical cannabinoid metabolites and uses thereof.... Agent: Polsinelli Shughart PC

20110046203 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.... Agent: Seed Intellectual Property Law Group PLLC

20110046202 - Method for testing a subject thought to have or to be predisposed to asthma: The present invention concerns a method of testing a subject thought to have or be predisposed to having asthma, allergy, atopic disease or atopic sensitization, which comprises the step of analyzing a biological sample from said subject for (i) detecting the presence of a mutation associated with the over-expression of... Agent: Foley And Lardner LLP Suite 500

20110046201 - Methods and compositions for seamless cloning of nucleic acid molecules: The present invention is in the fields of biotechnology and molecular biology. More particularly, the present invention relates to cloning or subcloning one or more nucleic acid molecules comprising one or more type IIs restriction enzyme recognition sites. The present invention also embodies cloning such nucleic acid molecules using recombinational... Agent: Life Technologies Corporation C/o Intellevate

20110046200 - Use of antisense oligonucleotides to effect translation modulation: The present invention provides methods for modulating translation of an mRNA using antisense oligonucleotides. The methods result in the stimulation or inhibition of a change in reading frame or stop codon readthrough during translation.... Agent: Workman Nydegger 1000 Eagle Gate Tower

20110046207 - C5a binding nucleic acids: The present invention is related to a nucleic acid, preferably binding to C5a, selected from the group comprising type A nucleic acids, type B nucleic acids, type C nucleic acids, type D nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ.ID.No. 73 to 79.... Agent: Mdip LLC

20110046206 - Double strand compositions comprising differentially modified strands for use in gene modulation: The present invention provides double stranded compositions wherein the first strand is modified to have a particular motif and the second strand is modified a selected motif. The motifs are defined by positioning of differentially modified nucleosides wherein at least the sugar moieties are different. More particularly, the present compositions... Agent: Woodcock Washburn LLP

20110046204 - Human zip1, zinc and citrate for prostate cancer screening: The present invention provides methods of detecting prostate cancer employing biomarkers, including hZIP1, zinc and citrate. Also provided are antibodies to detect hZIP1 protein or peptides and an expression vector comprising a genetic sequence effective to increase uptake of zinc into a prostate cell upon expression thereof. Furthermore, methods of... Agent: Frederick W. Gibb, Iii, Esq. Gibb I.p. Law Firm, LLC

20110046205 - Method for dissolving charged nucleic acid in an organic liquid: The invention relates to a method for dissolving charged nucleic acids in an organic first liquid which is immiscible with water. The method comprises the following steps: a) providing a solution of the nucleic acids in an aqueous second liquid, b) precipitating the nucleic acids by adding a complexing agent... Agent: Fish & Richardson P.C. (tc)

20110046208 - Nucleolar targeting of therapeutics against hiv: The HIV regulatory proteins Tat and Rev accumulate in nucleoli of human cells. No functional role has been attributed to this localization. Recently it was demonstrated that expression of Rev induces nucleolar re-localization of some nuclear factors involved in Rev export. Thus, it is likely that the nucleolus plays a... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20110046209 - Rna-induced translational silencing and cellular apoptosis: The invention is directed to RNA molecules that can be used to inhibit protein synthesis and to induce cells to undergo apoptosis. It also includes pharmaceutical compositions containing the RNAs that can be used in treating or preventing tumors; abnormal dermatological growths and viral infections.... Agent: Law Office Of Michael A. Sanzo, LLC

20110046082 - Deuterium-enriched nelarabine: The present application describes deuterium-enriched nelarabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20110046083 - Activators of pyruvate kinase m2 and methods of treating disease: The invention described herein features methods, compositions, and kits for the use of activators of PKM2 for the treatment, prevention, or amelioration of diseases related to PKM2 function, including, e.g., cancer, diabetes, atherosclerosis, restenosis, obesity, autoimmune disorders, and proliferative disorders.... Agent: Clark & Elbing LLP

20110046086 - Composition comprising polysaccharide extracted from panax ginseng preventing and treating liver diseases: The present disclosure relates to a Panax ginseng polysaccharide extract, which is useful for liver protection or for the prevention and treatment of liver diseases, and a method for preparing the same. Further, the present invention relates to a composition for the prevention and treatment of liver diseases, comprising the... Agent: Knobbe Martens Olson & Bear LLP

20110046084 - Exopolysaccharide: An isolated polysaccharide has the structure [-β(1,3)-D-GalpNAc-β(1,4)-D-Glcp-]n The polysaccharide may be from a Bifidobacterium strain NCIMB41003. The polysaccharide exhibits immunomodulatory activity.... Agent: Jacobson Holman PLLC

20110046085 - Oral immunostimulation of fish from (1-4) linked beta-d-mannuronic acid: An oral, immunostimulating material for mammals, birds, fish, and reptiles comprising an immunostimulating amount of an alginate having a M content of at least 40% and an acceptable carriers.... Agent: Patent Administrator Fmc Corporation

20110046087 - Pharmaceutical composition, methods for treating and uses thereof: The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20110046088 - Iminipyridine derivatives and their uses as microbiocides: Compounds of the formula (I) in which the substituents are as defined in claim 1 are suitable for use as microbiocides.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20110046089 - Substituted 2-phenyl-pyridine derivatives: wherein R1, R2, R4, R5, Ra, Rb, n, W and Z are as defined in the application, their preparation and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet... Agent: Hoxie & Associates LLC

20110046090 - Modulation of neurogenesis with gaba agents and gaba analogs: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a GABA agent or GABA analog, in combination with one or more other neurogenic agents, to stimulate or... Agent: Sughrue Mion, PLLC

20110046091 - Composition and methods used during anti-hiv treatment: This invention relates to a composition comprising an anti-HIV treatment and a treatment for side effects of said anti-HIV treatment in an HIV-infected patient. This invention is, for example, very useful in the treatment of side effects caused by certain anti-HIV treatments, for example premature aging and lipodystrophy, which can... Agent: Blank Rome LLP

20110046092 - Small molecules for neuronal differentiation of embryonic stem cells: A method of preparing neural precursor cells by exposing pluripotent stem cells or neural stem cells to a differentiation agent. The agent is a pyridine analog, which in preferred embodiments is a phenylethynyl-substituted or phenylazo-substituted pyridine. In other embodiments, a method of enhancing neural precursor cell survival is provided in... Agent: Fulbright & Jaworski, L.L.P.

20110046093 - Pyrimidine derivatives as protein kinase inhibitors: The present invention relates to a compound of formula (VII)I, or a pharmaceutically acceptable salt or ester thereof, wherein: X is NR7; Y is O or N—(CH2)nR19; n is 1, 2 or 3; m is 1 or 2; R1 and R2 are each independently H, alkyl or cycloalkyl; R4 and... Agent: Nelson Mullins Riley & Scarborough LLP Floor 30, Suite 3000

20110046094 - Methods and compositions for identifying and treating lupus: A unique set of genetic variations associated with lupus are provided. Also provided are methods for detecting such genetic variations and for assessing risk of developing lupus as well as for diagnosing and treating lupus.... Agent: Morrison & Foerster LLP

20110046095 - Steroid hormone products and methods for preparing them: The present invention relates to steroid hormone products, such as oral contraceptive products, including at least one steroid active ingredient mixed with an excipient and having improved dissolution and release rate properties. The invention further relates to methods for making such steroid hormone products, wherein a mixture of the hormone... Agent: Philip S. Johnson Johnson & Johnson

20110046096 - Novel piperazino-dihydrothienopyrimidine derivatives: The invention relates to the novel dihydrothienopyrimidine sulfoxides of formula (I) and to the pharmacologically acceptable salts thereof, wherein X represents SO or SO2, preferably however SO, and wherein R3, R4, R4′, R5, R6 and R7 are defined as in claim 1. The invention also relates to pharmaceutical compositions containing... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20110046098 - Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer, etc.: The present invention relates to methods of administering compositions comprising a progesterone receptor antagonist for use in treating estrogen-dependent conditions. The invention is also directed to methods for treating pain associated with endometriosis. The compositions may be administered to females with endometriosis as well as to females undergoing estrogen and/or... Agent: Howrey LLP - East

20110046097 - Substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors: The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20110046099 - Steroid hormone products and methods for preparing them: The present invention relates to steroid hormone products, such as oral contraceptive products, including at least one steroid active ingredient mixed with an excipient and having improved dissolution and release rate properties. The invention further relates to methods for making such steroid hormone products, wherein a mixture of the hormone... Agent: Philip S. Johnson Johnson & Johnson

20110046100 - Texaphyrin solutions and pharmaceutical formulations: A packaging system is described for a drug that provides protection from contamination, crystallization and/or degradation of the drug during storage of the system prior to its use. The packaging of the drug does not significantly absorb, react with, or otherwise adversely affect the therapeutic effectiveness of the drug or... Agent: Wilson, Sonsini, Goodrich & Rosati

20110046101 - Bate-lactamase inhibitors: p

20110046102 - Azabicyclic compounds, preparation thereof and use of same as drugs, especially beta-lactamase inhibitors: wherein one of R1 and R2 is a hydrogen and the other a fluorine or both represent a fluorine, in free form, in the form of zwitterions and of salts with pharmaceutically acceptable mineral or organic bases, the preparation thereof and their use as medicinal products inhibiting the action of... Agent: David Chen

20110046103 - Neurotherapeutic cephalosporin sulfoxide and sulfone-containing compositions: The treatment of neurological disorders using cefazolin compositions and pharmaceutical compositions including oral dosage forms that include cefazolin compositions are described.... Agent: Venable LLP

20110046105 - Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof: The invention relates to compounds of formula (I) wherein the groups R and R′, A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.... Agent: Scully, Scott, Murphy & Presser, P.C.

20110046107 - Sulfonyl-substituted carbapenem compounds: e

20110046109 - 2,4,8-trisubstituted-8h-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy: Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.... Agent: Glaxosmithkline Global Patents

20110046108 - Pyrimidine derivatives: The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, ring A, n, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the... Agent: Astrazeneca R&d Boston

20110046104 - Aminopyrimidines useful as kinase inhibitors: The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the... Agent: Vertex Pharmaceuticals Inc.

20110046106 - Aryl sulfonamides as effective analgesics: wherein A, B, R1, R2 and R3 are defined as in claim 1, the enantiomers, the diastereomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases, which have valuable properties, the preparation thereof, the pharmaceutical compositions containing the pharmacologically effective... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20110046110 - Quinolines and related analogs as sirtuin modulators: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Glaxosmithkline Global Patents -us, Uw2220

20110046111 - Quinazoline linked pyrrolo[2,1-c][1, 4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof: The present invention provides a compound of general formula 5, useful as potential antitumour agents against human cancer cell lines. The present invention further provides a process for the preparation of pyrrolo[2,1-c][1,4]benzodiazepine hybrids of general formula (5): wherein n=3, 4, 5, 6, 8 and wherein R1 and R2 is selected... Agent: Ladas & Parry LLP

20110046112 - Novel bicyclic sulfonamide derivatives which are l-cpt1 inhibitors: e

20110046113 - Amine compound and use thereof:

20110046114 - Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin:

20110046115 - Mirtazapine solid dosage forms: A non-effervescent, solid dosage form containing mirtazapine, which is used to form mirtazapine pharmaceutical tablets. The dosage form contains mirtazapine, a hydrophilic component, and at least one lubricant. In some embodiments, the dosage forms contain a salivating agent. Processes for producing mirtazapine orally disintegrating tablets are also provided.... Agent: Florek & Endres PLLC

20110046117 - Compositions of 5-ht3 antagonists and dopamine d2 antagonists for treatment of dopamine-associated chronic conditions: The present invention provides novel compositions comprising a combination of a 5-HT3 receptor antagonist and a selective dopamine D2 receptor antagonist for the treatment of alcohol dependence and other dopamine pathway-associated disorders or conditions. Preferably, the pharmaceutical compositions of the present invention comprise amounts of the 5-HT3 receptor antagonist ondansetron... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-13-a7

20110046116 - Sedative for use during eye surgery: A drug for sedating a patient, and especially a smoker, during eye surgery. The drug includes a sedative such as midazolam in a mix with nicotine. The mixture is injected into the patient prior to the eye surgery.... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20110046118 - Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use: This invention relates to novel 1,4-diaza-bicyclo [3.2.2]nonyl pyrimidine derivatives of formula (I) and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile... Agent: Birch Stewart Kolasch & Birch

20110046119 - Therapeutic treatment: A combination comprising candesartan and rosuvastatin for the prevention or treatment of atherosclerosis and for the prevention of cardiovascular events is described.... Agent: Morgan Lewis & Bockius LLP

20110046120 - Treatment of impulse control disorders: The present disclosure provides methods and compositions for treating Impulse Control disorders including, for example, pathological gambling using α2-adrenergic agonists, β-adrenergic receptor antagonists, or both.... Agent: Foley & Lardner LLP

20110046121 - Inhibitors of focal adhesion kinase: The invention provides inhibitors of focal adhesion kinase, an enzyme involved in the attachment of the cytoskeleton of a cell to an extracellular matrix, which has been implicated in processes such as cell migration, cell proliferation, and cell survival. The inhibitors are derivatives of a 5-substituted 2,4-diaminopyridine wherein the substituents... Agent: Schwegman, Lundberg & Woessner, P.A.

20110046122 - 3-amino-5-phenyl-5,6-dihydro-2h-[1,4]oxazines: e

20110046124 - Bait spray for controlling ant populations: The subject invention provides spray formulations, and methods of use, for controlling ant populations.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20110046123 - Pesticidal mixtures: The present invention relates to synergistic mixtures comprising, as active components, an insecticidal compound (I) selected from following nicotinic receptor agonists/antagonists compounds, an amide compound one or two further fungicidal compound(s) and/or an insecticidal compound selected from the group consisting of fipronil and ethiprole.... Agent: Brinks, Hofer, Gilson & Lione

20110046125 - Method for treating infections: The present invention relates to compounds for treating or preventing infection that inhibit the activity of Hsp90.... Agent: Foley & Lardner LLP

20110046126 - Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis: Novel methods and compositions for the prevention and treatment of all forms of atherosclerosis with 2,4-pyrimidinediamine compounds are described. Also disclosed is the coating of prosthetic devices, such as stents, with the compounds of the invention for the prevention and/or treatment of restenosis.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20110046127 - Imidazopyridazines for use as protein kinase inhibitors: There is provided compounds of formula (I): wherein Z, M, R1, X, R3, R4 and R5 have meanings given in the description, an pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein kinase (e.g. a PIM family... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20110046128 - Novel compounds advantageous in the treatment of central nervous system diseases and disorders: A series of novel compounds showing anticonvulsant, chemical countermeasure(s), and analgesic activities is described. Such pharmaceutically active compounds may also show utility in the treatment of other central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, Parkinson's disease, spasticity, Alzheimer's disease, and bipolar disorder.... Agent: Workman Nydegger 1000 Eagle Gate Tower

20110046129 - 2-phenylethylamino derivatives as calcium and/or sodium channel modulators: 2-Phenylethylamino substituted carboxamide derivatives and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies are presented.... Agent: Dechert LLP

20110046130 - Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists: The invention relates to compounds of formula (I), wherein X1a, X1 to X5, Ra, Rb, n and R have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds... Agent: Birch Stewart Kolasch & Birch

20110046131 - Purines as pkc-theta inhibitors: A chemical genus of purines, which are useful as PKCθ inhibitors, is disclosed. The genus is represented by the formula (I); A representative example is: (II)... Agent: Organon Usa, Inc. C/o Merck

20110046132 - Benzoimidazoles as prolyl hydroxylase inhibitors: The present invention is directed to benzoimidazole compounds of the formula (1) and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.... Agent: Philip S. Johnson Johnson & Johnson

20110046133 - Organic compounds: e

20110046135 - New compounds i:

20110046134 - Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase: The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20110046136 - Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associcated therewith: The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of... Agent: Jones Day

20110046137 - Pyrazole derivatives as p2x7 modulators: The pyrazole derivatives of formula (I) or salts thereof modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also relates to the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention... Agent: Glaxosmithkline Global Patents -us, Uw2220

20110046138 - Novel compounds advantageous in the treatment of central nervous system diseases and disorders: A series of novel compounds showing anticonvulsant activity is described. Such pharmaceutically active compounds may also show utility in the treatment of other central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, Parkinson's disease, spasticity, Alzheimer's disease, and bipolar disorder. Furthermore, such compounds may... Agent: Workman Nydegger 1000 Eagle Gate Tower

20110046139 - Benzocycloheptane and benzoxepine derivatives: s

20110046140 - Aminoalcohol and biocide compositions for aqueous based systems: Biocidal compositions and their use in aqueous media, such as metalworking fluids, the compositions comprising a biocidal agent; and a non-biocidal primary amino alcohol compound of the formula (I): wherein R1, R2, R3, R4, and R5 are as defined herein.... Agent: The Dow Chemical Company

20110046141 - Use of pde5 inhibitors for treating circadian rhythm disorders: A method of altering circadian rhythm in a mammal is provided. In certain embodiments, the method comprising: administering to the mammal a PDE5 inhibitor, e.g., sildenafil, vardenafil, tadalafil or zaprinast. The method may be employed to prevent a circadian rhythm disorders including, but not limited to transmeridian flight disorder (i.e.,... Agent: Young & Thompson

20110046142 - Antibiotic compounds: Methods for identifying prodrug antibiotic compounds and direct inhibitory antibiotic compounds utilizing various screens are provided. Also provided are methods for treating infections using these compounds.... Agent: Wilmerhale/boston

20110046143 - Disubstituted phthalazine hedgehog pathway antagonists: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.... Agent: Eli Lilly & Company

20110046144 - Imidazopyrazinol derivatives for the treatment of cancers: Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-IR enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the... Agent: Osi Pharmaceuticals, Inc.

20110046145 - Quinolizidinone m1 receptor positive allosteric modulators: The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions... Agent: Merck

20110046147 - 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases: The invention relates to 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) inhibitors, the preparation thereof and the use thereof for the treatment and prophylaxis of hormone-related, especially estrogen-related or androgen-related, diseases.... Agent: Briscoe, Kurt G. Norris Mclaughlin & Marcus, Pa

20110046146 - Phosphodiesterase 4 inhibitors: e

20110046148 - Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production: the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20110046149 - 2-amino-3-sulphonyl-tetrahydro-pyrazolo[1,5-a]pyrido-pyrimidine antagonists of serotonin 5-ht6 receptors, methods for the production and use thereof: wherein: Ar is optionally substituted aryl or optionally substituted heteroaryl; R1 is hydrogen, optionally substituted C1-C3 alkyl, C1-C4 alkyloxycarbonyl; R2 is hydrogen, halogen or optionally substituted C1-C3 alkyl; R13 and R23 represent optionally alike: hydrogen, optionally substituted C1-C3 alkyl or R13 and R23 together with the nitrogen atom to which... Agent: Ivashtchenko Alexander Vasilievich

20110046150 - Use of n--4-(3-pyridyl)-2-pyridine-amine for the treatment of pulmonary hypertension: e

20110046151 - Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor: The present invention is directed to piperazinyl derivatives useful as inhibitors of the NPY Y2 receptor, pharmaceutical compositions comprising said compounds, processes for the preparation of said compounds and the use of said compounds for the treatment and/or prevention of disorders, diseases and conditions mediated by the NPY Y2 receptor.... Agent: Philip S. Johnson Johnson & Johnson

20110046152 - Amide compounds, preparation methods and uses thereof: The present amide compounds have broad spectrum activity of killing pests and are effective on lepidopteran pests including ostrinia nubilalis, sugarcane borer, adoxophyes orana fischer von reslerstamm, apple fruit borer, grapholitha inopinata, lymantri dispar l., cnaphalocrocis medinalis, ostrinia furnacalis, helicoverpa assulta, grapholitha inopinata, plutella xylostella, spodoptera exigua, prodenia litura etc.,... Agent: Smith, Gambrell & Russell

20110046153 - Medicaments: A compound of formal (I) is described: wherein R1 and R2 are as defined in the text and wherein the compounds are intended for use in treating medical conditions characterized by an imbalance in dopamine receptor activity.... Agent: Swanson & Bratschun, L.L.C.

20110046154 - Use of aminopeptidase inhibitors or azaindole compounds for preventing or treating cancerous metastases from epithelial origin: The invention relates to the use of a compound selected from an aminopeptidase-inhibiting compound and an azaindole compound for producing a drug for preventing or treating cancerous metastases in humans or animals.... Agent: Oliff & Berridge, PLC

20110046155 - Hydrobenzamide derivatives as inhibitors of hsp90: The invention provides an acid addition salt of a compound of the formula (1) Also provided by the invention are processes for preparing the compound of formula (1) and alkyl analogues thereof, novel intermediates for use in the process and methods for preparing the intermediates. The invention also provides new... Agent: Vedder Price P.C.

20110046156 - Treatment of hearing and balance impairments with redox-active therapeutics: Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing or balance impairments involving neuronal damage, loss, or degeneration, by administration of a therapeutically effective amount of a redox-active therapeutic. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having... Agent: Morrison & Foerster LLP

20110046159 - Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes: The present invention relates to arylpyrazinone derivatives of formula (I), wherein R1, R2, R3 and A are as defined in claim 1, as insulin secretion stimulators. The invention also relates to the preparation and use of these pyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.... Agent: Millen, White, Zelano & Branigan, P.C.

20110046158 - Capped pyrazinoylguanidine sodium channel blockers: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110046160 - Novel class of spiro piperidines for the treatment of neurodegenerative diseases: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.... Agent: Pfizer Inc. Patent Department

20110046157 - Substituted hydroxamic acids and uses thereof: wherein R1, R2, G, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or... Agent: Janice M. Klunder

20110046161 - Hcv ns3 protease inhibitors: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.... Agent: Merck

20110046162 - Fused cyanopyridines and the use thereof: The present application relates to novel substituted fused cyanopyridine derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, preferably for the treatment and/or prevention of cardiovascular disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20110046163 - Furanopyrimidine cannabinoid compounds and related methods of use: e

20110046165 - Certain chemical entitles, compositions and methods: Chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with P13 kinase activity are described herein.... Agent: Wilson, Sonsini, Goodrich & Rosati

20110046166 - Purine derivatives as a3 adenosine receptor-selective agonists: Disclosed are (N)-methanocarba adenine nucleosides, e.g., of formula (I) as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides exhibit similar selectivities as agonists of the A3 versus the A1... Agent: Leydig, Voit & Mayer, Ltd.

20110046164 - Purine derivatives for treatment of cystic diseases: Provided herein are methods of treatment of a cystic disease by administering a compound of Formula I. In certain embodiments, the compound for use in the methods provided herein is roscovitine or an analog thereof.... Agent: Jones Day

20110046167 - Acyclic amine inhibitors of 5-methytioadenosine phosphorylase and nucleosidase: The present invention relates to compounds of the general formula (I) which are inhibitors of 5′-methylthioadenosine phosphorylase or 5′-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5′-methylthioadenosine phosphorylase or 5′-methylthioadenosine nucleosidase including... Agent: Amster, Rothstein & Ebenstein LLP

20110046168 - Methods of treating diseases using quinazoline derivatives and pharmaceutical compositions containing them: particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20110046169 - Fused heterocyclic derivatives and use thereof: r

20110046170 - Novel pyrimidine-pyridine derivatives: The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.... Agent: Hoxie & Associates LLC

20110046171 - Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists: This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20110046172 - medicinal compositions: A composition, in parenteral unit dosage form or in a unit dosage form suitable for delivery via the dermis or mucosa, comprises buprenorphine and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone delivered to or reaching the plasma of a patient is in the... Agent: Troutman Sanders LLP 5200 Bank Of America Plaza

20110046173 - Combination analgesic opioid pain therapy: Provided are pharmaceutical compositions and methods for the alleviation of pain in a patient with ratios of morphine and oxycodone that provide lower incidence of adverse side effects compared to equi-analgesic doses of morphine and oxycodone alone. The pharmaceutical compositions comprise an analgesic amount of morphine and an analgesic amount... Agent: King & Spalding

20110046174 - Kappa-opiate agonists for the treatment of diarrhea-predominant irritable bowel syndrome: The present invention concerns methods useful in treating a subject having diarrhea-predominant IBS (IBS-D) by administering N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and/or a pharmaceutically acceptable salt thereof to the subject.... Agent: Morrison & Foerster LLP

20110046175 - Benzofuran cannabinoid compounds and related methods of use: e

20110046176 - Furanopyridine cannabinoid compounds and related methods of use:

20110046177 - Therapeutic quinoline and naphthalene derivatives: Disclosed herein is a stable compound having a structure formula (I): therapeutic methods, compositions, and medicaments related thereto are also disclosed.... Agent: Allergan, Inc.

20110046178 - Thiazolylpiperidine derivatives as fungicides: s

20110046179 - Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors:

20110046180 - N-aryl-n-piperidin-4-yl-propionamide derivatives and their use as opioid receptor ligands:

20110046181 - Short duration depot formulations: Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, depot gel compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a short duration of time. The... Agent: Thomas P. Mccracken Durect Corporation

20110046183 - Crystal of benzimidazole compound: Provided is a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole showing an X-ray powder diffraction pattern having characteristic peaks at interplanar spacings (d) of 10.06±0.2, 8.70±0.2, 6.57±0.2, 5.59±0.2 and 4.00±0.2 Angstroms. The present invention provides a stable antiulcer drug superior in the absorbability.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20110046182 - Efficient aspirin prodrugs: Aspirin is one of the most widely used drugs in the treatment of inflammation, pain and fever. It has more recently found application in the prevention of heart attacks and stroke and is being studied as a cancer chemopreventative agent. Despite its value aspirin continues to be underutilized because it... Agent: Choate, Hall & Stewart LLP

20110046184 - Solid state forms of racemic ilaprazole: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention... Agent: Nixon Peabody, LLP

20110046186 - 1-substituted pyridyl-pyrazolyl amide compounds and uses thereof: The present invention discoses a kind of 1-substituted pyridyl-pyrazolyl amide compounds and uses thereof. The compounds have structures as represented by the general formula I, wherein the definitions of each substituent showed in the specification. The compounds of formula I are novel and have excellent insecticidal and fungicidal activities and... Agent: Smith, Gambrell & Russell

20110046185 - Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof: The invention relates to compounds of formula (I) wherein the groups R and R′ A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.... Agent: Scully, Scott, Murphy & Presser, P.C.

20110046187 - Assessing congestive heart risk in patients treated or potentially to be treated with a peroxisome-proliferator-activator-receptor-gamma agonist or a thiazolidinedione: Methods are provided for assessing a patient being treated with a peroxisome-proliferator-activator-receptor-γ (PPAR-γ) agonist or a thiazolidinedione (TZD), or having a condition treatable with a peroxisome-proliferator-activator-receptor-γagonist or a thiazolidinedione. Methods include measuring a galectin-3 concentration or a change in a galectin-3 concentration in a body fluid of a patient being... Agent: K&l Gates LLP

20110046188 - Compositions comprising novel ppar ligands and anti-hyperlipemic agents: Methods are provided for treating or preventing conditions comprising hypertension and dyslipidemia using antihyperlipemic agents and compounds that antagonize the angiotensin II type 1 (AT1) receptor, function as partial or full activators of peroxisome proliferator activated receptors (PPARs) and lower triglycerides or elevate blood HDL-cholesterol. Compositions are provided for treating... Agent: Morrison & Foerster LLP

20110046190 - Combinations comprising a selective cyclooxygenase-2 inhibitor: A combination therapy for treating patients suffering from pre-malignant colon lesions (e.g. polyps) and colon cancer, as well as other malignancies, is disclosed. The patient is treated concurrently with a cycloocygenase-2 inhibitor and at least one compound selected from the group consisting of a microtubule interfering agent, an epithelial growth... Agent: Novartis Corporate Intellectual Property

20110046189 - Heteroaryl-substituted bicyclic smac mimetics and the uses thereof: The invention relates to heteroaryl-substituted bicyclic mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.... Agent: Casimir Jones, S.c.

20110046191 - Combination of a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist: The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist selected, and a second active ingredient which is a β2-adrenoceptor agonist, of use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20110046192 - Therapeutic drug for hypertension or prehypertension: The present invention also relates to a therapeutic method or a preventive method for hypertension or high-normal blood pressure, comprising administering the above (a) and (b) in amounts effective for treating or preventing hypertension or high-normal blood pressure.... Agent: Sughrue Mion, PLLC

20110046193 - Deferacirox dispersible tablets: The invention pertains to dispersible tablets comprising as active ingredient 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid or pharmaceutically acceptable salt thereof in an amount of from 5 to 40% in weight by weight of the total tablet.... Agent: Novartis Corporate Intellectual Property

20110046194 - 3-triazolylphenyl-substituted sulphide derivatives as acaricides and insecticides: e

20110046196 - Insecticidal fertilizer mixtures:

20110046195 - Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing: Compounds which modulate quorum sensing in quorum sensing bacteria. Compounds of the invention inhibit quorum sensing and/or activate quorum sensing in various bacteria. Compounds that inhibit quorum sensing are particularly useful for inhibition of detrimental bacterial biofilm formation. Compounds that activate quorum sensing are particularly useful for promoting growth and... Agent: Greenlee Sullivan P.C.

20110046197 - 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof: A method for treating an inflammatory process selected from the group consisting of oedema, erythema, articular inflammation, rheumatoid arthritis, arthrosis, a colorectal tumor, a pulmonary carcinoma, an adenocarcinoma, and combinations thereof, in a person in need thereof, the method comprising administering to the person in need thereof, in an amount... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110046198 - Ketorolac tromethamine compositions for treating or preventing ocular pain: The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than... Agent: Allergan, Inc.

20110046199 - Small molecule inhibitors of hiv proteases: Described herein are compounds, compositions, and methods for treating HIV and related diseases.... Agent: Barnes & Thornburg LLP

20110046210 - Substituted thiopenecarboxamides as ikk-beta serine-, threonine-protein kinase inhibitors: Compounds of formula (IA) or (IB) are IKK inhibitors useful in the treatment of autoimmune and inflammatory diseases: wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; A is an optionally substituted aryl or heteroaryl of 5-13 ring atoms; Z is a radical of formula R1C(R2)(R3)NH—Y-L1-X1-(CH2)z— wherein R1 is a carboxylic... Agent: Banner & Witcoff, Ltd.

20110046211 - Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents: The present invention relates to therapeutic combinations and methods of inhibiting the proliferation of cancerous cells, the abnormal growth of cells, and tumor cell growth using the combination of a hedgehog inhibitor with chemotherapy and/or radiation therapy. The present invention also relates to methods of enhancing the antiproliferative effect of... Agent: Andrus, Sceales, Starke & Sawall, LLP

20110046212 - Use of oleuropein and derivatives in the treatment of type 2 diabetes mellitus and pathologies associated with protein aggregation phenomena: This invention relates to the use of oleuropein, specifically oleuropein in non-glycated form, and its derivatives in the treatment of type 2 diabetes mellitus. Furthermore, this invention relates to the use of oleuropein, specifically oleuropein in non-glycated form, and its derivatives both from synthesis and from degradation, in the treatment... Agent: Abelman, Frayne & Schwab

20110046213 - Production of delta 9 tetrahydrocannabinol: Δ9 THC is obtained by extracting Δ9 THC and Δ9 THC carboxylic acid from plant material using a non-polar solvent and decarboxylating the Δ9 THC acid into Δ9 THC in the same solvent, without a solvent swap, in the presence of aqueous base. The Δ9 THC is then washed to... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20110046215 - Abnormal intraocular pressure treatment: Methods and compositions for reducing intraocular pressure in a patient, particularly a human patient, are described. In particular, compositions are disclosed that contain an anthocyanoside or an extract comprising it, a proanthocyanidin or an extract comprising it and combinations thereof. The compositions are useful for lowering intraocular pressure.... Agent: Hoffmann & Baron, LLP

20110046214 - Composition inhibiting sex hormone-binding globulin: A composition for inhibiting sex hormone-binding globulin, comprising isoflavones as active ingredients.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20110046216 - Stable compositions of dehydroascorbic acid: Stable liquid compositions containing the oxidized form of vitamin C known as dehydroascorbic acid are provided. The compositions comprise dehydroascorbic acid and a pharmacologically acceptable liquid organic polyol solvent for said dehydroascorbic acid, wherein said polyol solvent comprises about 50% or greater of the total weight of said composition. The... Agent: Douglas Q. Kitt

20110046217 - Use of 2,2'-cyclolignans for inducing, restoring or stimulating the pigmentation of the skin, hair or hairs: The invention relates to the use of 2,2′-cyclolignanes in the cosmetic or pharmaceutical field for inducing, restoring or stimulating the pigmentation of the skin, hair or hairs.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20110046218 - Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base: The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20110046219 - (het)aryl-p-quinone derivatives for treatment of mitochondrial diseases: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 2-(3-hydroxy-3-methyl-butyl)-6-(het)aryl-p-quinone or as 2-(3-hydroxy-3-methylbutyl)-3-(het)aryl-p-quinone derivatives. Energy biomarkers useful in... Agent: Morrison & Foerster LLP

20110046220 - Paraben compounds: The invention relates to a Microbulbifer bacterial strain isolated from a marine sponge, to its use in a process for manufacturing paraben compounds. The invention also relates to paraben compounds obtained from that Microbulbifer strain and to their uses. The Microbulbifer strain of the invention is Microbulbifer strain named L4-N2... Agent: Morgan Lewis & Bockius LLP

20110046221 - Therapeutic intervention to mimic the effect of caloric restriction: Methods are provided for promoting longevity and decreasing the incidence of aging associated pathologies (e.g., cancer) by the administration of one or more of the following LFFA: linoleic, oleic and palmitic acid. Secondary LFFA derived from this set, as well as their CoA derivatives and synthetic analogs, are effective also... Agent: Hunton & Williams LLP Intellectual Property Department

20110046222 - Fatty acid amides and uses thereof: Provided are fatty acid amides of amino acids, uses thereof and pharmaceutical compositions including them.... Agent: The Nath Law Group

20110046224 - Methods to accelerate muscle development, decrease fat deposits, and enhance feeding efficiency in pigs: A natural method to promote or enhance food efficiency and muscle/fat ratio in animals is described, particularly for pigs, through the administration of an effective amount of pure ferulic acid, substantially pure ferulic acid or ferulic acid formulations. Prepared food and formulations for animals are also described, which can increase... Agent: Conley Rose, P.C. David A. Rose

20110046223 - Treatment of neurofibromatosis: Disclosed are methods of treating neurofibromatosis by administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally, in combination with colchicine. Also disclosed are pharmaceutical compositions comprising FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof;... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20110046225 - Pharmaceutical formulation containing palmitoyl ethanolamide and stearoyl ethanolamide: The invention concerns new pharmaceutical formulations containing a blend of palmitoyl ethanolamide or PEA and stearoyl ethanolamide or SEA compounds as active principles. The formulation is suitable for oral, parenteral, topical, transdermic, rectal, sublingual, nasal, topical, transdermic, rectal, nasal or sublingual administration, whereby the dosage form of said formulations can... Agent: Themis Law

20110046226 - Pharmaceutical compositions for prevention of overdose or abuse: The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that... Agent: Blank Rome LLP

20110046229 - Controlled release drug delivery systems and pharmaceutical compositions formed therewith: The present invention relates to controlled release drug delivery systems. In one embodiment, the present invention relates to controlled release drug delivery systems comprising a combination of at least one polyacrylic acid and at least one enteric polymer. In another embodiment, the present invention relates to a controlled release pharmaceutical... Agent: The Lubrizol Corporation

20110046228 - Methods for administration of colchicine with grapefruit juice: Methods for safe administration of colchicine together with consumption of grapefruit juice are disclosed.... Agent: Cantor Colburn LLP

20110046227 - Methods for concomitant administration of colchicine and a second active agent: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., atorvastatin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together... Agent: Cantor Colburn LLP

20110046230 - Salt of dimethylaminomethyl-phenyl-cyclohexane and crystalline forms thereof: t

20110046231 - Solid forms of (±)-o-desmethylvenlafaxine salts: The present invention relates to solid forms of (±)-O-desmethylvenlafaxine salts, processes for preparation, pharmaceutical compositions, and method of treating thereof. More particularly, the present invention provides solid forms of acid addition salts of (±)-O-desmethylvenlafaxine wherein the acid counter ion is provided by an acid selected from the group consisting of... Agent: Cantor Colburn LLP

20110046232 - Orally dissolving formulations of memantine: Orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs) comprising memantine and methods of treating conditions, including childhood behavioral disorders and Alzheimer's disease, by administering orally dissolving formulations are provided. The orally dissolving formulations of the present invention may be used to treat various conditions, but is particularly suited to... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20110046233 - Gossypol derivatives, production method thereof and uses of same: R3, R4, R5 and R6 representing, independently of each other, —H or a carbon-containing group with 1 to 10 carbon atoms, saturated or unsaturated, optionally substituted with one or more heteroatomic groups. The invention also relates to pharmaceutical compositions containing these compounds, and their uses, in particular in the context... Agent: Young & Thompson

20110046234 - Retinaldehyde in the treatment of obesity, diabetes and other conditions: The present invention is directed to methods of treating a patient for a disease or condition associated with adipogenesis or insulin resistance by administering a retinaldehyde compound to the patient or a compound that increases endogenous retinaldehyde levels by inhibiting the enzyme retinaldehyde dehydrogenase 1.... Agent: Law Office Of Michael A. Sanzo, LLC

20110046235 - Products comprising, and uses of, decarboxylated phenolic acids derived from chlorogenic acids of coffee: The present invention relates to uses of decarboxylated phenolic acid derived from chlorogenic acid of coffee as well as products comprising decarboxylated phenolic acid derived from chlorogenic acid of coffee, especially a coffee extract, and methods of producing such products. Coffee comprises chlorogenic acids, according to the invention these chlorogenic... Agent: K&l Gates LLP

20110046236 - Alcoholic compositions having a lowered risk of acetaldehydemia: e

20110046237 - Compounds with activity at estrogen receptors: Disclosed herein are methods of treatment and prevention of diseases and disorders related to estrogen receptors comprising administering novel di-aromatic compounds to patients in need thereof.... Agent: Techlaw LLP

20110046238 - Calcium based carrier particles: The present invention relates to a method for forming a calcium-based carrier particle consisting of the calcium-based material, an active, with or without a surface modification, a stabilizing agent, and the related composition. The calcium-based particle is illustrated by the general formula Cax(PO4)y(OH)zR and may also include a silica or... Agent: Nalco Company

20110046239 - Calcium based carrier particles: The present invention relates to a method for forming a calcium-based carrier particle consisting of the calcium-based material, an active, with or without a surface modification, a stabilizing agent, and the related composition. The calcium-based particle is illustrated by the general formula Cax(PO4)y(OH)zR and may also include a silica or... Agent: Nalco Company

20110046241 - Calcium based carrier particles: The present invention relates to a method for forming a calcium-based carrier particle consisting of the calcium-based material, an active, with or without a surface modification, a stabilizing agent, and the related composition. The calcium-based particle is illustrated by the general formula Cax(PO4)y(OH)zR and may also include a silica or... Agent: Nalco Company

20110046240 - Calcium-based carrier particles: The present invention relates to a method for forming a calcium-based carrier particle consisting of the calcium-based material, an active, with or without a surface modification, a stabilizing agent, and the related composition. The calcium-based particle is illustrated by the general formula Cax(PO4)y(OH)zR and may also include a silica or... Agent: Edward O. Yonter Patent And Licensing Department

20110046242 - Film forming, silicone containing compositions: The invention relates to silicone containing compositions able to form adhesive films on substrates, which typically comprises a curable silicone formulation containing: (a) a polyorganosiloxane polymer having at least two functional SiVi groups per molecule, each SiVi group containing an alkenyl functionality directly bonded to a silicon atom; (b) a... Agent: Dow Corning Corporation Co1232

  
02/17/2011 > patent applications in patent subcategories. patent applications/inventions, industry category

20110039757 - Agonists of bitter taste receptors and uses thereof: The present invention relates to agonists of the human bitter-taste receptor hTAS2R3 and its role in bitter taste transduction. The invention also relates to assays for screening molecules that modulate, e.g. suppress or block hTAS2R3 bitter taste transduction or bitter taste response.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20110039758 - Molecular interactions in neurons: Inhibitors that disrupt binding between a PDZ protein and cognate ligands such as N-methyl-D-aspartate (NMDA) receptors that are involved in various neurological disorders are provided. Pharmaceutical compositions containing such inhibitors and their use in treating neurological diseases such as stroke and ischemia are also disclosed. Screening methods to identify additional... Agent: Townsend And Townsend And Crew, LLP

20110039759 - Use of secretin-receptor ligands in treatment of cystic fibrosis (cf) and chronic obstructive pulmonary disease (copd): The invention is based on the finding that the secretin receptor is expressed in tissues present in the distal lung of humans. In patient with CF, levels of the receptor are elevated compared to the normal tissue. Treatment of tissue by secretin stimulates the movement of negative ions in the... Agent: Novartis Institutes For Biomedical Research, Inc.

20110039760 - Multimeric forms of antimicrobial peptides: The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the... Agent: Cooley LLP Attn: Patent Group

20110039761 - Targeted antimicrobial moieties: This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.... Agent: Weaver Austin Villeneuve & Sampson LLP

20110039762 - Targeted antimicrobial moieties: This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.... Agent: Weaver Austin Villeneuve & Sampson LLP

20110039763 - Targeted antimicrobial moieties: This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.... Agent: Weaver Austin Villeneuve & Sampson LLP

20110039764 - Therapeutic composition for bone infectious disease: A biodegradable composition containing an antibiotic or a physiologically active substance for use in surgical treatment of infection. A highly safe and biocompatible composition showing appropriately sustained release of an antibiotic or physiologically active substance which produces excellent antibiotic and bone regenerating effects. A composition having excellent effects in treatment... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110039765 - Bioactive molecules produced by probiotic bacteria: The present invention is a method for isolating bioactive molecules secreted by probiotic bacteria such as Lactobacillus rhamnosus, and methods for using such bioactive molecules to decrease replication of human immunodeficiency virus, expression of inflammatory cytokines and chemokines, expression of vasoendothelial growth factor, Erk1/Erk2 activation, and to inhibit HIV transmission.... Agent: Licata & Tyrrell P.C.

20110039766 - Methods for preventing or treating metabolic syndrome: The invention provides methods of preventing or treating metabolic syndrome in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.... Agent: Foley & Lardner LLP

20110039768 - Fish protein hydrolysate having a satietogenic activity, nutraceutical and pharmacological compositions comprising such a hydrolysate and method for obtaining same,: The present invention relates to a fish protein hydrolysate containing molecules capable of exerting a satietogenic activity and of regulating food intake in humans or animals. More specifically, the protein hydrolysate according to the invention enables stimulation of the secretion of endogenous cholescystokinins (CCKs) and of endogenous glucagon-like peptide 1... Agent: Thorpe North & Western, LLP.

20110039767 - Food compositions: The present inventors have found that collagen hydrolysate can be favorably used for the preparation of an edible composition for limiting voluntary food intake and hence are suitable for prevention and treatment of overweight and obesity.... Agent: Nixon & Vanderhye, PC

20110039769 - Insulin albumin conjugates: Insulin albumin conjugates consisting of an insulin analogue, a bifunctional linker and albumin can efficiently be used to treat diabetic patients.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20110039770 - Inhibitors of protein kinase c isoforms and uses thereof: Inhibitors of mammalian protein kinase C isoforms that comprise an inhibitor moiety, which is capable of inhibiting protein kinase activity, operatively associated with a peptide recognition element (PRE), which has an affinity for one or more PKC isoforms are provided. The targeted inhibitory molecules (TIMs) of the present invention are... Agent: Dla Piper LLP (us)

20110039771 - Small humanin-like peptides: Novel peptides referred to as small humanin-like peptides (SHLPs) are provided herein along with nucleic acids encoding SHLPs and probes that selectively bind SHLPs. SHLPs have wide-ranging activity, including neuroprotective activity, anticancer activity, and cell survival activity. Also provided herein are therapeutic methods comprising administering an effective amount of an... Agent: Fenwick & West LLP

20110039772 - Novel uses of vegfxxxb: The invention provides VEGFxxxb, or an agent which selectively promotes the expression of VEGFxxxb in preference to VEGFxxx in cells of a subject or in vitro, or an expression vector system which causes the expression of the VEGFxxxb in a host organism, for use in treating or preventing neuropathic and... Agent: Harness, Dickey, & Pierce, P.l.c

20110039773 - Bmp mutants with decreased susceptibility to noggin: The present invention provides modified, highly potent bone morphogenetic proteins. In particular, the present invention relates to the observation that BMP-6 and BMP-9 are less susceptible to inhibition by Noggin that are other members of the BMP subfamily of proteins. The present invention features chimeric bone morphogenetic proteins in which... Agent: K&l Gates LLP

20110039774 - Method for repairing neurodegeneration: The present invention provides for treating neurodegeneration caused by nerve compression syndrome or entrapment neuropathy comprising administering human acidic fibroblast growth factor (aFGF), fibrinogen, aprotinin and divalent calcium ions to a subject in need thereof.... Agent: Occhiuti Rohlicek & Tsao, LLP

20110039775 - Thyroid stimulating hormone fusion proteins: We disclose TSH fusion proteins comprising TSHα and/or TSH β and methods to treat diseases that would benefit from administration of TSH agonists and antagonists.... Agent: Klarquist Sparkman, LLP

20110039776 - Fusion peptide therapeutic compositions: Therapeutic compositions containing fusion proteins (FPs) including elastin-like peptides (ELPs) and peptide active therapeutic agents, and methods of making and using such compositions and fusion proteins. Therapeutic compositions of such type enable improved efficacy of the peptide active therapeutic agent to be achieved, in relation to the peptide active therapeutic... Agent: Cooley LLP Attn: Patent Group

20110039777 - Cancer treatment using natriuretic peptides: The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (i.e., the type of cancer with the highest mortality, with patients only surviving four months) was observed responsive to treatment. The application... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20110039778 - Peptide synthesis: A process for producing an insulin type peptide, for example a relaxin, involving oxidizing a methionine residue on a B-chain having cysteine residues and combining the B chain with an A chain having cysteine residues to form a peptide having intermolecular disulphide links and biological activity. Novel synthetic relaxin 1... Agent: Hamilton Desanctis & Cha, LLP

20110039779 - Igf-1r binding proteins and antagonists: The present invention is drawn to new peptides and proteins that bind to human insulin-like growth factor-1 receptor (HIGF-IR), as well as nucleic acids encoding the same, vectors and cells comprising such nucleic acids, pharmaceutical compositions comprising such compounds, and methods of using any thereof, are provided.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20110039780 - Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof: The present invention provides compositions and methods for treating or preventing vascular-associated disorders.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20110039781 - Treatment of conditions related to cecal ligation shock: Techniques, methods and lavages are disclosed for prevention or treatment of shock, particularly cecal ligation or cecal inoculation shock, by administering a specific therapeutic agent, which is able to use smaller volumes of reagent to achieve partial to complete inhibition, than other previously described techniques. The agent includes a combination... Agent: Moazzam & Associates, LLC

20110039782 - Soybean protein material for patients with renal disease and foods made from the same: Provided is a soybean protein material suitable for patients with renal disease which is highly effective in delaying the progression of renal disease, and foods for patients with renal disease made from the soybean protein material. The invention was completed upon obtaining knowledge that, among the acid-precipitable soybean proteins, fractionated... Agent: Wenderoth, Lind & Ponack, L.L.P.

20110039783 - Peptide having hypotensive activity: The present invention provides a novel peptide having a physiological activity. Because of having a hypotensive activity, this novel peptide is useful in treating a disease caused by hypertension. Also, an antibody to the novel peptide is provided.... Agent: Drinker Biddle & Reath (dc)

20110039784 - Composition for treatment of erectile dysfunction: Disclosed herein is a therapeutic composition for erectile dysfunction comprising as an active ingredient a gene functioning to inhibit expression of an ion channel involved in influx of ions into a tissue. When expressed, the gene inhibits the activity of the ion channel to effectively block calcium influx. Accordingly, the... Agent: Knobbe Martens Olson & Bear LLP

20110039785 - Polypeptide-nucleic acid conjugates and uses thereof: The present invention is directed to polypeptide-nucleic acid conjugates. These conjugates can allow for targeted application of a therapeutic RNAi agent across the blood-brain barrier to treat, for example, a cancer, neurodegenerative disease, or lysosomal storage disorder.... Agent: Clark & Elbing LLP

20110039786 - Metastin derivative and use thereof: e

20110039787 - Compositions, kits and methods for treating benign prostate hyperplasia: The present disclosure is directed to compositions and kits comprising degarelix or a pharmaceutically acceptable salt thereof for the treatment of benign prostate hyperplasia (BPH), methods for treating BPH, and methods for preparing compositions of degarelix or a pharmaceutically acceptable salt thereof.... Agent: Finnegan/ferring, B.v.

20110039788 - Compositions, methods and kits for detecting and treating cancer: Compositions, kits and methods for inhibiting cancer cell (e.g., breast cancer cell) growth and treating a subject with cancer (e.g., breast cancer) include a therapeutically effective amount of an LBH inhibitor for inhibiting cancer cell growth and a pharmaceutically acceptable carrier, and/or a therapeutically effective amount of Wnt7a protein or... Agent: Gregory A. Nelson Novak Druce & Quigg LLP

20110039789 - Use of huntingtin protein for the diagnosis and the treatment of cancer: The present invention relates to new methods of treatment of cancer, in particular of breast cancer, and methods of screening of compounds useful in the treatment of cancer. The present invention further provides new prognostic and/or diagnostic markers in human cancer.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20110039790 - Enhanced ocular neuroprotection and neurostimulation: Use of topically applied cyclosporine to enhance corneal sensitivity restoration rate in an eye of an individual after ocular surgery such as laser-assisted in situ keratomileusis (LASIK) in which nerves are severed.... Agent: Allergan, Inc.

20110039791 - Acetylcholinesterase (ache)-derived peptide as an inducer of granulocytopoiesis, uses and methods thereof: The present invention describes the use of an AChE-R-derived peptide, also known as ARP, as an inducer of hemopoietic cell differentiation and expansion, specifically for the granulocytic population. In addition, the use of ARP as an inducer of thrombopoietin and pro-inflammatory cytokines is also presented. ARP may further be used... Agent: Fleit Gibbons Gutman Bongini & Bianco Pl

20110039792 - Selective targeting agents for mitochondria: The present invention provides a composition and related methods for delivering cargo to a mitochondria which includes (a) a membrane active peptidyl fragment having a high affinity with the mitochondria and (b) cargo. The cargo may be selected from a wide variety of desired cargos which are to be delivered... Agent: Hirshman Law, LLC

20110039793 - Application of ginsenoside rb1 in preparing medicaments for treating dilated cardiomyopathy: A method of preparing medicaments for treating dilated cardiomyopathy includes the step of applying ginsenoside Rb1. Long-term treatment of ginsenoside Rb1 can reduce the mortality rate, improve the cardiac function, reduce the dilation of the left ventricular, reduce the hypertrophy of myocytes and the proliferation of collagen, reduce the uneven... Agent: Zhen Zheng Lu

20110039794 - Long acting injectable formulations: Long acting injectable formulations of macrocyclic lactones comprising a biologically acceptable and biodegradable polyester polymer in a solvent system for use in the field of veterinary medicine, especially for use in combating ecto- and endoparasites in animals.... Agent: Intervet/schering-plough Animal Health

20110039795 - 2'-o,3'-n-bridged macrolides: Novel 2′-O,3′-N-bridged macrolides useful in treatment of inflammatory diseases. More particularly, the invention relates to 2′-O,3′-N-bridged 14-membered macrolides and to 2′-O,3′-N-bridged 15-membered azalide macrolides useful in treatment of neutrophil dominated inflammatory diseases resulting from neutrophilic infiltration and/or diseases associated with altered cellular functionality of neutrophils, to intermediates for their preparation,... Agent: Glaxosmithkline Global Patents

20110039796 - Natural composition for anti-angiogenesis and anti-obesity: The combination of gallic acid, ellagic acid, and rubusoside was shown to inhibit angiogenesis by inhibition of pro-angiogenic factors. These three compounds were shown to be absorbed from the intestine making the compounds orally bioavailable. The ratio of the three compounds in the composition was a weight ratio of approximately... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20110039797 - Oligomer conjugates of heteropentacyclic nucleosides: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer.... Agent: Nektar Therapeutics

20110039913 - Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression: Antisense compounds, compositions and methods are provided for modulating the expression of hydroxysteroid 11-beta dehydrogenase 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding hydroxysteroid 11-beta dehydrogenase 1. Methods of using these compounds for modulation of hydroxysteroid 11-beta dehydrogenase 1 expression and for treatment of... Agent: Jones Day For Isis Pharmaceuticals, Inc.

20110039915 - Immunostimulatory sirna molecules: The present invention relates to a double-stranded siRNA molecule that is capable of silencing gene expression as well as inducing an immune response. The molecule comprises a sense strand and an antisense strand, wherein the antisense strand comprises a first nucleotide sequence that is specifically complementary to mRNA transcribed from... Agent: Knobbe Martens Olson & Bear LLP

20110039911 - Method of inhibiting nonsense-mediated mrna decay: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD a composition comprising an eIF5A inhibitor compound in an amount effective to prevent intracellular hypusination of eIF5A, whereby gene expression of NMD-susceptible mRNA is increased.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20110039909 - Methods and materials for reducing gli2 expression: Methods and materials for reducing expression of GLI2 are disclosed including nucleic acid molecules such as short hairpin RNAs that direct cleavage of GLI2 encoding transcripts and the use of such molecules for reducing prostate cancer cell growth.... Agent: Allison Johnson, P.A.

20110039914 - Modified rnai polynucleotides and uses thereof: The invention relates to improved RNAi constructs and uses thereof. The construct has a double stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For... Agent: Wolf Greenfield & Sacks, P.C.

20110039910 - Modulation of apolipoprotein (a) expression: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided.... Agent: Jones Day For Isis Pharmaceuticals, Inc.

20110039912 - Therapeutic agent for neuroblastoma targeting arid3b: It is intended to provide a therapeutic agent for neuroblastoma. More particularly, it is intended to provide the therapeutic agent for neuroblastoma containing an ARID3b inhibitor.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20110039916 - Helper virus-free herpesvirus amplicon particles and uses thereof: The invention features new helper virus-free methods for making herpesvirus amplicon particles that can be used in immunotherapies, including those for treating any number of infectious diseases and cancers (including chronic lymphocytic leukemia, other cancers in which blood cells become malignant, lymphomas (e.g. Hodgkin's lymphoma or non-Hodgkin's type lymphomas). Described... Agent: Mckeon Meunier Carlin & Curfman LLC

20110039917 - High concentration chitosan-nucleic acid polyplex compositions: The invention provides highly concentrated chitosan-nucleic acid polyplex compositions and dispersions, and methods for producing the compositions and dispersions. Methods of mixing the chitosan-nucleic acid polyplexes include an inline mixing of chitosan solution and nucleic acid solution, followed by further concentrating the dispersion of chitosan-nucleic acid polyplexes, optionally with an... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20110039918 - Single nucleotide polymorphisms (snps) in genes associated with inflammatory diseases: The present disclosure describes the identification of single nucleotide polymorphisms (SNPs) in inflammatory diseases and uses thereof, and methods of screening for, diagnosing, identifying susceptibility to or detecting a risk of developing an inflammatory disease comprising detecting the presence or absence of at least one SNP identified in a gene... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20110039799 - A1 adenosine receptor agonist polymorphs: Provided are polymorphs of an A1 adenosine receptor partial agonist, compositions thereof, methods for their preparation, and methods for their uses.... Agent: Cv Therapeutics, Inc. Gilead Palo Alto, Inc.

20110039798 - Substituted nucleoside derivatives with antiviral and antimicrobial properties: The present invention relates to fatty acid and fatty alcohol substituted nucleoside derivatives and nucleoside and nucleoside derivatives substituted on multivalent scaffolds (e.g., polymers, peptides, polycarboxylic acid substituted compounds, compounds containing polycycloSaligenyl groups) that display potent anti-HIV activity. Furthermore, they show enhanced activity against multi-drug resistant, R5, and cell-associated virus.... Agent: Wilmerhale/dc

20110039800 - Prolonged release bioadhesive therapeutic systems: The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. Said bioadhesive therapeutic system comprises quantities of natural proteins representing at least 50%... Agent: Dechert LLP

20110039801 - Nk1 receptor antagonist composition: An NK1 receptor antagonist composition of the present invention uses maltooligosaccharide having an NK1 receptor antagonistic activity as an active ingredient. A suitable amount of the maltooligosaccharide to be blended in the NK1 receptor antagonist composition of the present invention is 0.000001 to 70% by weight. The NK1 receptor antagonist... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110039802 - Npy y5 antagonist:

20110039803 - Solid forms of an anti-hiv phosphoindole compound: Solid forms comprising a compound useful in the treatment, prevention and management of various conditions and diseases are provided herein. In particular, provided herein are solid forms comprising (2-carbamoyl-5-chloro-1H-indol-3-yl)-[3-((E)-2-cyano-vinyl)-5-methyl-phenyl]-(R)-phosphinic acid methyl ester, including salts thereof, having utility for the treatment, prevention and management of conditions and disorders including, but not... Agent: Jones Day

20110039804 - composition of risedronate and vitamin d3: The present invention is focused on compositions that contain risedronate and vitamin D as active ingredients. This dose combines the pharmaceutical properties of risedronate, which avoids bone degradation, and those from vitamin D, which fixates calcium to the bone, which are used for treating postmenopausal osteoporosis.... Agent: Williams Mullen

20110039805 - Method for treating meibomian gland disease: A method for treating a patient having meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion, is disclosed. Preferably, the method concerns treatment of a patient with topical tetracycline, a derivative or analogue of tetracycline, or a chemically modified tetracycline (CMT). Oral administration of... Agent: Ropes & Gray LLP

20110039806 - Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders: The present invention provides combinations of an antipsychotic drug and a tetracycline, particularly minocycline, for the treatment of psychotic disorders, particularly schizophrenia. The invention also provides formulations wherein the release of one or both of the antipsychotic drug and the tetracycline is modified. The invention also provides methods using the... Agent: Fennemore Craig

20110039807 - Anti-parkinsonian compound acetylsalicylic acid maltol ester: The present application describes a composition comprising a neuroprotective effective amount of an antioxidant acetylsalicylic acid maltol ester (AME).... Agent: Jhk Law

20110039808 - Multitarget compounds active at a ppar and cannabinoid receptor: There is a need for pharmaceutical compounds which have activity at, at least one of a PPAR and a cannabinoid receptor. Thus there are provided such compounds, wherein the compound comprises: a PPAR pharmacophore and a cannabinoid pharmacophore linked together by a moiety comprising a fused bicyclic ring comprising a... Agent: Goodwin Procter LLP Patent Administrator

20110039809 - Combined use of 25-hydroxy-vitamin d3 and vitamin d3 for improving bone mineral density and for treating osteoporisis: We disclose the combined use of vitamin D (cholecalciferol) and 25-OH D3 (calcifediol) to treat and/or prevent osteoporosis. One or more bisphosphonate compounds to inhibit bone resorption may also be used. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed.... Agent: Nixon & Vanderhye, PC

20110039811 - Treating hyperglycemia with 25-hydroxyvitamin d3: We disclose treating hyperglycemia in a human with 25-hydroxyvitamin D3 (calcifediol). Blood glucose is reduced to a level which is closer to normal than baseline. Vitamin D3 (cholecalciferol) may optionally be used together with 25-hydroxy vitamin D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing... Agent: Nixon & Vanderhye, PC

20110039810 - Use of 25-hydroxy-vitamin d3 to affect human muscle physiology: We disclose the use of 25-OH D3 (calcifediol) to increase muscle strength, muscle function, or both. Vitamin D3 (cholecalciferol) may optionally be used together with 25-OH D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed.... Agent: Nixon & Vanderhye, PC

20110039812 - N-alkylcarbonyl-d-amino hydroxyalkyl ester compounds and their use: The present invention pertains to certain N-alkylcarbonyl-D-amino acid hydroxylalkyl esters (NACHE), including, for example, (R)-2-[((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-propionic acid 3-hydroxy-propyl ester, and compositions comprising such compounds, that target sensory elements on nerve fibers and which are usefully administered to refresh and cool the skin and mucous membranes. This disclosure generally relates to menthol-like... Agent: Glaxosmithkline Global Patents -us, Uw2220

20110039813 - Method of utilization of combination of benzophenone derivative or salt thereof and immunosuppressing agent, and pharmaceutical composition comprising these components: Disclosed are use of a benzophenone derivative represented by general formula (I) or a salt thereof and one or more immunosuppressing agents in combination, and a pharmaceutical composition containing the benzophenone derivative or a salt thereof and one or more immunosuppressing agents. The use and the composition are useful for... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110039814 - Lipid composition: We describe lipid based pharmaceutical compositions adapted for oral delivery and optionally delivery in accordance with a circadian rhythm.... Agent: Klarquist Sparkman, LLP

20110039815 - Macrocyclic metal complexes for their use as anticancer agents: In one embodiment the present invention relates to a method of treating cancerous cells in a mammal comprising the steps of administering to the cancerous cells an effective amount of a cyclic amine wherein the cyclic amine contains sulfur or nitrogen and the structure includes an interchealted metal ion.... Agent: Joseph J. Crimaldi Roetzel & Andress

20110039816 - Therapeutic substance, pharmaceutical composition, helicobacter pylori growth inhibitor and method for conducting anti-helicobacter therapy: The invention belongs to the area of medicine and can be used as a therapeutic substance and as an inhibitor of the growth of Helicobacter pylori during anti-helicobacter therapy. The invention targets the development of a new therapeutic substance that does not cause adverse reactions or side effects in the... Agent: Sughrue Mion, PLLC

20110039818 - Dosage regimen of an s1p receptor agonist: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.... Agent: Novartis Corporate Intellectual Property

20110039819 - Substituted phenoxybenzamides: The present invention relates to substituted phenoxybenzamide compounds of general formula (I): in which R1, R2, R3, R4, R5, X, R6 and q are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds... Agent: Barbara A. Shimei Director, Patents & Licensing

20110039821 - Fused phenyl amido heterocyclic compounds: Ring A, ring B, ring C, R1, R1a, R2, R3, R4, L2, n, t, w, and z are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of glucokinase,... Agent: Pfizer Inc. Patent Department

20110039822 - Heterocyclic janus kinase 3 inhibitors: In other words, it is verified that the compound according to the present invention has an inhibition activity against JAK3 and is thus useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g., rejection during organ/tissue transplantation, autoimmune diseases, multiple... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110039820 - Lactam compounds useful as protein kinase inhibitors: The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.... Agent: Millennium Pharmaceuticals, Inc.

20110039817 - 4-aminopyrimidine derivatives as histamine h4 receptor antagonists: 4-Aminopyrimidine derivatives of formula (I) that are useful as histamine H4 receptor antagonists.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20110039823 - Oxazolidinone antibiotics: The invention relates to compounds of formula (I) wherein U, V, W, X, R1, R2, R3, R4, R5, R6, A, B, D, E, G, m, and n are as defined in the description, to pharmaceutically acceptable salts of such compounds for use in the manufacture of a medicament for the... Agent: Hunton & Williams LLP Intellectual Property Department

20110039824 - 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors: Provided are certain 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate compounds which are useful for modulating the activity of nuclear receptors, such as farnesoid X receptors, and/or for the treatment, prevention, or amelioration diseases or disorders related to the activity of these receptors.... Agent: Wyeth LLC/finnegan Henderson, LLP

20110039825 - Ligands of alpha-adrenoceptors, dopamine, histamine, imidazoline and serotonin receptors and their use: The invention also relates to active ingredients, pharmaceutical compositions comprising the said ligands as active ingredients; to novel medicaments useful for treatment of diseases and conditions of central nervous system (CNS) of humans and warm-blooded animals.... Agent: Sughrue Mion, PLLC

20110039826 - Pharmaceutical compositions for the treatment of cancer and other diseases or disorders: or a pharmaceutically acceptable salt thereof, that are suitable for the bulk production of an oral pharmaceutical dosage form; processes for the production of said oral pharmaceutical dosage form; and the use of the pharmaceutical composition for the treatment of patients suffering from or subject to diseases, disorders, or conditions... Agent: Eileen J. Ennis Millennium Pharmaceuticals, Inc.

20110039827 - Substituted hydroxamic acids and uses thereof: wherein R1, R2, G, m, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases... Agent: Janice M. Klunder

20110039828 - Tetrahydroquinoline derivatives and a process for preparing the same: wherein R1 is alkoxycarbonyl or the like, R2 is alkyl or the like; R3 is hydrogen or the like; R4 is alkylene or the like; R5 is optionally substituted heterocyclic group; R6, R7, R8 and R9 are independently hydrogen; alkyl, alkoxy, or the like; R10 is optionally substituted aromatic ring,... Agent: Birch Stewart Kolasch & Birch

20110039833 - 1-benzoyl substituted diazepine derivatives as selective histamine h3 receptor agonists: The present invention relates to novel diazepanyl derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.... Agent: Glaxosmithkline Global Patents

20110039831 - 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives: wherein the substituents are as defined in the specification, the application of a compound of formula (I) in a process for the treatment of the human or animal body, in particular with regard to C-Met tyrosine kinase mediated disease; the use of a compound of formula (I) for manufacturing a... Agent: Novartis Institutes For Biomedical Research, Inc.

20110039830 - Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals: wherein A, R, R10, R20, R30, R40, n, p and q have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they inhibit the enzyme renin and modulate the activity of the renin-angiotensin system, and are useful for the treatment of diseases such as hypertension, for... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20110039832 - Dihydro)pyrrolo[2,1-a]isoquinolines: The invention relates to 5,6-dihydropyrrolo[2,1-a]isoquinoline and pyrrolo[2,1-a]isoquinoline derivatives according to general formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility.... Agent: Organon Usa, Inc. C/o Merck

20110039829 - Pyrazole-carboxamide derivatives as p2y12 antagonists: R1; R2; Z; A; B; D; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable, e.g., for the therapy... Agent: Scully, Scott, Murphy & Presser, P.C.

20110039834 - Novel pharmaceutical compositions for optimizing substitution treatments and extending the pharmacopoeia to global treatment of addictions: ;

20110039835 - Substituted arylamide diazepinopyrimidone derivatives:

20110039836 - Tricyclic antibiotics:

20110039837 - Oxadiazoanthracene compounds for the treatment of diabetes:

20110039839 - Cyanopyrroles: wherein, T is O, S, or absent; R1, and R2 are each, independently, hydrogen, alkyl, substituted alkyl; or R1 and R2 are taken together form a ring and together contain —CH2(CH2)nCH2—, —CH2CH2CMe2CH2CH2—, —O(CH2)pCH2—, —O(CH2)qO—, —CH2CH2OCH2CH2—, or —CH2CH2NR7CH2CH2—; n=1-5; p=1-4; q=1-4; R3 is hydrogen, OH, NH2, alkyl, substituted alkyl, alkenyl, substituted... Agent: Howson & Howson LLP / Wyeth LLC

20110039838 - Pyrrolotriazine compounds as kinase inhibitors: e

20110039840 - Spirocyclic derivatives as histone deacetylase inhibitors: This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; n is zero or an integer from 1 to 4; R1 is hydrogen; C1-C6 alkyl, optionally substituted by cycloalkyl, aryl or by heteroaryl; (CO)R3; (SO2)R4; cycloalkyl;... Agent: Mccormick, Paulding & Huber LLP

20110039841 - Novel compounds, their preparation and use: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular... Agent: High Point Pharmaceuticals, LLC

20110039842 - Compounds having antiviral properties: The present invention provides a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. The present invention further provides a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of formula (I)... Agent: Fish & Richardson P.C. (ny)

20110039843 - Harmful arthropod control composition, and fused heterocyclic compound: Disclosed is a harmful arthropod control composition comprising, as an active ingredient, a fused heterocyclic compound represented by formula (1) [wherein A1 and A2 independently represent a nitrogen atom or the like; R1 and R4 independently represent a halogen atom or the like; R2 and R3 independently represent a halogen... Agent: Panitch Schwarze Belisario & Nadel LLP

20110039845 - 2-aminoquinazoline derivative: A 2-aminoquinazoline derivative represented by formula (I) {wherein R1 represents a hydrogen atom, or the like, R2 represents a hydrogen atom, R3 represents formula (II) [wherein A1 represents formula (III), or the like, R8 represents lower alkyl, or the like, and R9 represents optionally substituted aryl, or the like], R4... Agent: Sughrue-265550

20110039844 - 6-7,dialkoxy quinazoline derivatives useful for treatment of cancer related disorders: In view of the great potential the quinazoline class of compounds offer, we started the synthesis and screening of a large number of new chemical entities with novel structural features. It has been surprisingly and unexpectedly found that quinazolines having 3-Ethynyl anilino group at the 4th position and specifically substituted... Agent: Merchant & Gould PC

20110039846 - Iminopyridine derivatives and use thereof: The present invention aims to provide an iminopyridine derivative compound having an α1D adrenergic receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like. The present invention provides a compound represented by the formula wherein each symbol... Agent: Sughrue Mion, PLLC

20110039847 - Amide derivatives as sirtuin modulators: Provided herein are novel sirtuin-modulating compounds represented by Structural Formula (I) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or... Agent: Ropes & Gray LLP Iprm - Floor 43

20110039848 - Five-membered ring compound: o

20110039849 - 5-substituted-2-imino-thiazolidinone compounds and their use as inhibitors of bacterial infection: A method for inhibiting Gram-negative bacterial pathogenesis, a method of screening for compounds that inhibit type III secretion in Gram-negative bacteria, and compounds that inhibit type III secretion in Gram-negative bacteria.... Agent: Christensen O'connor Johnson Kindness PLLC

20110039850 - Leukemia treatment: A combination of a BCR-ABL inhibitor and a hedgehog pathway inhibitor for the treatment of leukemia.... Agent: Novartis Corporate Intellectual Property

20110039851 - Ccr10 antagonists: or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein R1 to R11, W, X, Y, Z, and n are as defined herein. The invention also relates to methods of using the compounds of formula (I) and compositions thereof to treat various diseases and disorders in a patient. The... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20110039852 - N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating... Agent: Wilson, Sonsini, Goodrich & Rosati

20110039853 - N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly... Agent: High Point Pharmaceuticals, LLC

20110039854 - Linear and cyclic guanidine derivatives, method of preparation and uses thereof: The present invention relates to linear and cyclic guanidine derivatives, method of preparation and uses thereof, pharmaceutical compositions to be used as antifungal agents, in particular against Candida species.... Agent: Lucas & Mercanti, LLP

20110039855 - Tetrahydrocyclopenta[b]indole androgen receptor modulators: The present invention provides a compound of the Formula (I), or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating or preventing physiological disorders, particularly reduced bone mass, osteoporosis, osteopenia, reduced muscle mass... Agent: Eli Lilly & Company

20110039857 - Piperidine and pyroolidine compounds: e

20110039856 - Polymorphs of a c-met/hgfr inhibitor: This invention relates to polymorphs of 2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to compositions including such salts and polymorphs, and to methods of using such compositions in the treatment of abnormal cell growth in mammals, especially... Agent: Pfizer Inc

20110039858 - Novel compounds: R3 is hydrogen or fluoro; R4 is —NH2 or —NHSO2R5; and R5 is hydrogen, —CF3, or C1-C6 alkyl, or pharmaceutically acceptable salts thereof; at least one process for making at least one compound in accordance with Formula I; at least one method for treating at least one δ receptor associated... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20110039859 - Susceptibility to bone damage: In one aspect, the present invention provides methods for determining susceptibility to bone damage in a subject. In some embodiments, the methods comprise screening for polymorphisms in the MTHFR and collagen Iα1 genes that are associated with susceptibility to bone damage. In some embodiments, the methods comprise screening for elevated... Agent: Sheridan Ross PC

20110039860 - Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment: Compounds of the formula (I) or a pharmaceutically acceptable salt or solvate thereof is disclosed. The compounds are useful for treating diabetes, inflammation, atherosclerosis, hypertension, pain and the like. Pharmaceutical compositions and methods of use are also included.... Agent: Merck

20110039861 - Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals: wherein A, R, R10, R20, R30, R40, Y1, Y2, Y3, Y4, n, p and q have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they inhibit the enzyme renin and modulate the activity of the renin-angiotensin system, and are useful for the treatment of diseases... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20110039862 - Protease inhibitors: e

20110039863 - Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis: The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20110039864 - Therapeutic compounds: Disclosed herein is an alpha-adrenergic compound having a structure. Therapeutic methods, compositions, and medicaments for treating pain are also disclosed herein.... Agent: Allergan, Inc.

20110039865 - Phenyl(oxy/thio)alkanol derivatives: The present invention relates to novel phenyl(oxy/thio)alkanol derivatives, to processes for preparing these compounds, to compositions comprising these compounds and to their use as biologically active compounds, in particular for controlling harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20110039867 - Pyrimidine derivatives which are antagonist of the vitronectin receptor: e

20110039866 - Selective sphingosine-1-phosphate receptor antagonists: Described herein are compounds useful as antagonists of sphingosine-1-phosphate receptors. Further described herein is the use of these compounds and related pharmaceutical compositions to treat disorders associated with sphingosine-1-phosphate-3 (S1P3) receptor modulation.... Agent: Allergan, Inc.

20110039868 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Wilson, Sonsini, Goodrich & Rosati

20110039869 - Composition for inhibiting the activity of inositol 1,4,5-triphosphate receptor subtype iii: An agent for inhibiting the activity of inositol-1,4,5-triphospate receptor subtype 3 (IP3R3), containing caffeine and/or its analogs, and/or their pharmaceutically acceptable salts, as an active ingredient, is provided. A composition for preventing and/or treating a disease associated with Ca2+ release through IP3R3, containing the IP3R3 inhibiting agent, is also provided.... Agent: LexyoumeIPGroup, PLLC

20110039870 - Tetrahydro-pyrazolo[1,5-a]pyrido-pyrimidines as antagonists of serotonin 5-ht6 receptors, methods for the production and use thereof:

20110039871 - Process for preparing bosentan: The present invention relates to a novel intermediate useful in the preparation of bosentan and to processes for the preparation of said intermediate and bosentan. The invention further relates to compositions comprising bosentan prepared according to the processes of the invention and their use in the treatment of endothelin-receptor mediated... Agent: Hunton & Williams LLP Intellectual Property Department

20110039872 - Deuterium-enriched capecitabine: The present application describes deuterium-enriched capecitabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20110039873 - Substituted pyrazolo[1,5-a] pyridine compounds having multi-target activity: e

20110039874 - Monoacylglycerol lipase inhibitors for modulation of cannabinoid activity: Disclosed are compounds and compositions that inhibit the action of monoacylglycerol lipase (MGL) and fatty acid amide hydrolase (FAAH), methods of inhibiting MGL and FAAH, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors.... Agent: Wilmerhale/boston

20110039875 - Pharamaceutical compositions for treating chronic pain and pain associated with neuropathy: The present invention provides methods and compositions for the treatment of neuropathic pain. In certain embodiments, compositions comprising an dextromethorphan (or other N-methyl-D-aspartate receptor antagonist), tramadol, and gabapentin can synergistically act to reduce pain in a human patient. Pharmaceutical compositions may also comprise a capsaicinoid, an esterified capsaicinoid, and/or a... Agent: John M. Hammond Patent Innovations LLC

20110039876 - Solution formulations of sirolimus and its analogs for cad treatment: Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed... Agent: Philip S. Johnson Johnson & Johnson

20110039877 - Use of 3, 11b-cis-dihydrotetrabenazine in the treatment of multiple sclerosis and autoimmune myelitis: The invention provides a compound for use in treating multiple sclerosis wherein the compound is a 3, 11b-cis-dihydrotetrabenazine of the formula (Ia): or a pharmaceutically acceptable salt thereof.... Agent: Schwegman, Lundberg & Woessner, P.A.

20110039880 - Aryl substituted sulfonamide compounds and their use as anticancer agents: e

20110039881 - Compositions and methods for treating middle-of-the-night insomnia: The present invention provides compositions and methods for treating middle-of-the-night insomnia without residual sedative effects upon awakening by dosing an amount of zolpidem or a salt thereof to a subject who awakens from sleep and desires to resume sleep for less than 5 hours. The step of dosing is performed... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-13-a7

20110039879 - Methods for increasing white blood cells: The present invention relates to methods and compounds useful for increasing white blood cell levels in blood and bone marrow. Methods and compounds for increasing hematopoietic progenitor cells are also provided.... Agent: Fibrogen, Inc.

20110039878 - Methods for reducing blood pressure: The present invention provides methods and medicaments for reducing blood pressure. Methods and medicaments for treating or preventing hypertension are also provided.... Agent: Fibrogen, Inc.

20110039882 - Phosphodiesterase 10a inhibitor: e

20110039883 - Azolopyridin-2-one derivatives as lipase and phospholipase inhibitors: wherein the substituents are as defined herein. The compounds of formula I wherein R2 is hydrogen are distinguished by favorable effects on disorders of lipid metabolism. They beneficially influence the HDL to LDL ratio and increase in particular the HDL level and are suitable for the prevention and treatment of... Agent: Scully, Scott, Murphy & Presser, P.C.

20110039884 - Imidazopyridinones: e

20110039885 - Methods for increasing endothelial progenitor cells: The present invention relates to methods and compounds useful for increasing endothelial progenitor cell levels in blood and bone marrow. Methods and compounds for increasing endothelial progenitor cell mobilization are also provided.... Agent: Fibrogen, Inc.

20110039886 - Enhanced erythropoiesis and iron metabolism: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.... Agent: Fibrogen, Inc.

20110039887 - Carbostyril derivatives including cilostazol for treating fatty liver: The invention relates to a medicament for preventing and/or treating fatty liver which comprises as an active ingredient cilostazol or a pharmaceutically acceptable salt thereof.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20110039888 - Asymmetric alpha functionalization and alpha, alpha bisfunctionalization of aldehydes and ketones: The present invention relates, generally, to asymmetric α-functionalization and to asymmetric α,α-bisfunctionalization of ketones and aldehydes and, in particular, to chiral auxiliaries suitable for use in effecting such functionalizations and to methods of using same.... Agent: Nixon & Vanderhye, PC

20110039889 - Compounds: The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.... Agent: Glaxosmithkline Global Patents

20110039890 - 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine: The compound 4-[2,3-Difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine according to the structure (formula I), and pharmaceutically acceptable salts thereof are provided for the treatment of CNS related disorders, such as: depressive disorder, dysthymic disorder; mood disorder due to a general medical condition; atypical depression; seasonal affective disorder; melancholia; treatment resistant depression; partial responders; depression associated... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20110039891 - Methods for treating a disease in which rho kinase is involved: wherein the ring X is a benzene ring or a pyridine ring; R1 and R2 are hydrogen or alkyl or together form a cycloalkene ring; R3 is hydrogen, substituted alkyl, unsubstituted alkenyl, carboxyl or an ester or an amide thereof, amino or a cyano; R4 is hydrogen, hydroxyl, substituted or... Agent: Holtz, Holtz, Goodman & Chick PC

20110039892 - Iminopyridine derivative and use thereof: e

20110039893 - Gsk-3beta inhibitor:

20110039894 - Substituted enaminothiocarbonyl compounds: The present application relates to novel substituted enaminothiocarbonyl compounds, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20110039895 - Prolyl hydroxylase inhibitors: e

20110039896 - Novel 2-pyrrolidinyl-3-amido-6-amino-pyridine derivatives useful as potassium channel activators: This invention relates to novel 2-pyrrolidinyl-3-amido-6-amino-pyridine derivatives having medical utility, to use of the 2-pyrrolidinyl-3-amido-6-amino-pyridine derivatives of the invention for the manufacture of a medicament, to pharmaceutical compositions comprising the 2-pyrrolidinyl-3-amido-6-amino-pyridine derivatives of the invention, and to methods of treating a disorder, disease or a condition of a subject, which... Agent: Birch Stewart Kolasch & Birch

20110039897 - Liquid formulation for deferiprone with palatable taste: An oral pharmaceutical liquid formulation comprising deferiprone and a taste masking composition, said taste masking composition comprising an effective amount of a sweetener (such as sucralose) per litre of liquid composition, an effective amount of a thickening and suspension aid, (for example hydroxyethylcellulose), per litre of liquid composition, an effective... Agent: Mckinnons Patents Inc

20110039898 - Method for scavenging free radicals and inhibiting tyrosinase and melanin:

20110039899 - Gabapentin for the treatment of overactive bladder, stress incontinence and bph: Use of an alpha-2-delta ligand, or a pharmaceutically acceptable derivative thereof, for the manufacture of a medicament for the treatment of LUTS, other than urinary incontinence, associated with OAB and/or BPH.... Agent: Pfizer Inc. Patent Department

20110039900 - Isothiozoles for treating conditions of the eye: Disclosed herein are isothiozoles for treating conditions of the eye.... Agent: Allergan, Inc.

20110039901 - Process for preparing a crystalline form compound of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one: A process for preparing a crystalline form compound of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one is described, comprising the step of reacting 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one and fumaric acid in one or more solvents, wherein at least one solvent is a solvent having a carbon atom number of from 3 to 6, said solvent being non-halogenated and having... Agent: Steinfl & Bruno

20110039902 - Process for preparing a crystalline form compound of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one: A process for preparing a crystalline form compound of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one is described, comprising the step of reacting 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydroben-zo[d]isoxazol-4-one with oxalic acid in one or more solvents, wherein at least one solvent is a solvent having a carbon atom number of from 3 to 6, said solvent being non-halogenated and having... Agent: Steinfl & Bruno

20110039903 - Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning: Methods for treating an individual with a psychiatric disorder with a pharmacologic agent that enhances learning or conditioning in combination with a session of psychotherapy are provided. These methods of the invention encompass a variety of methods of psychotherapy, including exposure-based psychotherapy, cognitive psychotherapy, and psychodynamically oriented psychotherapy, and psychiatric... Agent: Jason P. Mcdevitt

20110039904 - Alcohol alkoxylates, agents comprising the same and use of the alcohol alkoxylates as adjuvants in the agrochemical field: t

20110039905 - Benzimidazole derivatives as calcium channel blockers:

20110039906 - Antibacterial combination therapy: There is described a composition comprising a therapeutically active imidazole, or a derivative thereof, and disulfiram, or a derivative thereof, for treating an infection contributed to or caused by multi-drug resistant bacterial species.... Agent: K&l Gates LLP

20110039907 - Ant control: The present invention relates to a method of ant control using mixtures of fipronil and lambda-cyhalothrin. The invention also relates to a method of reducing the foraging activity of ants using said mixtures.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20110039908 - Inhibiting amyloid-beta peptide/rage interaction at the blood-brain barrier: Small molecules are used to inhibit specific receptor-ligand interaction between Alzheimer's amyloid-β peptide (Aβ) and Receptor for Advanced Gly-cation Endproducts (RAGE). Objectives include treating Alzheimer's disease and other pathologies involving cerebral amyloid angiopathy; improving blood flow to or within the brain; decreasing the level of Aβ in the brain; reducing... Agent: Nixon & Vanderhye, PC

20110039919 - Pharmaceutical compositions for inhibiting angiogenesis: Provided is a pharmaceutical composition for inhibiting angiogenesis, comprising a therapeutically effective amount of a compound represented by Formula 1: (I) wherein R1 through R13 and X are as defined in the specification. Compounds used as an active ingredient in the pharmaceutical composition of the present invention bind to QP-C... Agent: Alston & Bird LLP

20110039920 - Inhibitors of ikk-beta serine-theronine protein kinase: Cyclopentyl(2S,4E)-2-amino-5-{3-[4-carbamoyl-5(carbamoylamino)-2-thienyl]phenyl}pent-4-enoate; Cyclopentyl 5-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-norvalinate; Cyclopentyl(2S,4E)-2-amino-5-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-5-methylphenyl}pent-4-enoate; Cyclopentyl(25,4E)-2-amino-5-{5-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-2-methylphenyl}pent-4-enoate; Cyclopentyl O-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-homoserinate; Cyclopentyl O-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-homoserinate; Cyclopentyl N-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl}-L-alaninate; and tert-Butyl N-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl}-L-alaninate are hydrolysed to the corresponding carboxylic acids by intracellular carboxylesterases, and are useful for the inhibition of IKKβ activity.... Agent: Banner & Witcoff, Ltd.

20110039921 - Cephalomannine derivatives, their preparation, pharmaceutical composition and use thereof: The present invention discloses cephalomannine derivatives of general formula (I), a process for preparation of such cephalomannine derivatives, a composition containing such compounds, and use of said compounds in the manufacture of a medicament for the treatment of tumors, especially multidrug resistant tumors.... Agent: Scully Scott Murphy & Presser, PC

20110039922 - 18beta-glycyrrhetinic acid derivatives and synthetic method thereof: e

20110039923 - Novel standardized composition, method of manufacture and use in the resolution of rna virus infection: The present disclosure is in relation to antiviral preparations obtained from plant sources namely Cinnamon, Litchi and Arachis. It provides a composition and a process to prepare the composition comprising pentameric procyanidin flavonoid, trimers and tetramers. The composition improves immunity response and found to be useful in treatment and management... Agent: Harness, Dickey & Pierce, P.L.C

20110039924 - Alpha-amino acid derivatives for improving solubility: The invention relates to the use of α-amino acid derivatives for improving the solubility of poorly soluble substances in water or aqueous solutions and to mixtures and preferred preparations.... Agent: Millen, White, Zelano & Branigan, P.C.

20110039925 - Cyclobutyl sulfones as notch sparing gamma secretase inhibitors: The invention encompasses a novel class of cyclobutyl sulfone derivatives which inhibit the processing of APP by the putative γ-secretase while sparing Notch signaling pathway, and thus are useful in the treatment or prevention of Alzheimer's disease without the development of Notch inhibition mediated gastrointestinal issues. Pharmaceutical compositions and methods... Agent: Merck

20110039926 - Use of enantiomer (1s, 2r) milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients: The invention concerns the substantially pure (1S,2R) enantiomer of milnacipran hydrochloride for its use for treating patients suffering from psychiatric disorders, while reducing the risk of suicidal behaviour or ideation in said patients, and/or for limiting the risk of suicidal behaviour induced by the treatment with one or several SSRIs... Agent: Birch Stewart Kolasch & Birch

20110039927 - Compositions comprising and processes for producing inorganic salts of hop acids: The invention relates to compositions and processes for producing novel hop acid formulations having improved bioavailability, and the use of such compositions as anti-inflammatory agents, dietary supplements, and pharmaceuticals.... Agent: Edwards Angell Palmer & Dodge LLP

20110039928 - Cetylated fatty acid and alkali buffered creatine anti-inflammatory composition: An anti-inflammatory composition for treatment of inflamed joints. This composition includes an alkali buffered creatine and a cetylated fatty acid. The composition can be used for treating inflammation either by oral ingestion or by topical treatment.... Agent: Richard C. Conover

20110039929 - Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides... Agent: Schwegman, Lundberg & Woessner, P.A.

20110039930 - Fast-acting naproxen composition with reduced gastrointestinal effects: The present invention relates to pharmaceutical formulations containing Naproxen and a delivery agent.... Agent: Jay Lessler Blank Rome LLP

20110039931 - Method of treating animal's exterior for cleaning and/or insect repellency: A method of treating animals to reduce the presence of annoying insects around the animal, help clean the animal's exterior, add luster and sheen to the animal's coat or hide, and provide stain repellency includes the application of a gelled composition to the exterior of an animal The composition includes... Agent: Clark & Brody

20110039932 - Polyunsaturated fatty acid monovalent and divalent metal salt synthesis: Methods for the preparation of a free-flowing, storage-stable fatty acid metal salt product by forming a reactive admixture of (a) an unsaturated fatty acid glyceride feedstock; and (b) from about 1 mol to about 3 mol of at least one monovalent metal hydroxide or at least one divalent metal hydroxide;... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20110039933 - S1p-1 receptor agonists: The invention provides compounds formula (I), their preparation, and their use as pharmaceutically active immuno-suppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SIP receptors.... Agent: Glaxosmithkline Global Patents

20110039934 - Process for the preparation of derivatives of 1-(2- halobiphenyl-4-yl)-cyclopropanecarboxylic acid: e

20110039935 - Use of pharmacologically active chemical compounds: The present invention relates to the new use of alpha-ketoglutarate, amides, and salts and mixtures thereof for the manufacture of a pharmaceutical preparation or a food or feed supplement for the in vivo therapeutic improvement of blood vessel elasticity, in particular arterial elasticity in a subject in need thereof. Improving... Agent: Morrison & Foerster LLP

20110039936 - N-substituted benzenepropanamide or benzenepropenamide derivatives for use in the treatment of pain and inflammation: Compounds for use in the treatment or prophylaxis of pain, including acute and chronic pain (e.g., nociceptive pain, neuropathic pain, headaches, migraine), represented by general formula (I) in which: the dotted line represents a single or a double bond; and R5 and R5′ are independently —H, —OH or —OR6, where... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20110039937 - Novel process for the preparation of vorinostat: The present invention relates to an improved process for the preparation of the active pharmaceutical ingredient, vorinostat. In particular it relates to an efficient process for the preparation of vorinostat of high purity without the requirement to isolate any synthetic intermediate compounds.... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20110039938 - Storage-stable formulation of paracetamol in aqueous solution: The present invention concerns a liquid formulation that is stable to oxidation and that is based on paracetamol in an aqueous solvent obtainable by the following steps: (i) dissolving in a reaction vessel paracetamol in an aqueous solvent having a temperature between 65° C. and 95° C., and having pH... Agent: Knobbe Martens Olson & Bear LLP

20110039939 - Storage-stable formulation of paracetamol in aqueous solution: The present invention concerns a liquid formulation that is stable to oxidation and that is based on paracetamol in an aqueous solvent obtainable by the following steps: (i) dissolving in a reaction vessel paracetamol in an aqueous solvent having a temperature between 65° C. and 95° C., and having pH... Agent: Knobbe Martens Olson & Bear LLP

20110039940 - Methods for concomitant administration of colchicine and a second active agent: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of... Agent: Cantor Colburn LLP

20110039941 - Use of a composition for treating the surfaces of livestock buildings and/or the material therein: The invention relates to the use of a composition for treating the surfaces of livestock buildings and/or the material therein in order to eliminate and/or inhibit pathogenic protozoa, and in particular coccidiosis oocysts. According to the invention, said composition essentially comprises the combination of an alkylamine and of a quaternary... Agent: Egbert Law Offices

20110039942 - Titration package: The present invention relates to a titration package for providing at least one pharmaceutical composition in at least two different dosages. The titration package comprises at least two sets. Each set comprises at least three individually addressable regions. Each addressable region preferably comprises or is represented by a pharmaceutical composition,... Agent: The Firm Of Hueschen And Sage

20110039943 - Methods for treating skin disorders with topical nitrogen mustard compositions: Provided are methods for treating skin disorders comprising topically applying to the affected skin a composition comprising a nitrogen mustard or a pharmaceutically acceptable salt thereof.... Agent: Wilson, Sonsini, Goodrich & Rosati

20110039944 - Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief: The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic dissolved in a solution comprising an extractive solvent, e.g., DMSO or NMP, in an amount effective to reduce pain. Chronic or acute pain may... Agent: Fulbright & Jaworski L.L.P.

20110039945 - Compositions containing resveratrol and pectin: The present invention relates to compositions, preferably in the form of a powder and/or granules, which contain resveratrol and pectin, and a process for the manufacture of such compositions.... Agent: Nixon & Vanderhye, PC

20110039946 - Method of improving atopic dermatological diseases, in which a composition comprising magnolol, honokiol or a combination thereof is administered to a patient with atopic dermatological diseases: Disclosed is a method of improving atopic dermatological diseases, in which a composition comprising magnolol, honokiol or a combination thereof is administered to a patient with atopic dermatological diseases.... Agent: Cantor Colburn LLP

20110039947 - Surface-modified nanoparticles: A composition comprises surface-modified nanoparticles of at least one metal phosphate. The nanoparticles bear, on at least a portion of their surfaces, a surface modification comprising at least one organosilane surface modifier comprising at least one organic moiety comprising at least about six carbon atoms.... Agent: 3m Innovative Properties Company

20110039948 - Novel polycarbonate-polyorganosiloxane- and/or polyurethane-polyorganosiloxane compounds: The present invention relates to novel polycarbonate-polyorganosiloxane and/or polyurethane-polyorganosiloxane compounds, methods for their production, their use, functional formulations containing them, precursors for their production, as well as reactive compositions containing the aforementioned precursors.... Agent: Rankin, Hill & Clark LLP

20110039949 - Pet food product and method of manufacture: A pet food is provided, comprising a sorbent food body and a fluid carrier comprising a functional ingredient absorbed into the body. The body preferably is realtively moist, having a moisture content for example of from 35% to 60% by weight and firm structure that is resilient under initial biting... Agent: K&l Gates LLP

20110039950 - Alkyl and/or alkenyl ethers of alkyl and/or alkenyl (poly)glycosides and their use: The present invention relates to nanoemulsions comprising alkyl and/or alkenyl ethers of alkyl and/or alkenyl (poly)glycosides, to a method for their preparation and also to their use. The present invention further relates to the alkyl and/or alkenyl ethers of alkyl and/or alkenyl (poly)glycosides themselves, and their use.... Agent: Fox Rothschild LLP

  
02/10/2011 > patent applications in patent subcategories. patent applications/inventions, industry category

20110034369 - Agonists of bitter taste receptors and uses thereof: The present invention relates to agonists of the human bitter-taste receptor hTAS2R7 and its role in bitter taste transduction. The invention also relates to assays for screening molecules that modulate, e.g. suppress or block hTAS2R7 bitter taste transduction or bitter taste response.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20110034368 - Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins and proteolysis: Disclosed are useful constructs and methods for the expression of proteins using primary translation products that are processed within a recombinant host cell. Constructs comprising a single open reading frame (sORF) are described for protein expression including expression of multiple polypeptides. A primary translation product (a pro-protein or a polyprotein)... Agent: Client 447 C/o Greenlee Sullivan P.C.

20110034370 - Bis-met histones: The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20110034371 - L. casei rhamnosus secreted factors and use thereof: The present invention relates to a composition for inhibiting gastrointestinal inflammation comprising an effective amount of Lactoacillus casei rhamnosus secreted factors 5 to 30K fraction.... Agent: Wpat, PC Intellectual Property Attorneys

20110034372 - Truncated activin type ii receptor and methods of use: The present invention provides a substantially purified growth differentiation factor (GDF) receptor, including a GDF-8 (myostatin) receptor, as well as functional peptide portions thereof. In addition, the invention provides a virtual representation of a GDF receptor or a functional peptide portion thereof. The present invention also provides a method of... Agent: Dla Piper LLP (us)

20110034375 - Non-basic melanin concentrating hormone receptor-1 antagonists: e

20110034374 - Oxyntomodulin for preventing or treating excess weight: Compositions and methods for use in the prevention or treatment of excess weight in a mammal have been developed. The compositions comprise oxyntomodulin which is shown to reduce food intake.... Agent: Lando & Anastasi, LLP

20110034373 - Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity: The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in... Agent: Eli Lilly & Company

20110034376 - Use of lipid-rich nutrition for the treatment of post-operative ileus: The invention pertains to the use of a lipid-rich nutrition for the manufacture of a composition for the prevention and/or treatment of post-operative ileus. The lipid fraction inhibited IL-6 and TNF-α levels in peritoneal lavage fluid, and/or wherein the lipid fraction prevents influx of neutrophils in the intestinal muscularis following... Agent: Banner & Witcoff, Ltd.

20110034377 - Exendin and exendin agonists for eating disorders: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20110034378 - Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc.: The present invention relates to a combination, such as a combined preparation or pharmaceutical composition comprising: (a) compound of formula (I), and/or (II) or a pharmaceutically acceptable salt thereof; (b) at least one therapeutic agent selected from the group consisting of: an antihypertensive agent; an antidiabetics agent; a hypolipidemic agent;... Agent: Jacobson Holman PLLC

20110034379 - Gastrin compositions and formulations, and methods of use and preparation: An embodiment of the invention provided herein is a pharmaceutical composition comprising a gastrin compound having an extended activity upon administration to a subject in comparison with native gastrin. Methods are provided of conjugating portions of the amino acid sequence of gastrin having functional ability to bind to the gastrin/CCK... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20110034380 - Combination of a selective ppar-gamma modulator and an incretin for the treatment of diabetes and obesity: The present invention relates to pharmaceutical compositions and methods for the treatment of diabetes, obesity or disorders related to diabetes or obesity. The compositions comprise a combination of a selective PPARγ modulator and an incretin. The methods include the administration of the combination of a selective PPARγ modulator and an... Agent: Wood, Phillips, Katz, Clark & Mortimer

20110034381 - Methods for therapeutic treatment of benign prostatic hypertrophy (bph): Therapeutic methods for treatment of benign prostatic hypertrophy by inhibition of the activity of insulin-like growth factor-I (IGF-I). Methods encompass the use of IGF-I antagonists, as well as the use of compounds that lower the effective level of IGF-I or interfere with post receptor effects of IGF-I action in the... Agent: Klauber & Jackson

20110034382 - Use of liver growth factor (lgf) as a neural tissue regenerator: The invention comprises the use of LGF in the production of medicinal products that can be used in the pleiotropic tissue regeneration of one or more damaged tissues, in which at least one of the damaged tissues forms part of the central nervous system and the medicinal product is intended... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110034383 - Cxcl12 gamma a chemokine and uses thereof: Fragments of CXCL12 Gamma A chemokine having improved chemotaxis activity in vivo defined by an unprecedented capacity to associate and immobilise on extracellular glycans.... Agent: Young & Thompson

20110034384 - Combination vegfr2 therapy with mtor inhibitors: The present disclosure relates to improved methods of treating neoplastic disorders by combining VEGFR2 specific inhibitor treatment with mTOR inhibitors. The present disclosure also relates to methods of preventing the development of VEGFR2 resistance.... Agent: Ropes & Gray LLP Iprm - Floor 43

20110034385 - Compositions useful for the treatment of diabetes and other chronic disorder: The present invention provides a supramolecular protein assembly useful as a protein therapeutics for the treatment of metabolic disorders particularly diabetes. The supramolecular protein assembly disclosed in the present invention consists of insoluble and aggregated oligomers the protein. The invention also provides pharmaceutical compositions comprising supramolecular protein assembly. The composition... Agent: Mcandrews Held & Malloy, Ltd

20110034386 - Dendroaspis natriuretic peptide for treatment of cancer: Disclosed is a method of inhibiting the growth of a cancer cell using Dendroaspis natriuretic peptide (DNP), isolated from the Green Mamba snake venom with similar structure to ANP, with or without four cardiac natriuretic peptides i.e., atrial natriuretic peptide (ANP), vessel dilator, long acting natriuretic peptide (LANP), and kaliuretic... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20110034387 - Polypeptide inhibiting angiogenesis and application thereof: Provided is a low molecular polypeptide that can inhibit angiogenesis consisting of amino acid sequence YRGKKA, which is same to one portion sequence in apolipoprotein (a) Kringle V. Also provided are pharmaceutical composition and the uses for preventing or treating diseases relating to angiogenesis.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20110034388 - Collagen and fibrin microthreads in a discrete thread model of in vitro acl scaffold regeneration: Compositions that include fibrin microthreads are provided. The compositions can include one or more therapeutic agents including cytokines and interleukins, extracellular matrix proteins and/or biologically active fragments thereof (e.g., RGD-containing peptides), hormones, vitamins, nucleic acids, chemotherapeutics, antibiotics, and cells. Also provided are methods of making compositions that include fibrin microthreads.... Agent: Duane Morris LLP - BostonIPDepartment

20110034389 - Active agents, compositions, and methods for inhibiting and reversing platelet function: Active agents, compositions, and methods for inhibiting and reversing platelet function are provided herein. In particular embodiments, the active agents provided herein inhibit or reverse platelet function. In particular embodiments, the compositions described herein are pharmaceutical formulations. Methods of inhibiting and reversing platelet function are also provided herein. In particular... Agent: Stoel Rives LLP - Slc

20110034390 - Peptides, compositions, and uses thereof: Compositions for regenerating tissue and wound repair, among other applications, are described.... Agent: Fish & Richardson P.C. (bo)

20110034391 - Shaped article: The shaped article is obtained via a cementitious reaction of a particulate composition reactive with water, whereby said reaction is obtained between said composition and an aqueous, liquid or gaseous phase. The particles of the shaped article are present in the form of interlocked particles, whereby the interlocking of said... Agent: Rankin, Hill & Clark LLP

20110034392 - Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type ii and method of making same: Hydrolyzed collagen type II powder compositions for inducing cartilage formation in an individual, method of preparing the compositions and use of the compositions in treating connective tissue disorder, replenishing skin viscoelasticity. The compositions are administered through an orally ingestible delivery medium for absorption into the gastrointestinal tract. The compositions are... Agent: Fish & Associates, PC Robert D. Fish

20110034394 - Composition comprising protein and disperse fat: The present invention relates to a method for the manufacture of a composition comprising proteins and fats, said method providing a simple and non-expensive way of obtaining fat-containing proteinaceous products of high nutritional value that are easy to handle and at the same time possess high stability towards coalescence and... Agent: Jacobson Holman PLLC

20110034393 - Use of a novel natural agent in cosmetic compositions: The invention relates to cosmetic or dermatological compositions containing mannoproteins as an active ingredient and/or adjuvant, to the use of said cosmetic or dermatological compositions and to cosmetic treatment methods.... Agent: Law Office Of Delio & Peterson, LLC.

20110034395 - Compositions and methods of inhibiting apoptosis: A method of inhibiting apoptosis in a cell includes administering to a cell an effective amount of a cell penetrating peptide (CPP), wherein the CPP consists of about 5 to about 41 amino acids and is substantially homologous to a portion of the C-terminal region of IFNγR2.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20110034396 - Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions: The present disclosure provides methods of use of saratin, including the prevention or mitigation of the development of adhesions, keloids and scars. The adhesions, keloids and scars can be due to surgery, such as plastic surgery or orthopedic surgery, or can be pre-existing scars. Adhesion, keloid and/or scar formation may... Agent: Wilson, Sonsini, Goodrich & Rosati

20110034397 - Intestinal immune system stimulator: Disclosed is an agent, γ-glutamylcysteine, which can effectively and safely stimulate the intestinal immune system. γ-Glutamylcysteine can be formulated in a pharmaceutical composition, a food, and/or a beverage, and used for the treatment or prevention of infectious diseases, diarrhea, polyps, tumors, enteritis or allergy.... Agent: Cermak Nakajima LLP Acs LLC

20110034398 - Use of imp3 as a prognostic marker for cancer: Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20110034399 - Liquid and freeze dried formulations: The present invention relates to stable parenteral formulations comprising a new class of compounds, which is a non proteinic compound, a method for preparing such formulations as well as the use of certain compounds for stabilizing these formulations.... Agent: Hunton & Williams LLP Intellectual Property Department

20110034400 - Compositions and methods for analyzing bacterial adherence and anti-adherence to mucus, epithelial cells and other cells: The present invention generally relates to methods for detecting, identifying, and measuring bacterial adherence to mucus and epithelial cells. In particular, the present invention provides assays for detecting and identifying the presence or absence of bacterial adherence to mucus (epithelial cells (e.g., present in the intestines), or other portion of... Agent: Casimir Jones, S. C.

20110034401 - Novel process for solubilizing protein from a proteinaceous material and compositions thereof: The process for solubilizing proteinaceous material of the present invention includes subjecting the proteinaceous material to a sufficient amount of a basic solution to obtain a supernatant that has a basic pH and exposing the supernatant to the basic solution for a sufficient length of time and temperature for hydrolysis... Agent: Mckee, Voorhees & Sease, P.L.C

20110034402 - C-aryl glycoside compounds for the treatment of diabetes and obesity: This invention relates to a compound of generic formula (I): (I) as well as a pharmaceutically acceptable salt thereof a tautomer, optical isomer or a mixture of optical isomers in any proportion, in particular a mixture of enantiomers, and particularly a racemate mixture, in particular for use thereof as a... Agent: Foley And Lardner LLP Suite 500

20110034403 - use of ginsenoside rg1, its metabolites ginsenoside rh1 and/or ppt: The present invention relates to use of an active ingredient selected from ginsenoside Rg1, its metabolites ginsenoside Rh1 and Ppt for preparing a medicament and a health care product for improving sexual function of male mammals, and for providing the effect of spermatogenesis. The present invention further relates to a... Agent: Brinks Hofer Gilson & Lione/ann Arbor

20110034404 - Pest control agents: Disclosed is a composition for use as a pest control agent, comprising a compound represented by formula (I) or an agriculturally and horticulturally acceptable salt thereof as active ingredient and an agriculturally and horticulturally acceptable carrier:... Agent: Wenderoth, Lind & Ponack, L.L.P.

20110034405 - Novel aminoglycoside antibiotics, process for producing the same, and pharmaceutical use thereof: s

20110034406 - System and method for controlling bacterial persister cells with weak electric currents: A system and method for treating persister cells with an electrochemical process, alone or in combination with antibiotics. Weak electric currents are used to effectively eliminate persister cells and the efficacy can be further improved through synergistic effects with antibiotics. The method may be adapted for novel therapies of chronic... Agent: Bond Schoeneck & King, PLLC

20110034537 - Compositions and methods for inhibiting expression of cd45 gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the CD45 gene.... Agent: Alnylam/fenwick

20110034533 - Compositions and methods modulating mg29 for the treatment of diabetes: Disclosed herein are compositions and methods for treatment of muscle dysfunction, including diabetes. In addition, the invention relates to therapeutic compositions comprising nucleotides and/or polypeptides of the invention in combination with a pharmaceutically acceptable carrier, wherein the composition facilitates the treatment of skeletal muscle disorders. Moreover, the invention relates to... Agent: Mccarter & English, LLP Hartford Cityplace I

20110034536 - Controlling the potential of primate neural stem cells by regulating pax6: A transcription factor both necessary and sufficient for human neuroectoderm specification, Pax6, as well as applications thereof, is disclosed.... Agent: Quarles & Brady LLP

20110034538 - Microrna-based methods and compositions for the diagnosis, prognosis and treatment of gastric cancer: Methods and compositions for the diagnosis, prognosis and/or treatment of gastric cancer associated diseases are disclosed.... Agent: Macmillan Sobanski & Todd, LLC

20110034532 - Modulation of t cell signaling threshold and t cell sensitivity to antigens: MicroRNAs (miRNAs) are a diverse and abundant class of ˜22-nucleotide (nt) endogenous regulatory RNAs that play a variety of roles in animal cells by controlling gene expression at the posttranscriptional level. Increased miR-181a expression in mature T cells is shown to cause a marked increase in T cell activation and... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20110034535 - Positive controls for expression modulating experiments: The invention pertains to the use of an apoptosis inducing combination of at least a. a first expression modulating compound silencing the expression of at least a first target gene involved in apoptosis and b. a second expression modulating compound silencing the expression of at least a second target gene... Agent: Seed Intellectual Property Law Group PLLC

20110034534 - Sirna compounds and methods of use thereof: The present invention relates to compounds, pharmaceutical compositions comprising same and methods of use thereof for the inhibition of certain genes, including SOX9, ASPP1, CTSD, CAPNS1, FAS and FAS ligand. The compounds and compositions are useful in the treatment of subjects suffering from diseases or conditions and or symptoms associated... Agent: Cooper & Dunham, LLP

20110034544 - Compositions comprising ghrh and gnrh and methods of using the same: Compositions and kits comprising a nucleotide sequence that encodes GHRH and a nucleotide sequence that encodes GnRH and compositions and kits comprising a GHRH protein and GnRH protein are disclosed. Use of such compositions and kits in methods of enhancing fertility in mammals comprising the step of administering said compositions... Agent: Vgx Pharmaceuticals, LLC

20110034543 - Dna vaccination for treatment of multiple sclerosis and insulin-dependent diabetes mellitus: A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive... Agent: Townsend And Townsend And Crew, LLP

20110034545 - Double-stranded lipid-modified rna having high rna interference effect: An object of the present invention is to provide a novel double-stranded RNA that has high resistance to nuclease and cellular uptake efficiency and that can produce an excellent RNA interference effect. The present invention provides a double-stranded lipid-modified RNA comprising a sense strand having a nucleotide sequence complementary to... Agent: Sughrue Mion, PLLC

20110034541 - Inhibitors of dna immunostimulatory sequence activity: The invention consists of oligonucleotides which inhibit the immunostimulatory activity of ISS-ODN (immunostimulatory sequence oligodeoxynucleotides) as well as methods for their identification and use. The oligonucleotides of the invention are useful in controlling therapeutically intended ISS-ODN adjuvant activity as well as undesired ISS-ODN activity exerted by recombinant expression vectors, such... Agent: Bozicevic, Field & Francis LLP

20110034539 - Methods for treating blood coagulation disorders: The present invention relates to a method of treating an individual having a blood coagulation defect (e.g., hemophilia A, hemophilia B), comprising administering to the individual an effective amount of a DNA vector encoding modified Factor VII (FVII), wherein the modified Factor VII leads to generation of Factor VIIa in... Agent: Genzyme Corporation Legal Department

20110034546 - Methods to produce rod-derived cone viability factor (rdcvf): The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally... Agent: Robins & Pasternak

20110034542 - Novel synthetic analogs of sphingolipids: The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined... Agent: Hunton & Williams LLP Intellectual Property Department

20110034540 - Use of the cyp46a1 gene for the treatment of alzheimer's disease: The invention relates to a viral vector for treating Alzheimers disease, which vector comprises a cholesterol 24-hydroxylase (CYP46A1) encoding nucleic acid. In a preferred embodiment, the viral vector may be an Adeno-Associated-Virus (AAV) vector, preferably an AVV5 vector. The vector may be useful for the manufacture of a pharmaceutical composition... Agent: Thompson Coburn LLP

20110034408 - High oil content o/w emulsions stabilized with a hydrophobically modified inulin and a hydrophilic acrylic polymer: The invention relates to a composition in the form of an oil-in-water emulsion comprising, in a physiologically acceptable medium: i) at least 0.005% by weight, preferably at least 0.01% by weight, relative to the total weight of the composition, of at least one inulin modified with hydrophobic chains, and ii)... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110034409 - Use of pharmaceutical compound in the treatment of wounds: A pharmaceutical composition that can be used in the treatment of wounds, comprising at least a sulfated polysaccharide and wherein the polysaccharide/s are in the form of solids as powder, flakes or sheets obtained through a lyophylization process. Particularly, this invention relates to the use of one or more sulfated... Agent: Young & Thompson

20110034407 - Use of sphingomyelin and non-digestible carbohydrates for improving intestinal microbiota: A composition comprising sphingophospholipid or its degradation product and at least one non-digestible carbohydrate for providing and/or maintaining an optimal intestinal microbiota is provided. The composition is especially suitable for infant nutrition.... Agent: Foley And Lardner LLP Suite 500

20110034410 - Wound dressing and method for controlling severe, life-threatening bleeding: This invention is directed to advanced hemorrhage control wound dressings, and methods of using and producing same. The subject wound dressing is constructed from a non-mammalian material for control of severe 5 bleeding. The wound dressing for controlling severe bleeding is formed of a biomaterial comprising chitosan, a hydrophilic polymer,... Agent: Ryan Kromholz & Manion, S.c.

20110034411 - Methods and compositions for improving gastrointetinal health: Methods for maintaining or improving the gastrointestinal health of animals susceptible to or suffering from poor gastrointestinal health by administering to the animal a gastrointestinal health maintaining or improving amount of a food composition comprising from about 1 to about 20% carbohydrate; from about 3 to about 10% total dietary... Agent: Wendell Ray Guffey Nestle Purina Petcare Global Resources, Inc.

20110034412 - Visually observable material for medical treatment: A visually observable material for medical treatment, which is preferable as an adhesion preventive material and a hemostatic material for biological organisms includes a crosslinking composition comprising at least two components of a crosslinking polysaccharide derivative with an active ester group reactive with active hydrogen in the co-presence of an... Agent: Buchanan, Ingersoll & Rooney PC

20110034413 - Novel quercetin derivatives as anti-cancer agents: wherein R1 is hydrogen, benzyl or substituted benzyl; R2 is hydrogen, benzyl or substituted benzyl, linear or branched (C1-C6) alkyl, substituted alkyl, aryl, substituted aryl, heterocycle and substituted heterocycle, useful for treatment of various disorders including cancer, multi-drug resistant cancers, viral infections etc. The invention also provides a process for... Agent: Ladas & Parry LLP

20110034414 - Fluoroalkyloxy alkanes, process for production and uses thereof: The present invention relates to fluoroalkyloxy alkanes having formula (I): RF—R1—O—R2 wherein: RF is a linear or branched perfluoroalkyl group, having from 1 to 12, preferably from 2 to 8, carbon atoms; R1 is a linear or branched, non-fluorinated alkylene group, having from 1 to 6, preferably from 2 to... Agent: Pearne & Gordon LLP

20110034415 - Walnut extracts for nutraceutical applications: The invention describes to walnut oil extracts that have increased amounts of enriched in phospholipids, especially phosphatidylethanolamine (PE), phosphatidylcholine (PC), and phosphatidylinositol (PI) relative to walnut oil found in naturally occurring walnuts. It has been found that there are synergistic therapeutic effects when PE/PC and/or PI are combined.... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20110034416 - 4-pyridinone compounds and their use for cancer: e

20110034417 - Substituted piperidine compounds and methods of their use: Novel 3,4-disubstituted-4-aryl-piperidine compounds are disclosed. Pharmaceutical compositions containing the 3,4-disubstituted-4-aryl-piperidine compounds and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as antagonists of opioid receptors.... Agent: Feldman Gale, P.A.

20110034418 - Pharmaceutical composition with bisphosphonate: The present invention relates to depot formulations comprising a poorly water soluble salt of a bisphosphonate forming together with one or more biocompatible polymers, to poorly water-soluble salts of such bisphosphonates, to crystalline forms of the free compounds and the salts and to other related aspects, where the compounds are... Agent: Novartis Institutes For Biomedical Research, Inc.

20110034419 - Cardioprotective drugs and diagnostics for assessing risk of cardiovascular disease: Disclosed are methods of diagnosing cardiovascular disease comprising measuring sphingolipids. Also disclosed are methods of predicting cardiovascular disease comprising measuring sphingolipids. Also disclosed are methods of identifying subjects at risk of developing cardiovascular disease comprising measuring sphingolipids.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20110034420 - Novel crystalline form b of (2r)-(3-amino-2-fluoropropyl)phosphinic acid: The present invention relates to a novel crystalline form of (2R)-(3-amino-2-fluoropropyl)phosphinic acid, the present invention is also directed to the use of the crystalline form for the treatment of gastrointestinal disorders as well as to a pharmaceutical compositions comprising the same and a process for the preparation of the crystalline... Agent: White & Case LLP Patent Department

20110034421 - Creatine oral supplementation using creatine hydrochloride salt: The present invention is directed to a third generation form of creatine, specifically a creatine hydrochloride salt, that drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.... Agent: Hanify & King Professional Corporation

20110034422 - Dendrimers for sustained release of compounds: Dendrimer-based compositions and methods are provided, that are useful for administering pharmaceutical compositions to target cells and tissues for treatment of ocular diseases including macular degeneration, diabetic retinopathy, and retinitis pigmentosa.... Agent: Douglas Gergich Intellectual Property Docketing Department

20110034423 - Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists: The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition... Agent: Pepper Hamilton LLP

20110034424 - Method for the long term nsaid use: Provided is a method for the long term treatment of a condition or disease which is one of the indications for NSAID use in a human patient, which comprises administering to the patient a pharmaceutically effective amount of a NSAID and at least 36 mcg per day of cobiprostone or... Agent: Sughrue Mion, PLLC

20110034425 - Method of treatment for acute myelogenous leukemia: This invention relates to a method of treating acute myelogenous leukemia with TPA along with Dexamethasone and choline magnesium trisalicylate.... Agent: University Of Medicine And Dentistry Of New Jersey Suite 2100

20110034426 - Method of preventing renal disease and treating symptoms thereof: The invention relates to novel methods of using 2-methylene-19-nor-20(S)-1,25-dihydroxyvitamin D3 to prevent renal disease, particularly Lupus nephritis, in a subject at risk of developing renal disease. Methods of preventing symptoms of renal disease, such as proteinuria, splenomegaly or glomerular damage are also provided. Methods of treating symptoms of renal disease,... Agent: Quarles & Brady LLP

20110034427 - Anti-aging properties of quercetin, 18alpha-glycyrrhetinic acid and hederagenin and their derivatives: Quercetin, 18 α-glycyrrhetinic and/or hederagenin and/or their derivatives are used as anti-aging and/or whitening agents for the topical treatment of skin. Methods for testing the anti-aging and whitening properties of these compounds are disclosed.... Agent: Eckert Seamans Cherin & Mellott, LLC

20110034428 - Treatment of prostate cancer: Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat androgen receptor mediated diseases or conditions. The present invention provides therapies and therapeutic regimens for the treatment of prostate cancer.... Agent: Wilson, Sonsini, Goodrich & Rosati

20110034429 - 5a-androstane-3,6,17-trione (kneller's trione) and methods of use therefor: Disclosed are compounds such as 5α-androstane-3,6,17-trione, formulations comprising said compounds, and methods of use thereof to stimulate endogenous testosterone production and improve athletic performance and libido.... Agent: Morse, Barnes-brown & Pendleton, P.C. Attn:IPManager

20110034430 - Phospholipid gel compositions for drug delivery and methods of treating conditions using same: The present invention relates to pharmaceutical compositions in the form of a gel for controlled- or sustained-release of a pharmaceutically active agent and to methods for treating or preventing a condition in an animal by administering to an animal in need thereof the pharmaceutical compositions. One particular type of condition... Agent: Townsend And Townsend And Crew, LLP

20110034431 - Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer: Disclosed herein are novel zinc ionophores, zinc chelators and/or zinc complexes with enhanced aqueous solubility. Methods of treating cancer using at least one zinc ionophore and/or zinc chelator are also disclosed. Also disclosed herein are compositions and methods for treating cancer with combination therapy using at least one texaphyrin metal... Agent: Wilson, Sonsini, Goodrich & Rosati

20110034433 - 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use: The present invention relates to novel 4-(4-cyano-2-thioaryl)dihydropyrimidin-2-one derivatives, to processes for their preparation, to their use alone or in combination for the treatment and/or prevention of diseases and also to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of... Agent: Barbara A. Shimei Director, Patents & Licensing

20110034432 - Benzamide derivatives and their use as glucokinase activating agents: e

20110034434 - Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase: The invention relates to prodrugs of fused heterocyclic inhibitors of D-amino oxidase (DAAO) and methods of treating diseases and conditions, wherein modulation of D-amino acid oxidase activity, D-serine levels, D-serine oxidative products and NMDA receptor activity in the nervous system of a mammalian subject is effective.... Agent: Morgan, Lewis & Bockius LLP (sf)

20110034435 - Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers: A compound of formula (A); wherein ring A is an aromatic ring or a heteroaromatic ring; R1 is independently halogen, cyano, etc., each of X1, X2 and X3 is CR2 or nitrogen, R2 is independently hydrogens, etc., n is 0, 1, 2, 3 or 4; -D-Y is —O—CH2COOH, etc, and... Agent: Birch Stewart Kolasch & Birch

20110034436 - spirocyclic aminoquinolnes as gsk-3 inhibitors: Provided herein are spirocyclic aminoquinolones of formula I and compositions containing the compounds. The compounds and compositions provided herein are useful in the prevention, amelioration or treatment of GSK-3 inhibitors mediated diseases. In Formula (I): X1 is O or NR8; A is bond or substituted or unsubstituted C1-C2 alkylene, wherein... Agent: Jones Day

20110034437 - Isoxazolines as inhibitors of fatty acid amide hydrolase: o

20110034438 - Structural mimetics of proline-rich peptides and the pharmaceutical use thereof: The invention relates to compounds of general formula (I), which can be used particularly as structural mimetics of proline-rich peptides and are therefore capable of binding PRM binding domains (proline-rich motif binding domains) of proteins. The invention also relates to the use of said compounds as pharmaceutical active agents and... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20110034439 - Acylthiourea compound or salt thereof, and use thereof: (wherein each of R1 and R2, which may be the same or different, represents a hydrogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted C3-10 cycloalkyl group, an optionally substituted C6-14 aromatic hydrocarbon group, or an optionally substituted saturated or unsaturated heterocyclic group, or R1 and R2 may... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110034440 - Homocysteine synthase inhibitor: h

20110034441 - Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof: Described herein are methods of treating a disorder or disease in which aberrant Wnt signaling is implicated, with a variety of compounds, including Wnt inhibitor compounds. More particularly, it concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt... Agent: Fish & Richardson P.C. (tc)

20110034442 - Use and methods of use for an antagonist of the serotin3 receptor (5-ht3) and a selective modulator of chloride channels for the treatment of addiction to or dependence on medicines/drugs or nervous system disorders: The present invention relates to the composition and methods of using a combination of a serotonin3 (5-HT3) receptor antagonist, such as ondansetron, and a selective chloride channel modulator, such as flumazenil, for treatment of patients with drug addiction or dependence. Examples of the drugs include prescription drugs as well as... Agent: Eckert Seamans Cherin & Mellott

20110034444 - Selected cgrp antagonists, processes for preparing them and their use as pharmaceutical compositions: wherein R1, R2, R3 and R4 are as defined in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases,... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20110034443 - Uses of substituted imidazoheterocycles: e

20110034445 - Fungicide hydroximoyl-heterocycles derivatives: The present invention relates to hydroximoyl-heterocycle derivatives, their process of preparation, intermediate compounds for their preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.... Agent: Ostrolenk Faber Gerb & Soffen

20110034446 - R(-)-2-methoxy-11-hydroxyaporphine and derivatives thereof: The invention features derivatives of R(−)-2-methoxy-11-hydroxyaporphines and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.... Agent: Clark & Elbing LLP

20110034447 - Tdp-43-storing cell model: Disclosed is a transformed cell (a cell model) which can form a cytoplasmic inclusion body derived from TAR DNA-binding protein of 43 kDa (TDP-43) that is found in the brain of a patient suffering from a neurodegenerative disease such as FTLD and ALS. The transformed cell is characterized by having,... Agent: Birch Stewart Kolasch & Birch

20110034448 - Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems: Biocompatible intraocular drug delivery systems include a carbonic anhydrase inhibitor therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain... Agent: Allergan, Inc.

20110034449 - N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase: are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R1, R2, R3 and R4 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed... Agent: Merck

20110034450 - Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof: The present application relates to novel carboxylic acid derivatives having an oxo-substituted azaheterocyclic partial structure, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20110034452 - Triazolium salts as par1 inhibitors, production thereof, and use as medicaments: where X, A−, Q1, Q2 Q3, R2, R3, R4, R5, R6, R7, R8 and R9 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and... Agent: Scully, Scott, Murphy & Presser, P.C.

20110034451 - Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments: where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20110034453 - Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders: The present application relates to prodrug derivatives of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of thromboembolic disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20110034454 - Morpholino pyrimidine derivatives and their use in therapy: A compound of formula (I) or a salt, ester or prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K... Agent: Astrazeneca R&d Boston

20110034455 - Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: This invention relates to novel compounds of the Formula (I*), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods... Agent: Foley & Lardner LLP

20110034456 - Imidazopyridazines as par1 inhibitors, production thereof, and use as medicaments: where R1, R2, R3, R4, R5, R6, R7, R8, R9, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to... Agent: Scully, Scott, Murphy & Presser, P.C.

20110034457 - Pyridothiophene compounds: Ar1, Alk1, Z, Alk2 and Q being as defined in the specification; m, p, r and s are independently 0 or 1; R3 is hydrogen, an optional substituent, or an optionally substituted (C1-C6)alkyl, aryl or heteroaryl radical; and R4 is a carboxylic ester, carboxamide or sulfonamide group; or a salt,... Agent: Banner & Witcoff, Ltd.

20110034458 - Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors: The present invention is related to pyridine methylene azolidinone derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110034459 - 6,7-dialkoxy quinazoline derivatives and methods of treating drug resistant and other tumors: Methods of inhibiting a receptor tyrosine kinase in a subject in need thereof. Methods of inhibiting the growth of a tumor cell in a subject in need thereof. Methods of treating pancreatic cancer in a subject in need of treatment for pancreatic cancer. Methods of treating HER2 positive breast cancer... Agent: Merchant & Gould PC

20110034460 - Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them: t

20110034462 - Organic compounds: The present invention relates to compounds of the formula; and their use in therapy.... Agent: Novartis Vaccines And Diagnostics Inc.

20110034461 - Sf5 derivatives as par1 inhibitors, production thereof, and use as medicaments: where R1, R2, R3, R4, R5, R9, Ar, Q1, Q2 and Q3 are each as defined below. The compounds of the formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of the formula I and to... Agent: Scully, Scott, Murphy & Presser, P.C.

20110034464 - Iminopyridine derivatives and use thereof: e

20110034463 - Type iii secretion inhibitors, analogs and uses thereof: The invention, in some aspects, relates to compounds and compositions useful for inhibiting Type III secretion systems in pathogenic bacteria, such as Yersinia Pestis. In some aspects, the invention relates to methods for discovering inhibitors of the Type III secretion system and uses of such inhibitors in the treatment and... Agent: Wolf Greenfield & Sacks, P.C.

20110034466 - Novel five-membered ring compound: (In the formula, R1 represents a halogen atom or a phenyl group which may be substituted by a C1-C3 alkyl group or a C1-C3 alkoxy group; R2 represents a C1-C3 alkylene group which may be substituted by a C1-C3 alkyl group or a carbonyl group; R3 represents a C1-C3 alkyl... Agent: Wenderoth, Lind & Ponack, L.L.P.

20110034465 - Processes for the preparation of rivaroxaban and intermediates thereof: Provided are process for the preparation of (R)- and/or (S)-Rivaroxaban, and compounds which are intermediate compounds used in the processes for the preparation of (R)- and/or (S)-Rivaroxaban.... Agent: Mckinnons Patents Inc

20110034467 - Dihydro-pyrrolopyridine-, dihydro-pyrrolopyridazine- and dihydro-pyrrolopyrimidine-derivatives and use thereof: The invention relates to novel dihydro-pyrrolopyridine, dihydro-pyrrolopyridazine and dihydro-pyrrolopyrimidine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20110034468 - Triazolo compounds useful as dgat1 inhibitors: Disclosed are triazolopyridine compounds of Formula (I), including pharmaceutically acceptable salts thereof. Also, disclosed are methods of using the compound in the treatment of obesity, dyslipidemia, diabetes and atherosclerosis, and to pharmaceutical compositions comprising at least one compound of Formula (I) or a stereoisomer or pharmaceutically acceptable salt thereof.... Agent: Louis J. Wille Bristol-myers Squibb Company

20110034469 - Heterocyclic compound: s

20110034470 - Inhibitors of jnk: wherein p, q, Y′, r, R1, R2, X, X1, X2, X3, and X4 are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders,... Agent: Hoffmann-la Roche Inc. Patent Law Department

20110034473 - Novel (pyrroloquinoxalinyl) pyrazinecarbohydrazide-oxalic acid co-crystal for treatment of cancer and other diseases: A novel co-crystal of N′-(7-fluoropyrrolo[1,2a]quinoxalin-4-yl)pyrazine-2-carbohydrazide with oxalic acid is disclosed. The disclosed oxalic acid co-crystal demonstrates cancer cell growth inhibition and is more bioavailable than the corresponding free base when administered as a suspension.... Agent: Knobbe Martens Olson & Bear LLP

20110034471 - Novel combinations comprising a phoshodiesterase-5 inhibitor and their use: The invention relates generally to novel pharmaceutical methods for the treatment of various conditions. Compositions comprising: at least one phosphodiesterase-5-inhibitor in combination with one or more of the following medications: a selective serotonin reuptake inhibitor; a serotonin-norepinephrine reuptake inhibitor; a cholinesterase inhibitor; a dopamine agonist; or a medication suitable to... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20110034472 - Novel compounds for treatment of cancer and disorders associated with angiogenesis function: Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian... Agent: Dla Piper US LLP

20110034474 - Pyridazinone derivatives: Compounds of the formula (I), in which R1, R2, R3, W and D have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20110034475 - 1-aza-bicyclo[3.3.1]nonanes: The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I); wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them. Formula (I), wherein A represents O or N(R1); Y represents a group of formula, or wherein... Agent: Fanelli Strain & Haag PLLC

20110034476 - Genetic polymorphisms and infertility: Methods of screening for a cause of low sperm motility and/or for mitochondrial impairment in subjects are provided, comprising determining a genotype of the subject with respect to at least one choline metabolism gene and comparing the genotype of the subject with at least one reference choline metabolism genotype associated... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20110034477 - Crystalline polymorph of doxazosin mesylate (form iv) and process for preparation thereof: Crystalline Form IV of doxazosin mesylate, a process for its preparation and uses thereof.... Agent: Conley Rose, P.C.

20110034478 - Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas: The present invention provides a solid molecularly dispersed composition comprising a poorly water soluble and weakly basic azole antifungal compound and a pH sensitive polymer, pharmaceutical compositions, comprising the solid molecularly dispersed composition of the invention and methods of treating and/or preventing a fungal infection in a patient in need... Agent: Merck Patent Department (k-6-1, 1990)

20110034479 - Deuterium-enriched alkyl sulfonamides: The present invention is concerned with deuterium-enriched isobutyl and cyclohexylmethyl sulfonamides of formula I and II, and pharmaceutically acceptable salts and methods of use thereof for the treatment of general anxiety disorders, major depressive disorders, attention deficit disorders, attention deficit hyperactivity disorder, Alzheimer's disease, frontotemporal dementia, cognitive impairment associated with... Agent: Dr. D. S. Dhanoa

20110034480 - Compositions comprising cetirizine and a non beta-2-adrenoreceptor agonist, a beta-2-adrenoreceptor agonist or an anti-inflammatory and the use thereof for the treatment of respiratory disorders: There is described a pharmaceutical composition comprising a therapeutically effective amount of cetirizine, or a pharmaceutically acceptable derivative thereof, and a therapeutically effective amount of one or more compounds selected from the group consisting of a non beta-2-adrenoreceptor agonist; a beta-2-adrenoreceptor agonist and an anti-inflammatory agent; in admixture with a... Agent: K&l Gates LLP

20110034481 - Novel tetrahydroisoquinoline derivative: R1 represents a phenylaminocarbonyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group A, a benzoxazol-2-yl group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group A, or the like; R2 independently represents a C1-C6 alkyl group; R3 represents... Agent: Dorsey & Whitney LLP Intellectual Property Department

20110034484 - 1,5-diphenyl-pyrrolidin-2-one compounds as cb-1 ligands: CB-1 receptor inverse agonist compounds of Formula (I) and pharmaceutical compositions for the treatment of obesity or cognitive impairment associated with schizophrenia.... Agent: Eli Lilly & Company

20110034483 - 2-aminoimidazole beta-secretase inhibitors for the treatment of alzheimer's disease: which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of... Agent: Merck

20110034482 - Amine salts of a crth2 antagonist: Provided are amine salts of {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl}-acetic acid, processes for their preparation, pharmaceutical compositions containing them, and their use for treating, preventing, or ameliorating one or more symptoms of a CRTH2-mediated disorder or disease.... Agent: Jones Day

20110034485 - Nitrone compounds, process of preparation thereof, and use thereof in medicament manufacture: The present invention provides novel nitrones, their preparation and use. The novel compounds have the following formula: I The compounds of the present invention have strong antioxidative activity, and are thrombolytic. These compounds can be used to treat and/or prevent diseases caused by overproduction of free radicals and/or formation of... Agent: Workman Nydegger 1000 Eagle Gate Tower

20110034486 - Use of pterocarpans as active anti-cellulite ingredients: e

20110034487 - Cxcr3 antagonists: Compounds, compositions and methods that are useful in the treatment of inflammatory and immune conditions and diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of a chemokine receptor. The subject methods are useful for the treatment of inflammatory and immunoregulatory disorders and... Agent: Amgen Inc.

20110034491 - 5-fluoro-2-oxopyrimidine- 1(2h)-carboxylate derivatives: This present disclosure is related to the field of 5-fluoro-2-oxopyrimidine-1-(2H)-carboxylates and their derivatives and to the use of these compounds as fungicides.... Agent: Charles W. Arnett Dow Agrosciences LLC

20110034488 - Method of assaying 5-fu: The present invention provides methods, compositions, devices and kits for assaying 5-FU.... Agent: Myriad Genetics Inc. Intellectual Property Department

20110034490 - N1-acyl-5-fluoropyrimidinone derivatives: This present disclosure is related to the field of N1-acyl-5-fluoropyrimidinones and their derivatives and to the use of these compounds as fungicides.... Agent: Charles W. Arnett Dow Agrosciences LLC

20110034492 - N1-substituted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives: This present disclosure is related to the field of N1-substituted-5-fluoro-2-oxopyrimidinone-1-(2H)-carboxamides and their derivatives and to the use of these compounds as fungicides.... Agent: Charles W. Arnett Dow Agrosciences LLC

20110034493 - N1-sulfonyl-5-fluoropyrimidinone derivatives: This present disclosure is related to the field of N1-sulfonyl-5-fluoropyrimidinones and their derivatives and to the use of these compounds as fungicides.... Agent: Charles W. Arnett Dow Agrosciences LLC

20110034494 - Reversible inhibition of sperm receptor synthesis for contraception: Methods are disclosed for reversibly inhibiting sperm receptor activity in animals. Nicarbazin, its derivatives and modifications which retain pharmacological activity are shown to inhibit activity of zona pellucida proteins and concomitant synthesis and/or assembly of the sperm receptor on the oocyte surface necessary for fertilization. Nicarbazin is easily administered, for... Agent: Mckee, Voorhees & Sease, P.L.C Attn: Pennsylvania State University

20110034489 - Solid dosage forms of hiv protease inhibitors: The present invention relates to a solid dosage form comprising a solid dispersion composition of at least one HIV protease inhibitor and water soluble polymer having a glass transition temperature (Tg) of at least about 50° C. in an amount of less than 50% by weight of the dosage form.... Agent: Ranbaxy Inc.

20110034497 - Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation... Agent: Fish & Richardson P.C. (tc)

20110034495 - Method of modulating stress-activated protein kinase system: A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 2-position by a carbonyl- or sulfonyl-linked pyrrolidin-1-yl or related moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.... Agent: Marshall, Gerstein & Borun LLP

20110034496 - Post-harvest treatment: The present invention relates to methods for the protection of harvested fruit, cutflowers or vegetables against decay caused by certain storage diseases or disorders expressed in storage conditions. In particular the invention relates to the application of certain fungicidal active compounds to protect harvested fruit, cutflowers or vegetables against phytopathogenic... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20110034498 - Dosing regimens for the treatment of cancer: The invention relates to a method of treating cancer. The method includes administering systemically a therapeutically effective amount of a small molecule hedgehog pathway inhibitor, such that the concentration of the inhibitor in the blood does not vary by more than about ±30% from the average concentration, and such that... Agent: Morrison & Foerster LLP

20110034500 - Spiroheterocyclic compounds and their uses as therapeutic agents: k, j, p, Q, R1, R3a, R3b, R3e, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, that are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical... Agent: SeedIPLaw Group PLLC

20110034499 - Spiroindolines as modulators of chemokine receptors:

20110034501 - Method of restoring the incretin effect: The present invention relates to methods of treating metabolic syndrome, Type 2 diabetes mellitus, atherogenic dyslipidemia and/or obesity. The present invention also relates to methods of restoring the incretin effect, to restoring physiologic control of glucagon levels, to restoring first-phase insulin secretion, and to restoring the physiologic glucose-dependent insulin secretion.... Agent: Whyte Hirschboeck Dudek S.c. Intellectual Property Department

20110034502 - Nalmefene prodrugs: The present invention relates to ester prodrugs of nalmefene of formula (I), pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of substance abuse disorders such as alcohol abuse and alcohol dependence and impulse control disorders such as pathological gambling and addiction... Agent: Philip S. Johnson Johnson & Johnson

20110034503 - Rapamycin and its derivatives for the treatment of liver-associated fibrosing disorders: A method for treating liver-associated fibrosing disorders or lupus, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula optionally in conjunction with a co-agent.... Agent: Novartis Corporate Intellectual Property

20110034504 - Agent for preventing and/or treating vascular diseases: [Means for Solution] Useful to provide a pharmaceutical composition for preventing and/or treating vascular diseases, which comprises 1) a COX-1 selective inhibitor and 2) clopidogrel or a pharmaceutically acceptable salt thereof. The present invention is useful as an excellent pharmaceutical composition for preventing and/or treating vascular diseases is provided and... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110034505 - Thienopyridone derivatives as amp-activated protein kinase (ampk) activators: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diseases and disorders modulated by AMP agonists. The invention is also directed to intermediates and to... Agent: Millen, White, Zelano & Branigan, P.C.

20110034506 - Triazolopyridine compounds useful as dgat1 inhibitors: Disclosed are triazolopyridine compounds of the following Formula (I); or stereoisomers or salts thereof. Also, disclosed are methods of using the compound in the treatment of obesity, dyslipidemia, diabetes and atherosclerosis, and to pharmaceutical compositions comprising at least one compound of Formula (I) or a stereoisomer or pharmaceutically acceptable salt... Agent: Louis J. Wille Bristol-myers Squibb Company

20110034507 - Farnesoid x receptor agonists: The present invention relates to farnesoid X receptors (FXR, NR1H4). FXR is a member of the nuclear receptor class of ligand-activate transcription factors. More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same. Novel isoxazole compounds... Agent: Glaxosmithkline Global Patents

20110034509 - Beta-2-adrenoreceptor agonists: e

20110034508 - Treatment of bdnf-related disorders using laquinimod: This application provides for a method of increasing brain-derived neurotrophic factor (BDNF) serum level in a human subject comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to increase BDNF serum level in the human subject. The method can further comprise periodically administering... Agent: Cooper & Dunham, LLP

20110034510 - Enantiomer-enriched alpha-,omega-amino alcohol derivatives, their production and use as insect- and mite-repelling agents: The invention relates to an insect- and mite-repelling agent, characterized by a content of at least one substituted, enantiomer-enriched α-,ω-amino alcohol derivative of formula (1) wherein X represents hydrogen, COR11 or R13, R13 represents C1-C6 alkyl, R1 represents C1-C7 alkyl, C3-C7alkenyl or C2-C7 alkinyl, R2 R11, R13 are identical or... Agent: Lanxess Corporation

20110034511 - Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists: provided that when R1 is C2-C6 alkyl or substituted C2-C6 alkyl, R2 is hydrogen or methyl; R3a, R3b and, when X is —C(R3c)═, R3c, are each independently hydrogen, fluoro, or methyl, provided that no more than one of R3a, R3b, and R3c may be other than hydrogen; R4 is hydrogen... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20110034512 - Indazole compounds as ccr1 receptor antagonists: Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20110034513 - Heterocyclic sulfonamide inhibitors of beta amyloid production: s

20110034514 - 5-lipoxygenase-activating protein (flap) inhibitors: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.... Agent: Glaxosmithkline Global Patents

20110034515 - Indole modulators of the alpha 7 nicotinic acetylcholine receptor: This invention relates to modulation of the α7 nicotinic acetylcholine receptor (nAChR) by a compound of formula (I) or a salt thereof... Agent: Glaxosmithkline Global Patents -us, Uw2220

20110034516 - Aminopyrazole derivatives: i

20110034517 - Selective subtype alpha 2 adrenergic agents and methods for use thereof: The invention provides well-defined heterocyclic compounds that are useful as subtype selective alpha 2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with selective subtype modulation of alpha 2 adrenergic receptors.... Agent: Allergan, Inc.

20110034518 - Pharmaceutical composition: Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.... Agent: Foley And Lardner LLP Suite 500

20110034519 - Nutritional supplements: A process for improving the health of a subject, the process comprising orally administering a composition comprising hydroxytyrosol to the subject to provide the subject with a daily dose of about 0.1 to about 750 μg hydroxytyrosol per kg of body weight, and a dietary supplement in dosage unit form... Agent: Bryan Cave LLP

20110034520 - Inhibitors of p38 map kinase: Compounds of formula (I) are p38 MAP kinase inhibitors useful for the treatment of autoimmune and inflammatory diseases: wherein: G is —N═ or —CH═; D is an optionally substituted divalent mono- or bi-cyclic aryl or heteroaryl radical having 5-13 ring members; R6 is hydrogen or optionally substituted CrC3 alkyl; P... Agent: Banner & Witcoff, Ltd.

20110034521 - Compounds and methods for treating zinc matrix metalloprotease dependent diseases: The present invention provides compounds and methods for treating zinc matrix metalloprotease dependent diseases. In certain embodiments, the compounds of the present invention have the following formulas:... Agent: Brown Rudnick LLP

20110034522 - Methods for alleviating deleterious effects of 3-deoxyglucosone: Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter... Agent: Dann, Dorfman, Herrell & Skillman

20110034523 - Crystalline forms of rufinamide: a crystalline form, hereinafter designated as Form β, characterised by an XRPD spectrum as shown in FIG. 3, wherein the most intense peaks fall at 4.5, 9.0, 13.5, 18.0, 18.8, 19.5, 20.6, 24.6, 25.7, 26.5, 27.4, 27.9, 28.7, 30.0 and 31.8±0.2° in 2θ.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20110034524 - Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor: The invention relates to the compound (2S)-2-amino-2-{5-[4-(octyloxy)-3-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl}-1-propanol hemi-fumarate, processes for its preparation, pharmaceutical compositions containing them and its use in the treatment of conditions or disorders which are mediated via the S1P1 receptor.... Agent: Glaxosmithkline Global Patents

20110034525 - Nonsedating alpha-2 agonists: The present invention provides an α-2A/α-1A selective agonist that includes a compound represented by Structure 1 or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. The present invention further provides a pharmaceutical composition that contains a pharmaceutical carrier and a therapeutically effective amount of an α-2A/α-1A selective... Agent: Allergan, Inc.

20110034526 - Benzimidazole compounds: e

20110034527 - Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels: This invention relates to novel 2-amino benzimidazole derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Birch Stewart Kolasch & Birch

20110034528 - Elansolids, novel natural metabolites of flexibacter and antibiotically active derivatives thereof: The present invention describes Elansolids, a new class of novel anti-bacterial compounds of formula (I).... Agent: Licata & Tyrrell P.C.

20110034529 - Benzene, pyridine, and pyridazine derivatives: wherein R1, R2, R3, R4, R5, R6, R7, n, Q1, Q2, Q3, Y, and X1-X4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions... Agent: Pfizer Inc

20110034530 - Process for the preparation of fipronil and analogues thereof: The present invention relates to a new and efficient process for preparing 5-amino-1-(2,6-dichloro-4-(trifluo-romethyl)phenyl)-4-(trifluoromethylthio)-IH-pyrazole-3-carbonitrile (hereinafter referred to as compound of formula I), which is useful as an intermediate for the antiparasitic agent fipronil, and a process for preparing 5-amino-3-cyano-1-(2,6-dichloro-4-tri-fluoromethylphenyl)-4-trifluoromethyl sulfinylpyrazole (hereinafter referred to as compound of formula II or fipronil). In... Agent: Blank Rome LLP

20110034531 - Use of hdac inhibitors for the treatment of melanoma: The invention relates to the use of an HDAC inhibitor, more specifically or a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for the treatment of melanoma; the use of an HDAC inhibitor or a pharmaceutically acceptable salt thereof in the treatment of melanoma; a method of treating... Agent: Novartis Corporate Intellectual Property

20110034547 - Chondropsin-class antitumor v-atpase inhibitor compounds, compositions and methods of use thereof: e

20110034548 - Method for suspending a flavonoid in a beverage: Disclosed is a method for suspending microparticulated flavonoid in a beverage by incorporating a microparticulated flavonoid and at least one suspension agent into a beverage. A composition comprising microparticulated quercetin and a suspension agent is also disclosed.... Agent: Banner & Witcoff, Ltd. And Attorneys For Client No. 006943

20110034549 - Antitumoral compounds: s

20110034550 - Inclusion compounds of fumagillol derivative or its salt, and pharmaceutical compositions comprising the same: The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-β-cyclodextrin or sulfobutylether-7-β-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or... Agent: Goodwin Procter LLP Patent Administrator

20110034551 - Methods of increasing sarcosine levels for treating schizophrenia: Methods for increasing sarcosine levels in a patient are provided. The methods include activating the PPARα receptor. Increasing sarcosine levels can be used, for example, as part of a treatment for schizophrenia.... Agent: K&l Gates LLP

20110034552 - Long-chain oxyaminopolyol based gelator and gel: t

20110034553 - Novel conjugates for treating neurodegenerative diseases and disorders: A conjugate comprising L-DOPA covalently linked to at least one y-aminobutyric acid (GABA) moiety, an ester and/or an addition salt thereof are disclosed, as well as uses thereof for treating a neurodegenerative disease or disorder.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20110034554 - Compositions and methods for treating macular degeneration: Methods of retarding formation of a lipofuscin pigment in the retina and of treating or ameliorating the effects of a disease characterized by an accumulation of a lipofuscin pigment in a retina are provided. These methods include the step of administering to a patient in need thereof a substituted C20-retinoid... Agent: Bryan Cave LLP

20110034555 - Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.... Agent: K&l Gates LLP

20110034556 - Use of transglutaminase inhibitor in skin treatment: Human skin is treated for cosmetic purposes, in particular for the management of skin irritation and/or inflammation as well as inhibiting ageing effects, which result therefrom by using a topical cream containing at least one transglutaminase inhibitor such as putrescine.... Agent: Sim & Mcburney

20110034557 - Antimicrobial compositions and uses thereof: Antimicrobial compositions and methods of using the compositions are described herein. The compositions include an antibacterial acyl amino acid. In some embodiments, the acyl amino acid is a fatty acylated glutamate. The methods herein include methods of using acyl amino acids for treating and preventing bacterial infections.... Agent: Choate, Hall & Stewart LLP Patent Department

20110034558 - Dp2 antagonist and uses thereof: Described herein is the DP2 antagonist [2′-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable... Agent: Wilson, Sonsini, Goodrich & Rosati

20110034559 - Cell repair and regeneration by suramin and related polysulfonated naphthylureas: Disclosed herein are compositions and methods for promoting the repair and regeneration of injured tissues, such as injuries resulting from ischemic damage. Also disclosed are compositions and methods for accelerating wound healing in diabetic and elderly patients and inhibiting allograft failure.... Agent: Ballard Spahr LLP

20110034560 - Liquid formulations of compounds active at sulfonylurea receptors: The invention provides liquid formulations of compounds that act at sulfonylurea receptors that are suitable for intra-venous and intra-arterial infusion. Compounds active at a sulfonylurea receptor include glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, midaglizole, LY397364, LY389382, glyclazide, and glimepiride. Liquid formulations may be concentrated solutions suitable for storage; may be diluted... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20110034561 - Antibacterial cosmetic applicator: Provided is an antibacterial brush material for make-up with long-lasting antibacterial properties, wherein the loss of the antibacterial agent through washing or the like is prevented by treating a synthetic fiber with a phenol compound and one or more quarternary ammonium salts selected from among: alkyl ammonium salts, alkyl benzyl... Agent: Knobbe Martens Olson & Bear LLP

20110034562 - Psycho-pharmaceuticals: The invention provides a selective Sigma 1 or Dopamine D3 receptor agonist or a 5HT2c receptor ligand for use in the treatment of symptoms of anxiety and/or depression associated with an affective disorder and/or symptoms associated with cognitive impairment disorder. Particularly useful are diphenhydramine derivatives of Formula (I) and particularly... Agent: Hunton & Williams LLP Intellectual Property Department

20110034563 - Compartment-specific plant extract combination of ginkgo biloba extract and ginseng extract having a tandem effect: The invention relates to a plant extract combination of ginkgo and ginseng which is effective especially in a (synergistic) over-additive manner and optionally comprises whitethorn extract. Ginseng is used in the form of an ethanol/ethanol/water extract while ginkgo is used in the form of an acetone/acetone-water extract, for example, and... Agent: Collard & Roe, P.C.

20110034564 - Soluble complexes of curcumin: A composition comprising a water-soluble and stable complex formed by an alkyl ether derivative of gamma-cyclodextrin and curcumin and optionally comprising non-complexed cyclodextrin, the molar ratio of curcumin to cyclodextrin being between 1:1 and 1:6, and a method of manufacturing such a composition. The water-soluble and stable complex of curcumin... Agent: Sughrue Mion, PLLC

20110034565 - Psycho-pharmaceuticals: The invention provides a compound for use in the treatment of symptoms associated with psychosis, schizophrenia, a cognitive impairment disorder, a mood disorder, a nervous system disorder and/or a behavioral disorder. The compound has the formula ? and is administered to a subject in need thereof in an effective amount.... Agent: Hunton & Williams LLP Intellectual Property Department

20110034566 - Long term drug delivery devices with polyurethane based polymers and their manufacture: e

20110034567 - Semi-crystalline, fast absorbing polymer formulation: The present invention relates to a composition comprising a semi-crystalline, absorbable copolymer formulation wherein the first component is hydroxy-capped polycondensation product of diglycolic acid and a mixture of two idols, diethylene glycol (DEG) and ethylene glycol (EG), with DEG added in larger molar amount, and wherein the second component, glycolide... Agent: Philip S. Johnson Johnson & Johnson

20110034568 - Compositions comprising lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity: A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to... Agent: Katten Muchin Rosenman LLP (c/o Patent Administrator)

  
02/03/2011 > patent applications in patent subcategories. patent applications/inventions, industry category

20110028383 - Activated forms of notch and methods based thereon: The present invention is directed to methods for detecting or measuring Notch activation by observing or measuring the appearance of Notch on the cell surface or by observing or measuring Notch cleavage products that are indicative of Notch activation. The present invention is also directed to methods for detecting a... Agent: Jones Day

20110028382 - Treatment of oral pharyngeal dysphagia: The invention provides compounds for use in a method of treating oral pharyngeal dysphagia in an individual and related products. One embodiment of the invention comprises administering to an individual an effective amount of a vanilloid receptor 1 (VR-1) agonist or high-affinity partial agonist to promote a swallow reflex.... Agent: Nestle Healthcare Nutrition

20110028384 - Rap variants for drug delivery: The present invention relates to stabilized RAP variants and methods of use thereof. Conjugates of stabilized RAP variants to therapeutic compounds and stabilized RAP fusion proteins comprising therapeutic polypeptides are also presented.... Agent: Wolf Greenfield & Sacks, P.C.

20110028385 - Combination of immunomodulator and anti-pathogenic agent: A compound comprising combination of an immunomodulator and to at least one anti-pathogenic agent for treating of facultative or strict infections caused by intracellular microorganisms, the components of the combination or association of substances of the invention, the immunomodulator (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) and at least... Agent: Stites & Harbison PLLC

20110028386 - Antimicrobial peptides: Disclosed are antimicrobial peptides with useful or superior properties such as antimicrobial activity, desirable levels of hemolysis, and advantageous therapeutic index against various microorganisms, especially Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Also provided are methods of to control microbial growth and pharmaceutical compositions to treat or prevent microbial infections.... Agent: Greenlee Sullivan P.C.

20110028388 - Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof: The growth hormone with high biological activity modified by the double-stranded polyethylene glycol at a single site and the preparation method thereof are provided. The PEGylated growth hormone has a higher biological activity and a longer half-life than the unmodified growth hormone. The composition comprising the PEGylated growth hormone is... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20110028387 - Methods of screening of pp1-interacting polypeptides or proteins, peptides inhibiting pp1c binding to bcl-2 proteins, bcl-xl and bcl-w, and uses thereof: The invention relates to methods for identifying novel PP1-interacting polypeptides and proteins, compounds which are able to inhibit the binding of PP1c to certain factors naturally interacting with it, especially proteins of the Bcl-2 family (such as Bcl-xL and Bcl-w).... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110028390 - Pyrazolospiroketone acetyl-coa carboxylase inhibitors: The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of acetyl-CoA carboxylase enzyme(s) in an animal.... Agent: Pfizer Inc. Patent Department

20110028389 - Use of infant formula with reduced protein content: A method of continuously reducing the circulating level of insulin like growth factor 1 (IGF-1) in the first few months of the life of an infant comprises administering to the 5 infant a nutritional composition comprising proteins in an amount such that the composition contains less than 2.25 g of... Agent: K&l Gates LLP

20110028391 - Use of glp-1 peptides: GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20110028392 - Methods for use of branched amino acids: The invention provides an orally-administrable nutritional product comprising a dipeptide including a branched chain amino acids (BCAA). In one embodiment, the nutritional product comprises a dipeptide selected from at least one of the following: alanyl-leucine, alanyl-isoleucine, alanyl-valine, glycyl-leucine, glycyl-isoleucine, and glycyl-valine.... Agent: Nestle Healthcare Nutrition

20110028393 - Flowable paste and putty bone void filler: The present invention provides a composition that may be used as an implant or a bone graft substitute or extender for filling voids and/or promoting fusion of osseous tissues. The implant may comprise ceramic granules such as calcium phosphate granules and one or more polysaccharide excipients, and may be in... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20110028394 - Therapeutic agents for reducing parathyroid hormone levels: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds... Agent: King & Spalding LLP

20110028395 - Peptide modulators of angiogenesis and use thereof: The invention generally features compositions and methods that are useful for modulating blood vessel formation, as well as methods that provide for the systematic and efficient identification of angiogenesis modulators. As described in more detail below, a systematic computational methodology based on bioinformatics was used to identify novel peptide modulators... Agent: Edwards Angell Palmer & Dodge LLP

20110028396 - Medical composition: It is an object of the present invention to attach a biopolymer composition to a synthetic polymer substrate without the use of a toxic adhesive. The present invention provides a medical composition, wherein a synthetic polymer substrate and a composition mainly composed of a biopolymer directly adhere to each other... Agent: Sughrue Mion, PLLC

20110028397 - Use of urokinase type plasminogen activator inhibitors for the treatment of corneal disorders: The invention concerns the use of inhibitors of the urokinase type of plasminogen activator (uPA) appearing in the anterior segment of the eye, for the treatment and prevention of corneal ulcers and other disorders. The invention further concerns pharmaceutical compositions, comprising inhibitors of uPA, preferably eye drops and eye ointments.... Agent: Hahn & Voight PLLC

20110028398 - Methods for treating and limiting fibrotic disorders and keloids: The present invention provides methods for treating and/or limiting fibrotic disorders and/or treating or limiting scars selected from the group consisting of keloids and hypertrophic scars comprising administering to an individual in need thereof an amount effective to treat and/or limit scars selected from the group consisting of keloids and... Agent: Foley & Lardner LLP

20110028399 - Citrullinated cytokines: The present invention provides natural occurring, recombinant and synthetic chemokines, interleukins and cytokines in which at least one arginine residue is replaced by or modified into a cltrulline residue. The present Invention also relates to the use of said chemokines, interleukins or cytokines and pharmaceutical compositions comprising said chemokines, interleukins... Agent: Dinsmore & Shohl LLP

20110028400 - Sulfated unsaturated disaccharidic chondroitin sulfate in connective tissue protection and repair: The present invention generally relates to the protection and repair of connective tissues. In particular, the present invention relates to the use of chondroitin sulfates and its derivatives in connective tissue protection and repair. The present inventors have found that unsaturated disaccharidic chondroitin sulfate can be used for the preparation... Agent: K&l Gates LLP

20110028401 - Cripto blocking molecules and therapeutic uses thereof: The present invention concerns a monomeric or multimeric tripeptide molecule able of inhibiting Cripto signalling in embryonic stem cells, thereby enhancing dopamine specification and differentiation, after transplantation in animal models of Parkinson's disease, as well as reducing tumor formation, and uses thereof.... Agent: Lucas & Mercanti, LLP

20110028402 - Substance p-saporin (sp-sap) conjugates and methods of use: Lastly, this invention provides a method for treating a NK-1R-associated disorder in a subject, which comprises administering to the subject an amount of the pharmaceutical composition comprising substance P, or an analog thereof, and a protein such as Saporin that inhibits protein synthesis, in an effective amount to treat the... Agent: Mcdermott, Will & Emery LLP

20110028403 - Hsp70-based treatment for autoimmune diseases and cancer: A non-natural HSP70 activating region that activates dendritic cells. Polypeptides that bind to the HSP70 activating region can be used to treat autoimmune diseases, such as vitiligo, by binding to HSP70 and preventing HSP70 form activating dendritic cells. The HSP70 binders can be constructed in the form of fusions proteins... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20110028404 - Composition comprising vegetable peptone for promoting stem cell proliferation: The present invention relates to a composition for promoting stem cell proliferation which contains a vegetable peptone. More specifically, this invention relates to: a serum-free composition for culturing stem cells which contains a vegetable peptone; a composition for improving skin condition containing the vegetable peptone as an active ingredient; and... Agent: Clark & Elbing LLP

20110028406 - Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant: Pharmaceutical compositions, which enable high absorption when administered orally, and which comprise a cyclosporin or cyclosporin derivative dissolved in a solvent-surfactant system further comprising a hydrophilic surfactant and a lipophilic surfactant, with minimal quantities of solvents.... Agent: Mckinnons Patents Inc

20110028405 - Sulfamides as zap-70 inhibitors: wherein X, R1, R2, R3, R8, R9 have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of ZAP-70 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds,... Agent: Klauber & Jackson

20110028408 - diagnostic molecule and therapeutic target: Provided herein are methods and compositions for regulating airway tissue remodelling and for treating or preventing conditions associated with airway inflammation and/or airway tissue remodelling. The methods comprise normalising fibulin-1 levels in said tissue relative to normal endogenous levels. In an embodiment the methods comprise administering to a subject in... Agent: Lowe Hauptman Ham & Berner, LLP

20110028407 - Enhancement of innate resistance to infection: The present invention provides compounds and compositions that enhance the innate immune system. The present invention comprises methods of preventing, treating or ameliorating an infectious disease comprising administering said compounds to a subject. The invention also comprises methods of formulation and administration of said compounds.... Agent: Cooley LLP Attn: Patent Group

20110028409 - Detection of anti-ribosomal p protein antibodies by means of synthetic peptides: The present invention refers peptides and methods for the identification of diagnostic antibodies in auto-immune diseases such as Systemic Lupus Erythematosus (SLE), and therefore useful tools for diagnosis or therapeutic treatment of SLE.... Agent: Lucas & Mercanti, LLP

20110028411 - Alpha-galactoceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them: The invention relates to α-galactoceramide analogs, their methods of manufacture, intermediate compounds useful in these methods. It also relates to pharmaceutical compositions containing the α-galactoceramide analogs. The methods of manufacture of the invention involve the use of unsaturated intermediate compounds which enable to synthesize α-galactoceramide analogs by a mere metathesis... Agent: Morgan Lewis & Bockius LLP

20110028414 - Glucopyranoside derivatives: Novel compounds of the formula (I), in which X has the meaning indicated in Patent Claim 1, are suitable as antidiabetics.... Agent: Millen, White, Zelano & Branigan, P.C.

20110028412 - Herbal enhanced analgesic formulations: The analgesic properties of L-tryptophan and 5-HTP can be safely enhanced with the coadministration of salacin. Salacin can be effectively provided in the form of white willow bark along with other ingredients to further enhance the formulation's analgesic effect. As salacin can cause the loss of vitamin C in humans,... Agent: Lawrence J. Shurupoff

20110028413 - Methods of reducing methotrexate nephrotoxicity: The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs such as methotrexate. The invention provides compositions comprising a substituted cyclodextrin, methotrexate and a pharmaceutically acceptable carrier, where the cyclodextrin is present in an amount effective for substantially inhibiting the nephrotoxic effect of the methotrexate.... Agent: Merchant & Gould PC

20110028410 - Use of amygdalin analogues for the treatment of psoriasis: The compounds of formula (1), wherein n is an integer from 0 to 4; R1 is a radical selected from the group consisting of H, CH3, CH2-CH3, C(CH3)3, COOH, CONH2 and C=CH; R2, R3, R4 and R5 are radicals independently selected from the group consisting of H, F, Cl, Br,... Agent: Berenbaum Weinshienk PC

20110028416 - Nutritional compositions for promotion of bone growth and maintenance of bone health comprising extracts of for example rosemary or caraway: Compositions and methods for maintenance of bone health or prevention, alleviation and/or treatment of bone disorders are presented. The present invention also provides the manufacture of a nutritional product, a supplement or a medicament for promoting bone growth or for the maintenance of bone health and methods regarding same. In... Agent: K&l Gates LLP

20110028415 - Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukenia management: The present invention relates to the use of a compound of formula (I) wherein R1 is H, C1-C6-alkyl, phenyl-C1-C4-alkyl or phenyl, R2 is a phenyl group which is substituted with 2 or 3 C1-C6-alkoxy groups and R3 is indolyl or azaindolyl which may carry one or two substituents independently selected... Agent: Viksnins Harris & Padys Pllp

20110028417 - Macrocyclic compounds and methods of use thereof: The invention features novel macrocyclic compounds, methods of making the compounds, pharmaceutical compositions including the compounds, and methods of treatment using the compounds.... Agent: Edwards Angell Palmer & Dodge LLP

20110028418 - Use of gabba receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness: GABAA receptor mediated hypersomnia can be treated by administering a GABAA receptor antagonist (e.g., flumazenil; clarithromycin; picrotoxin; bicuculline; cicutoxin; and oenanthotoxin). In some embodiments, the GABAA receptor antagonist is flumazenil or clarithromycin. The GABAA receptor mediated hypersomnia includes shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, narcolepsy, excessive sleepiness, hypersomnia... Agent: Fish & Richardson P.C. (at)

20110028419 - Fungicide composition for agriculture and horticulture and method for preventing plant diseases: B

20110028532 - Methods of treating eye diseases in diabetic patients: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.... Agent: Cooper & Dunham, LLP

20110028533 - Novel fer -like protein, pharmaceutical compositions containing it and method for its use: Provided is a novel Fer-like protein, referred to as “FerC” (Fer colorectal cancer). FerC is a 47kDa protein having a unique N-terminal sequence and was found to be present in six colon cancer cell-lines and in five hepatocarcinoma (liver cancer) cell-lines, but not in CCD33 normal colon epithelial cells or... Agent: The Nath Law Group

20110028531 - Novel sirna compounds for inhibiting rtp801: The present invention provides chemically modified siRNA compounds that target RTP801 and pharmaceutical compositions comprising same useful for treating microvascular disorders, eye diseases, hearing impairment, neurodegenerative diseases and disorders, spinal cord injury and respiratory conditions.... Agent: Cooper & Dunham, LLP

20110028535 - Oligonucleotides-transferring preparations: Preparations for transferring efficiently oligonucleotides necessary in antisense therapy or the like into animal cells so as to be useful in treatment for various diseases, which comprises a collagen as an essential component are provided.... Agent: Birch Stewart Kolasch & Birch

20110028534 - Rnai inhibition of ctgf for treatment of ocular disorders: RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention.... Agent: Alcon

20110028536 - Methods and compositions for topoisomerase i modulated tumor suppression: Disclosed herein are methods and compositions for enhancing the sensitivity of cells to the effects of topoisomerase I inhibitors. Also disclosed are methods and compositions for inducing apoptosis and/or growth arrest which may be used for tumor suppression.... Agent: Foley & Lardner LLP

20110028538 - Methods and compositions related to tr4 ligand: Disclosed are compositions and methods related to TR4 and aging.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20110028537 - Somatic cell reprogramming: The present invention relates to methods for reprogramming a somatic cell to pluripotency by administering into the somatic cell at least one or a plurality of potency-determining factors. The invention also relates to pluripotent cell populations obtained using a reprogramming method.... Agent: Quarles & Brady LLP

20110028420 - Regression of established atherosclerotic plaques, and treating sudden-onset asthma attacks, using parp inhibitors: A method is disclosed for treating and inducing the regression of established atherosclerotic plaques. A method is disclosed for treating asthma, including treatment of an ongoing asthma attack. In both cases, treatment with PARP inhibitors, such as the PARP inhibitor TIQ-A (Thieno[2,3-c]isoquinolin-5-one), can lead to regression of existing disease and... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20110028422 - Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia: The invention relates to a combination which comprises (a) a DNA damaging agent; and (b) 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide (“nilotinib”); a pharmaceutical composition comprising such a combination and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment chronic lymphocytic leukemia (CLL); the use of... Agent: Novartis Corporate Intellectual Property

20110028421 - Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals: e

20110028423 - Agent that modulates physiological condition of pests, involved in insect choline acetyltransferase activity: The present invention provides an agent that modulates physiological condition of pests, wherein the agent has an ability to modulate the activity of an insect choline acetyltransferase; a method for assaying pesticidal activity of a test substance, which comprises measuring the activity of a choline acetyltransferase in a reaction system... Agent: Sughrue Mion, PLLC

20110028424 - Oil-in-water microemulsion carrying large amount of oil: An oil-in-water microemulsion is provided, which includes, on the basis of its total weight, the following components of A) 55-95 wt % of a water phase; B) 0.1-20 wt % of an oil phase, wherein the oil phase comprises at least one oil/fat component containing polyoxypropylene chains; and C) 1-25... Agent: Leopold Presser, Scully, Scott, Murphy & Presser

20110028425 - Vesicle and cosmetic containing the same: A vesicle according to the present invention is characterized in that it comprises a sucrose fatty acid diester and an acyl methyl taurate in an amount of 5 to 30 wt % relative to the diester and that the sucrose fatty acid diester is contained as a main component of... Agent: Rankin, Hill & Clark LLP

20110028426 - Dewatering biomass material comprising polysaccharide, method for extracting polysaccharide from biomass material, and dewatered biomass material: A process for dewatering biomass material comprising polysaccharide and water. The process comprises wetting the biomass material with a wetting composition comprising an alcohol to form a biomass slurry comprising wetted biomass material and a liquid component, mechanically separating a portion of the liquid component from the biomass slurry, and... Agent: Peter G. Pappas Sutherland Asbill & Brennan LLP

20110028427 - Dietary fiber and method for preparing dietary fiber: The invention relates to a soluble antioxidant dietary fiber obtained from pineapple and a method of processing pineapple pulp to provide a soluble antioxidant fiber.... Agent: Nixon Peabody LLP - Patent Group

20110028428 - Hirsutella sinensis mycelia compositions and methods for treating sepsis and related inflammatory responses: Compositions comprising Hirsutella sinensis mycelia extracts and chromatographically separated polysaccharide-enriched fractions thereof are provided. Methods for extracting Hirsutella sinensis mycelia are provided. Compositions for methods for their use in amelioration, prevention and treatment of sepsis, acute endotoxemia and inflammatory responses are disclosed.... Agent: Basu Intellectual Property, PC

20110028429 - Combination of polychitosamine and hmg-coa reductase inhibitor for hyperlipidemia: Combinations of therapeutic compounds for prophylaxis or treatment of hyperlipidemia and hyperlipidemia related disorders, such as hypercholesterolemia and the resultant atherosclerosis in a mammal. The combinations are useful for reducing serum cholesterol, and/or cholesteryl ester, triglycerides, phospholipids and fatty acids in a mammal. The methods of the preferred embodiments comprise... Agent: Choate, Hall & Stewart LLP

20110028430 - Injectable viscous medicinal preparation comprising ethanol and an x-ray opaque fat-soluble compound: An injectable medicinal preparation is including ethanol and at least one at least partially X-ray opaque, fat-soluble compound, characterized in that it further comprises an ethanol-soluble compound which, when dissolved, has a viscosity ranging from 10 to 700 cP and preferably from 90 to 350 cP at 25° C., so... Agent: Young & Thompson

20110028431 - Oral mucoadhesive dosage form: A direct compression formulation suitable for preparing buccal and/or sublingual and dosage forms incorporates a combination of a non-ionic polymeric solubility enhancer, a mucoadhesive polymer, a filler, a disintegrant, and a pharmaceutically active agent. Cannabinoid-cyclodextrin complexes exhibiting an improved property selected from improved stability, higher product yield and improved product... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20110028432 - Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases: The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma.... Agent: Jacobson Holman PLLC

20110028433 - Quinazolinone derivatives as tubulin polymerization inhibitors: e

20110028434 - Long-chain polyunsaturated fatty acids (lc-pufa) in maternal nutrition during pregnancy and lactation: The present invention relates in general to maternal food compositions. In particular, the present invention relates to maternal food compositions comprising LC-PUFA and their uses. Embodiments of the present invention relate to maternal food compositions comprising a source of lipids, wherein the source of lipids includes at least one LC-PUFA... Agent: K&l Gates LLP

20110028435 - Crystallization method and bioavailability: Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.... Agent: J.a. Lindeman & Co. PLLC

20110028436 - Oral combination of vitamins: This invention provides compositions for treating and preventing nausea and other disorders, the compositions comprising vitamins as active ingredients, including vitamin B6, vitamin K, and vitamin C, and a method for treating nausea or morning sickness with the oral compositions.... Agent: Daniel J Swirsky

20110028437 - Phosphorylated pyrone analogs and methods: The invention relates to phosphorylated polyphenols, phosphorylated flavonoids, and phosphorylated pyrone analogs. Methods and compositions for the modulation of side effects of substances using such phosphorylated compounds are described. Methods and compositions are described for the modulation of blood-tissue barrier (BTB) transporter activity to increase the efflux of drugs and... Agent: Seed Intellectual Property Law Group PLLC

20110028438 - Medical use of 3-2,2,2-trimethylhydrazinium propionate salts.: The present invention relates to highly effective treatment of ischemic heart disease with 3-(2,2,2-trimethylhydrazinium) propionate hydrogen fumarate, and 3-(2,2,2-trimethylhydrazinium) propionate dihydrogen phosphate.... Agent: The Firm Of Hueschen And Sage

20110028439 - Combination hormone replacement therapy (hrt) and melatonin to prevent and treat mammary cancer: A combination hormone and melatonin therapy is provided to reduce the risk of developing, or to reduce the severity of, breast cancer by administering at least one estrogen hormone and optionally at least one progesterone-receptor-binding compound or composition and melatonin together, preferably at normal bed time.... Agent: Barbara E. Johnson, Esq.

20110028440 - Simultaneous method for the preparation of a mixture of 3-acetoxy-17-acetamido-16-formyl-androst-5,17-diene and 3-acetoxy-2'-chloro-5-androsteno[17,16-b]pyridine: The present invention relates to preparation and biological evaluation of 3-acetoxy-17-acetamido-16-formyl-androst-5,17-diene (4) and 3-acetoxy2′-chloro-5-androsteno[17,16-b]pyridine (5) as gastric proton pump inhibitor and their comparison to that of omeprazole, a clinically employed anti-gastric ulcer drug. Compound (4) exhibited dose dependent inhibition of histamine-stimulated acid secretion in gastric parietal cell with an IC50... Agent: Fulbright & Jaworski L.L.P.

20110028442 - Derivatives of 4-(2-amino-1-hydroxyethyl) phenol as agonists of the beta2 adrenergic receptor: The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the β2 adrenergic receptor.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20110028441 - Novel phenyl-substituted piperazino-dihydrothienopyrimidines: The invention relates to novel dihydrothienopyrimidines of the formula 1, and to pharmacologically acceptable salts thereof, formula (1) in which X is SO or SO2, but preferably SO, and either R3 is a monosubstituted phenyl ring in the ortho position or in the meta position, or R3 is a phenyl... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20110028443 - Ligands for nematode nuclear receptors and uses thereof: e

20110028444 - Pharmaceutically acceptable salts of anti-infection quinolone compounds: The invention discloses the pharmaceutically acceptable salts of an optically active quinolone compound useful against infection, specifically the pharmaceutically acceptable salts of (S)-6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid. The pharmaceutically acceptable salts of the present invention are stable and have improved water solubility. They possess higher biological activity, less toxicity for kidney and no... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20110028446 - Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors: or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L1, M and R11 are as defined herein. The compounds of Formula (I) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa,... Agent: Louis J. Wille Bristol-myers Squibb Company

20110028447 - Indazole derivatives: This invention relates to compounds, pharmaceutical compositions and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of formula (I) wherein R1,... Agent: Pfizer Inc. Patent Department

20110028449 - Novel aminomethyl benzene derivatives: The invention relates to novel aminomethyl benzene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.... Agent: Hoxie & Associates LLC

20110028448 - Pyridine compounds: The invention relates to pyridine compounds, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.... Agent: Hoxie & Associates LLC

20110028445 - Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use: The present invention relates to compounds defined by formula (I) wherein the groups A, B, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20110028451 - Dihydrobenzoindazoles: e

20110028452 - Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists: wherein the variables R1, R2, R3, R4 and R5 are as described herein. Also provided are pharmaceutical compositions comprising the compounds of formula I as well as methods of treatment employing compounds of formula I to treat a disease or disorder characterized by abnormal bone or mineral homeostasis such as... Agent: Pfizer Inc. Patent Department

20110028450 - Ring-annulated dihydropyrrolo[2,1-alpha]isoquinolines: e

20110028453 - Treating negative symptoms of schizophrenia associated with defective neuregulin 1: Use of a compound that is a serotonin transporter inhibitor, a selective norepinephrine reuptake inhibitor, or a 5-HT1A agonist for alleviating negative symptoms in a schizophrenia patient who carries a defective neuregulin 1 gene.... Agent: Occhiuti Rohlicek & Tsao, LLP

20110028454 - Deuterium-enriched bazedoxifene: The present application describes deuterium-enriched bazedoxifene, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20110028455 - Indole-substituted 3-cyanopyridines as kinase inhibitors: Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X is —O—, —N(R3)—, —S—, —S(O)— or —S(O)2—; R2 is a C1-4 alkyl group or —CF3; and R1, R3, R4 and p are as defined herein; wherein the compounds are useful as kinase inhibitors. Also disclosed are pharmaceutical... Agent: Wyeth LLC Patent Law Group

20110028458 - Inhibition of cell migration by a farnesylated dibenzodiazepinone: The invention relates to the discovery that dibenzodiazepinone analogues have cell migration inhibiting activities on neoplastic and endothelial cells. The migration of neoplastic cells from various tumor types, such as a glioma tumor that may comprise an EGF and/or PTEN mutation, or a Ras-, Raf, or EGFR-mediated tumor, may be... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20110028457 - Pharmaceutical preparation comprising permethylated cyclodextrin: The invention relates to a pharmaceutical preparation for applying a pharmaceutical agent. According to the invention, the preparation contains: a) a pharmaceutical agent which has an aromatic group or an aromatic part and the molecule of which has a maximum diameter of ≦2 nm; b) a permethylated cyclodextrin having a... Agent: Casimir Jones, S.c.

20110028456 - Solid pharmaceutical dosage form: A pharmaceutical composition comprising a solid unit dosage form comprising: one or more of pharmaceutically active ingredients selected from valacyclovir, olanzapine, voriconazole, topotecan, artesunate, amodiaquine, guggulosterone, ramipril, telmisartan, tibolone, atorvastatin, simvastatin, amlodipine, ezetimibe, fenofibrate, tacrolimus, valgancyclovir, valsartan, clopidrogel, estradiol, trenbolone, efavirenz, metformin, pseudoephedrine, verapamil, felodipine, valproic acid/sodium valproate, mesalamine, hydrochlorothiazide,... Agent: Conley Rose, P.C.

20110028459 - Wound healing: A phenothiazinium compound, compositions and medicaments for use in promoting wound healing and a method for promoting wound healing or cosmetic use by applying or administering a phenothiazinium compound to a wound site or the skin, and optionally exposing the wound site or skin to light.... Agent: Morgan Lewis & Bockius LLP

20110028460 - Topical formulation: It has been discovered that certain combinations compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of active agents. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. There is... Agent: Foley And Lardner LLP Suite 500

20110028461 - Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists: The present invention provides compounds of Formula I, pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.... Agent: Merck

20110028463 - Amide compounds: e

20110028465 - Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same:

20110028468 - Compounds having npy y5 receptor antagonistic activity:

20110028467 - Heterocyclic derivatives: The present invention relates to heterocyclic derivatives, and more particularly, to novel heterocyclic derivatives useful for the preparation of medicaments for treating diseases related to uric acid.... Agent: Birch Stewart Kolasch & Birch

20110028464 - Inhibitors of human immunodeficiency virus replication: Compounds of formula I: wherein c, R2, R3, R4, R5, R6, R7 and R8 are defined herein, are useful as inhibitors of HIV replication.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20110028462 - Niacin receptor agonists, compositions containing such compounds and methods of treatment: A method of treating atherosclerosis and related conditions using compounds of formula I: as well as pharmaceutically acceptable salts and solvates is disclosed. The compounds are useful for treating dyslipidemias, and in particular, reducing serum LDL, VLDL and triglycerides, and raising HDL levels.... Agent: Merck

20110028466 - Nitroimidazooxazine and nitroimidazooxazole analogues and their uses: The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for Mycobacterium tuberculosis, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency against Trypanosoma cruzi or Leishmania donovani, and for the treatment of other microbial... Agent: Jackson Walker LLP

20110028469 - Thiphene-2-carboxamide derivatives as modulators of ccr9 receptor: Provided are compounds of Formula (I) or of Formula (II) that are modulators of CCR9 receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or amelioratin diseases associated with modulation of CCR9 receptor activity.... Agent: Pfizer Inc. Patent Department

20110028470 - Detection and treatment of schizophrenia: The present invention provides a method for diagnosing schizophrenia, and a schizophrenia diagnostic reagent or device for use in the method. The present invention further provides a therapeutic or ameliorating agent for schizophrenia, which is effective for the treatment or amelioration of schizophrenia. The therapeutic or ameliorating agent for schizophrenia... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20110028471 - Combination therapy 238: There is provided a combination product comprising a VEGFR tyrosine kinase inhibitor and a m TOR-selective kinase inhibitor, and methods for the production of an anti-cancer effect in a patient, which is accordingly useful in the treatment of cancer in a patient.... Agent: Astrazeneca R&d Boston

20110028472 - Thienopyrimidines: Novel thienopyrimidines of the formula (I), in which R1, R2 and X have the meanings indicated in Claim 1, are inhibitors of TGF-beta receptor kinase, and can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20110028473 - Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives: Method of manufacturing a medicament including a compound of formula (I) for treating a subject suffering from growth of a tumor cell; for treating a subject suffering from pancreatic cancer; for treating a subject suffering from HER-2 positive breast cancer; or for treating a subject suffering from drug resistant non-small... Agent: Merchant & Gould PC

20110028474 - Protein kinase and phosphatase inhibitors: The present invention provides a method for identifying inhibitors of protein kinases and/or protein phosphatases. Methods are also provided for inhibiting protein kinase and/or protein phosphatase activity. Specific non-peptide protein tyrosine kinase and/or protein phosphatase inhibitors are provided. The protein kinase or protein phosphatase inhibitors of the present invention may... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20110028475 - Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics: wherein R1, R2, n and B are as defined in the disclosure, their preparation and their use in therapies for the treatment of central nervous system diseases such as vigilance and sleep disorders, narcolepsy, Alzheimer's disease and other dementias, Parkinson's disease, attention disorders in hyperkinetic children, memory and learning disorders,... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20110028476 - Proton pump inhibitors: wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2, R3 and R4 are the same or different and... Agent: Edwards & Angell, LLP

20110028477 - Stable ophthalmic formulations: Disclosed herein are stable formulations suitable for the treatment of glaucoma and ocular hypertension.... Agent: Wilson, Sonsini, Goodrich & Rosati

20110028478 - Isoxazolines as inhibitors of fatty acid amide hydrolase: s

20110028480 - Orodispersable formulations of phosphodiesterase-5 (pde-5) inhibitors: Orodisperable formulations of phosphodiesterase-5 (PDE-5) inhibitors and methods of manufacturing such are provided. Further, an improved dosage form and method of treating sexual dysfunction are provided.... Agent: Akerman Senterfitt

20110028479 - Substituted pyrrolotriazines and their use: The present application relates to new, substituted pyrrolo[2,1-f][1,2,4]triazine derivatives of the formula (I) as prostacyclin (PGI2) IP receptor activators for the treatment and/or prophylaxis of cardiovascular disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20110028481 - Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.... Agent: Merck

20110028483 - Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds for example, indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles,... Agent: Millen, White, Zelano & Branigan, PC

20110028482 - Isoxazolines as inhibitors of fatty acid amide hydrolase: e

20110028485 - 1,5-diphenylpyrazoles ii as hsp90 inhibitors: Novel 1,5-diphenylpyrazole derivatives of the formula (I) in which R1-R6 have the meanings indicated in claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.... Agent: Millen, White, Zelano & Branigan, P.C.

20110028486 - Indoles as modulators of nicoticic acetylcholine receptor subtype alpha-7: The present invention relates to modulation of the α7 nicotinic acetylcholine receptor (nAChR) by a compound of List A or a salt thereof, which may be represented, but is not limited to the compound N-[(2-Trifluoromethyl-1H-indol-5-yl)methyl]-5-(trifluoromethyl)-2-pyrimidinecarboxamide.... Agent: Glaxosmithkline Global Patents -us, Uw2220

20110028487 - Imidazopyrimidines and uses thereof: The present invention provides a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. The present invention further provides a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of formula (I)... Agent: Fish & Richardson P.C. (ny)

20110028488 - Combination product comprising src kinase inhibitor azdo530 and an antioestrogen or egfr-tk-inhibitor: The invention relates to a combination for use in the synergistic treatment of breast cancer comprising an antioestrogen and the Src kinase inhibitor AZD0530, a combination for the synergistic treatment of cancer comprising an EGFR TKI and the Src kinase inhibitor AZD0530 and a triple combination for the synergistic treatment... Agent: Morgan Lewis & Bockius LLP

20110028489 - Pyrimidine derivatives and their use for treating bone-related disorders: The present invention relates to a new use of pyrimidine derivatives of formula I, as a free base or a pharmaceutically acceptable salt thereof in the manufacture of a medicament in the treatment and/or prophylaxis of Alzheimer's Disease:... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20110028484 - 2-phenyl-4-cyclopropyl-pyrimidine derivatives: The present invention relates to 2-phenyl-4-cyclopropyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.... Agent: Hoxie & Associates LLC

20110028490 - 4-phenyl-piperazin-1-yl-alkyl-benzoimidazol-2-one derivatives and their use as monoamine neurotransmitter re-uptake in-hibitors: This invention relates to novel 4-phenyl-piperazin-1-yl-alkyl-benzoimidazol-2-one derivatives of structure (I) useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy, and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Birch Stewart Kolasch & Birch

20110028491 - Apoptosis inhibitor: It is directed to provide a novel apoptosis inhibitor. Specifically directed is an apoptosis inhibitor containing a biphenylcarboxamide compound represented by the following formula (1) as an active ingredient, wherein R1 represents a hydrogen atom or a lower alkoxy group; R2 represents a hydrogen atom or a lower alkanoyl group;... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110028492 - Heteroaryl compounds and their uses:

20110028493 - Heterocyclic derivative and use thereof:

20110028494 - Hcv ns3 protease inhibitors: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.... Agent: Merck

20110028495 - The use of 6-halogeno-[1,2,4]-triazolo-[1,5-a]-pyrimidine compounds for combating pests in and on animals: e

20110028496 - Deuterium-enriched pyrimidine compounds and derivatives:

20110028497 - Novel derivatives of purinic and pyrimidinic antiviral agents and use thereof as potent anticancer agents: Novel N-acylated, O-acylated and (bis or tris)-N,O-acylated derivatives of purinic and pyrimidinic nucleoside analogs, pharmaceutical compositions containing same, and uses thereof for treating proliferative diseases or disorders are disclosed.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20110028498 - Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase: The present invention provides a method of selection of a patient, who is a candidate for treatment with a RET drug, whereby to predict an increased likelihood of response to a RET drug. The invention provides a method for determining the sequence of RET. The method provides ARMS primers optimised... Agent: Astrazeneca R&d Boston

20110028499 - Pharmaceutical combination comprising vitamin k: It is found that compounds having PPARδ agonistic activity induced abnormal blood coagulation or muscular disorder. A pharmaceutical combination comprising vitamin K and a compound having PPARδ agonistic activity can prevent the abnormal blood coagulation. A pharmaceutical composition comprising vitamin K can prevent muscular disorder.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20110028500 - Plant pathogen inhibitor combinations and methods of use: Combinations, compositions and methods of use for modulating plant pathogen infection using plant extracts containing anthraquinone derivatives which induce resistance to plant phytopathogens and an antimicrobial agent, a biological control agent and/or a surfactant having fungicidal activity... Agent: Cheryl H Agris Phd

20110028501 - Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment: Substituted cyclopropyl compounds of formula (I) are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.... Agent: Merck

20110028502 - Dihydropyrimidone amides as p2x7 modulators: b

20110028503 - Compositions and methods for inhibition of the jak pathway: Compounds I and II as well as salts and pharmaceutical compositions containing them are useful for treating diseases and/or disorders of the eye.... Agent: Weaver Austin Villeneuve & Sampson LLP

20110028504 - Formulation of radioprotective alpha beta unsaturated aryl sulfones: A pharmaceutical composition is provided for administration prior to or after exposure to ionizing radiation for reducing toxic effects of the radiation in a subject. An effective amount of the pharmaceutical composition provided comprising an effective amount of at least one radioprotective α, β unsaturated aryl sulfone, and at least... Agent: Law Offices Of Khalilian Sira, LLC

20110028505 - Compositions and methods for reducing food cravings: Disclosed are compositions for reducing food cravings, comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is an α-MSH agonist. Also disclosed are methods of reducing food cravings, comprising identifying an individual in need thereof and treating that individual... Agent: Knobbe Martens Olson & Bear LLP

20110028508 - Novel process for the preparation of scopine esters: The present invention relates to novel processes for the preparation of scopine esters and their quaternary salts. In particular, the present invention relates to a process for the preparation of tiotropium bromide, pharmaceutical compositions comprising tiotropium bromide and the use of such compositions in the treatment of respiratory disorders.... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20110028506 - Pharmaceutical composition for preventintion and treatment of restenosis comprising isoxazole derivatives: There is provided a pharmaceutical composition for prevention and treatment of restenosis comprising isoxazole derivatives. The pharmaceutical composition includes a therapeutic effective amount of isoxazole derivatives represented by Formula 1 or pharmaceutically available salts thereof. The pharmaceutical composition may be useful to prevent and treat vascular restenosis since the pharmaceutical... Agent: Gibbons P.C.

20110028507 - Pyridine derivatives and methods of use thereof: Disclosed herein are pyridine derivatives, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, pharmaceutical compositions comprising the same, and methods of modulating the level or activity of HIF in a subject, inhibiting hydroxylation of HIF α in a subject, modulating expression of HIF-regulated genes in a subject, treating... Agent: Woodcock Washburn LLP

20110028509 - Sulfonamides: s

20110028512 - Bis-heterocyclic imidazolyl compounds: Heterocyclic compounds of the general formula (I) are provided in which R, R1, R2, R3, R4 and n have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these compounds as medicaments, particularly as aldostereone synthase inhibitors,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20110028510 - Compositions, methods, and kits for treating influenza viral infections: The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infection caused by an influenza virus).... Agent: Gearhart Law LLC

20110028513 - Method for treating neurological disorders with imidazolium and imidazolinium compounds: There is presently provided methods for delivering a neuroprotective agent to a neural cell. The methods comprise contacting a neural cell with an imidazolium or imidazolinium compound as described herein, including an imidazolium or imidazolinium salt.... Agent: Klarquist Sparkman, LLP

20110028511 - Process for the manufacture of pharmaceutically active compounds: e

20110028514 - Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators: The present invention relates to methods of treatment of certain metabolic diseases, and to novel compounds and their prodrugs, and/or pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds useful in treating such diseases. In particular, this invention relates to the use of novel compounds and compositions for treatment of cardiovascular... Agent: Fish & Richardson P.C. (bo)

20110028515 - New piperidine derivatives: e

20110028516 - Stabilized and preserved ketoifen ophthalmic compositions: Ophthalmic compositions comprising ketotifen and a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w/v) of hydrogen peroxide, and methods for the treatment and prevention of allergic conjunctivitis using these compositions are provided herein.... Agent: Novartis Corporate Intellectual Property

20110028517 - 4-methyl-4,5-dihydro-1h-pyrazole-3-carboxamide useful as a cannabinoid cb1 neutral antagonist: The present invention relates to 4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide, and pharmaceutically acceptable salts and solvates thereof. It further concerns pharmaceutical compositions comprising this compound as active ingredient as well as processes and intermediates for preparing this compound and compositions. The referred compound is a cannabinoid CB1 neutral antagonist useful in the prophylaxis and... Agent: Barnes & Thornburg LLP

20110028518 - Dexlansoprazole process and polymorphs: Processes for the preparation of dexlansoprazole, an amorphous form of dexlansoprazole, a solid dispersion of amorphous dexlansoprazole and a pharmaceutically acceptable carrier, and processes for their preparation. Also provided are crystalline compounds 2-[(R)-[(4-chloro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and 2-[(R)-[(4-nitro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, and methods for their preparation.... Agent: Dr. Reddy''s Laboratories, Inc.

20110028519 - Small molecule insulin mimetics absent quinones: o

20110028520 - 1,5-diphenyl-pyrrolidin-2-one compounds as cb-1 ligands: CB-1 receptor inverse agonist compounds of Formula and pharmaceutical compositions for the treatment of obesity or cognitive impairment associated with schizophrenia.... Agent: Eli Lilly & Company

20110028521 - Pesticidal composition, and method for controlling pests: and each of R2 and R3 which are independent of each other, is a hydrogen atom, a halogen atom, C1-6 alkyl or C1-6 alkoxy) or its salt and at least one potency-enhancing component selected from the group consisting of a nonionic surface active agent, an anionic surface active agent, a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20110028522 - Fullerene therapies for inflammation: Described herein are methods for treating inflammatory disorders. The methods comprise administering to a subject in need thereof a therapeutically effective amount of a synthetically modified fullerene.... Agent: Buchanan, Ingersoll & Rooney PC

20110028523 - Selective alpha 2b/2c agonists: Described herein are compounds useful as agonists of alpha 2B/2C receptors. Pharmaceutical compositions including the presently described compounds and methods of treatment of diseases and conditions with the presently described compounds also are disclosed.... Agent: Allergan, Inc.

20110028524 - Pharmaceutical compositions for poorly soluble drugs: The invention relates to solid dispersions of poorly soluble compounds formed by co-precipitation and hot melt extrusion, resulting in improved stability and bioavailability. The invention also relates to hot melt extrusion processes used to prepare such solid dispersions.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20110028525 - Synergistic microbicidal compositions: This invention relates to synergistic combinations of selected isothiazolin-3-one microbicides in combination with a second microbicide or formulation ingredient or raw material. The combinations have greater efficacy than would be expected from combinations of the individual components. The combinations include mixtures of (a) Methyl-4-isothiazolin-3-one or (b) 1,2-Benzisothiazolin-3-one with one or... Agent: Rohm And Haas Company Patent Department

20110028526 - Valsartan solid oral dosage forms and methods of making such formulations: The invention relates to melt granulation processes for preparing immediate release and sustained release pharmaceutical formulations comprising valsartan.... Agent: Novartis Corporate Intellectual Property

20110028527 - Methods of treating neuropathic pain with benzimidazole derivative agonists of ppargamma: Embodiments of the invention relate to the treatment of neuropathic pain in mammals. Embodiments of the invention include methods for treating neuropathic pain with benzimidazole derivatives with PPARgamma agonist activity, as well as methods for preparing medicaments used in such treatments of mammalian pain.... Agent: Aestus Therapeutics Inc.

20110028528 - Pesticidal aqueous suspension composition: When an organosilicone surface active agent is added to a pesticidal aqueous suspension composition containing an active ingredient compound of a sparingly water-soluble pesticide for the purpose of attaining activity enhancement and formulation, the following problems arise: such that (1) the viscosity of the composition increases; (2) a large amount... Agent: Sughrue-265550

20110028529 - Novel crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid 471: New crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.... Agent: Morgan Lewis & Bockius LLP

20110028530 - Novel crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid 471: New crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.... Agent: Morgan Lewis & Bockius LLP

20110028539 - Biologically active taxane analogs and methods of treatment: wherein R1 and R2 are each selected from H, alkyl, alkenyl or aryl; R3 is hydroxyl or OP1; R4 is OH or R7COO; R7 is alkyl, alkenyl or aryl, R8 and R9 are each independently selected from H, alkyl or alkenyl. The compounds of the present application may particularly be... Agent: Morgan, Lewis & Bockius LLP

20110028541 - Lubiprostone crystal, the use and the method for the preparation thereof: The present invention relates to a lubiprostone crystal, the method for the preparation thereof, and a pharmaceutical composition or kit comprising the same, as well as the use of said crystal in the preparation of a medicament for the treatment of gastrointestinal tract diseases, especially constipation. The X-ray powder diffraction... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20110028540 - Synthesis of macrocyclic cancer chemotherapy agents and methods of use: Herein are described a process for forming a quaternary carbon useful in the preparation of macrolactones, an enantioselective synthesis of (+)-peloruside A, and methods for treating a patient in need of relief from cancer or a cancer-related disease. The described processes are useful for preparing compounds containing quaternary carbons, including... Agent: Barnes & Thornburg LLP

20110028542 - Compositions for prevention or treatment of anorexia-cachexia syndrome and uses thereof: A pharmaceutical composition for 1) increasing weight gain; and/or 2) decreasing weight loss; and/or 3) increasing appetite in a subject in need thereof, comprising purified β-caryophyllene together with a pharmaceutically acceptable carrier. Also provided are pharmaceutical compositions for use in the prevention or treatment of Anorexia-Cachexia Syndrome, the pharmaceutical composition... Agent: Goudreau Gage Dubuc

20110028543 - Formulations and methods of using nitric oxide mimetics in cancer treatment: The present invention relates to methods and formulations for inhibiting, treating and preventing a malignant cell phenotype, cell, tumor and/or disease. Administration of nitric oxide mimetics, such as low doses, is sufficient to increase, restore or maintain nitric oxide-mediated signaling in cells so that malignant cell phenotypes, cells, tumors and/or... Agent: Dowell & Dowell P.C.

20110028544 - Catechol protected levodopa diester prodrugs, compositions, and methods of use: Catechol protected levodopa diester prodrugs pharmaceutical, compositions comprising catechol protected levodopa diester prodrugs, and methods of using such prodrugs and pharmaceutical compositions for treating diseases such as Parkinson's disease are provided.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20110028545 - Process for incorporating antimicrobial products into soap compositions: The present invention relates to a process for producing concentrates of antimicrobial active ingredients, the concentrates themselves and their use for producing solid, liquid or pasty body cleaning compositions, such as in particular soaps.... Agent: Lanxess Corporation

20110028546 - Novel antimicrobial formulations incorporating alkyl esters of fatty acids and nanoemulsions thereof: The present invention relates to a novel antimicrobial composition and method comprising any of the C1-C4 monohydric alcohol esters of C8 to C22 fatty acids, and most preferably the C1-C4 monohydric alcohol esters of C8 to C12 fatty acids, namely, caprylic, capric, and lauric fatty acids. Specifically the invention is... Agent: Townsend And Townsend And Crew, LLP

20110028547 - Novel use of capsiate or dihydrocapsidate: The present invention relates to a new use of capsiate or dihydrocapsiate, more particularly to a composition for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease or for suppressing immunity comprising capsiate, dihydrocapsiate or a pharmaceutically acceptable salt thereof as an effective ingredient. The composition and immunosuppressant of... Agent: Edwards Angell Palmer & Dodge LLP

20110028548 - Beneficial effects of increasing local blood flow: The present invention generally relates to the improvement of tissue health by increasing local blood flow. In some aspects of the invention, increased local blood flow is effected by the transdermal delivery of the nitric oxide precursor L-arginine and/or its derivatives alone, or optionally in conjunction with an adjunct such... Agent: Wolf Greenfield & Sacks, P.C.

20110028550 - Compositions and methods for control of listeria monocytogenes: The present invention relates to methods for inhibiting the growth of pathogenic microbes in food products. In an embodiment the invention is a preservative composition including lactic acid or a salt thereof, acetic acid or a salt thereof, and propionic acid or a salt thereof. In an embodiment, the invention... Agent: Pauly, Devries Smith & Deffner, L.L.C.

20110028551 - Novel process for the preparation of sodium gamma-hydroxybutyrate: The present invention is directed to a process for the preparation of the saponification products of lactones, preferably three- to eight-membered lactones. The present invention is also directed to a process for the preparation of compounds having general formula (I): wherein M is selected from the group consisting of cationic... Agent: Ballard Spahr LLP

20110028549 - Use of a monoterpene to treat or prevent stress: The present invention relates to the use of a monoterpene for the prevention, alleviation or treatment of a pathological or non-pathological stress condition of an individual.... Agent: Birch Stewart Kolasch & Birch

20110028552 - Mexiletine amino acid and peptide prodrugs and uses thereof: The present invention concerns prodrugs of mexiletine (and mexiletine's active metabolite) with amino acids or peptides and pharmaceutical compositions containing such prodrugs. Methods for providing pain relief, treating arrhythmia, decreasing the adverse GI side effects associated with mexiletine, increasing the bioavailability of mexiletine, and improving the pharmacokinetic reproducibility of mexiletine... Agent: Mcdermott Will & Emery LLP

20110028553 - Treating critically ill patients with intravenous ibuprofen: Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in... Agent: Davidson, Davidson & Kappel, LLC

20110028554 - pharmaceutical compositions comprising diiodothyronine and their therapeutic use: The present invention relates to a pharmaceutical composition comprising, as active substance, at least one hormone chosen among 3,5-diiodothyronine (3,5-T2), 3′,3-diiodothyronine (3′,3-T2), 3′,5-diiodothyronine (3′,5-T2), 3′-iodothyronine (3′-T), 3-iodothyronine (3-T) or 5-iodothyronine (5-T), in association with a pharmaceutically acceptable vehicle.... Agent: Young & Thompson

20110028555 - Antiinflammatory and analgesic preparation for external use: It is intended to provide an antiinflammatory and analgesic preparation for external use whereby side effects of a nonsteroidal antiinflammatory and analgesic drug on the skin can be regulated, the nonsteroidal antiinflammatory and analgesic drug can be prevented from degeneration with time due to a dibenzoylmethane derivative contained as an... Agent: Licata & Tyrrell P.C.

20110028556 - Treating critically ill patients with intravenous ibuprofen: Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20110028558 - Treating critically ill patients with intravenous ibuprofen: Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in... Agent: Davidson, Davidson & Kappel, LLC

20110028557 - Treating patients with intravenous ibuprofen: Methods of treating a patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen in an amount effective to treat at least one condition in the patient chosen from pain, inflammation, and fever and to provide a clinically relevant effect on mean arterial... Agent: Davidson, Davidson & Kappel, LLC

20110028559 - Substituted fluoroethyl ureas as alpha 2 adrenergic agents: Treating pain in mammals with a compound having the formula (I) is disclosed herein.... Agent: Allergan, Inc.

20110028560 - Self-emulsifiable liquid florfenicol composition intended to be incorporated into the drinking water of livestock: The invention relates to a self-emulsifiable liquid composition intended to be diluted in an aqueous intermediate solution and then incorporated into the drinking water of livestock animals, and also to the use of such a composition. The invention is characterized in that the composition comprises at least—between 1% and 12%... Agent: Volpe And Koenig, P.C.

20110028561 - Protection of neural retina by reduction of rod metabolism: Described herein are methods for treatment or prevention of retinal dysfuntion by reduction of rod cell energy demand. Particular embodiments include methods for improving rod-mediated retinal function in a developing retina by administering an agent that reduces energy demand in the rod cell. Such agents that target rod cell energy... Agent: David S. Resnick

20110028562 - Derivatives of aminoalkanols, method of obtaining of aminoalkanols and their use: The subject of the invention is a group of new derivatives of aminoalkaπols, more specifically [(phenoxy)alkyl]aminoalkanols and [(phenoxy)acyl)aminoalkanols, their method of obtaining and their use for production of a medicine which is used in the prophylaxis, prevention and/or treatment of diseases or symptoms having neurological background and for production of... Agent: Brinks Hofer Gilson & Lione

20110028563 - Anti-microbial composition: The present invention relates to an anti-microbial composition and method of use thereof. In particular, the present invention relates to an anti microbial composition comprising farnesol and cetrimide.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20110028564 - Compositions and methods for treatment of filovirus-mediated diseases: The invention features compositions, methods, and kits useful for the treatment of filovirus-mediated diseases, e.g., hemorrhagic fever caused by Ebola virus, in an animal.... Agent: Clark & Elbing LLP

20110028565 - Exo-s-mecamylamine formulation and use in treatment: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine... Agent: Womble Carlyle Sandridge & Rice, PLLC

20110028566 - Compositions and products containing cycloaliphatic diol antimicrobial agents and methods of using the compositions and products: Compositions comprising at least one cycloaliphatic diol antimicrobial agent and at least one other antimicrobial agent and methods of making and using these compositions are provided. The cycloaliphatic diol antimicrobial agents comprise 1,1-cyclohexanedimethanol, 1,2-cyclohexanedimethanol, 1,4-cyclohexanedimethanol, 2,2,4,4-tetramethyl-1,3-cyclobutanediol, or mixtures thereof.... Agent: Polly C. Owen

20110028567 - Smooth muscle contraction inhibitors: An emulsion comprising L-Menthol, a fat or oil and a surfactant wherein oil particles have an average diameter of 100 nm or less inhibits a content reduction attributed to, for example, evaporation of L-menthol, enhances a light transmission through liquid and is stable despite long-term storage. Thus, the emulsion can... Agent: Wenderoth, Lind & Ponack, L.L.P.

20110028568 - Preparation for magnesium ammonium phosphate cements: The invention relates to a preparation for a magnesium ammonium phosphate cement. There is provided a preparation comprising (a) a magnesium calcium phosphate of the formula MgxCay(PO4)2Oz, wherein x+y≦4, x>1, y>0, z=x+y−3 and z≧0; (b) an ammonium salt; and (c) water; wherein the ammonium salt and the water can be... Agent: Emerson, Thomson & Bennett, LLC

20110028569 - Mixtures of hydrolysis resistant organomodified trisiloxane ionic surfactants: The present invention provides for a mixture comprising a siloxane having the formula: M1 D M2 wherein M1=(R1)(R2)(R3)SiO1/2; M2=(R4)(R5)(R6) SiO1/2 and D=(R7)(Z) SiO2/2 where R1, R2, R3, R4, R5, W and R7 are each independently selected from the group consisting of 1 to 4 carbon monovalent hydrocarbon radicals, aryl, and... Agent: Dilworth & Barrese, LLP

20110028570 - Self emulsifying granules and process for the preparation of emulsions therefrom: A process for making a self-emulsifying granule suitable for use in forming latex emulsions includes contacting a resin with a solid or highly concentrated surfactant, a solid neutralization agent and water in the absence of an organic solvent to form a mixture, melt mixing the mixture, and forming self-emulsifying granules... Agent: Xerox Corporation (cdfs)

20110028571 - Silicone-modified wax-containing composition and cosmetic preparation containing the composition: A composition for cosmetic preparation and a cosmetic preparation including the composition are provided. The composition includes a silicone-modified wax having a melting point of 100° C. or above and an unctuous agent having a melting point of 80° C. or below. The composition is prepared by cooling after dissolving... Agent: Birch Stewart Kolasch & Birch

20110028572 - Product for treating a toilet flush cistern and bowl: The present invention relates to a liquid additive product including at least one acid, intended, in combination with the water contained in a toilet flush cistern of a WC, to constitute an agent for treating polluting elements contained in the cistern, characterized in that the viscosity of the additive product... Agent: Young & Thompson

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141218: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 4.05654 seconds

PATENT INFO